Study of brain injury and neuroregenerative effects of D-cycloserine using an asphyxial cardiac arrest rat model by Combs, Vélvá M.
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A bstract
Cardiac arrest (CA) affects over 300,000 Americans annually and results in severe 
brain injury (impaired motility, memory loss, or death) due to poor recovery. Over
stimulation of glutamatergic N-methyl-D-aspartate receptor (NMDAR) channel
2+activation, allows Ca ions to enter cells, triggers a cascade of excitotoxic events and 
eventual neuronal death, but down-regulation of NMDAR post arrest may contribute to 
progressive injury. Previous studies have indicated that NMDARs are down-regulated 
within hours to days after resuscitation, therefore re-stimulation of NMDARs after CA 
should improve neurological outcome.
The purpose of this thesis was to: 1.) Implement an in vivo asphyxial CA (ACA) 
rat model at UAF to reproduce CA seen clinically in prenatal/pediatric populations, and 
2.) Test the hypothesis that partial NMDAR agonist (D-cycloserine, DCS) would 
improve recovery from neuronal injury. Male Sprague Dawley rats (250-330g ) were 
administered a low dose of DCS (10mg/kg, IP) 24 and 48hr after resuscitation from either 
6 or 8-min ACA. Behavioral Neurological Deficit Scores (NDS) were taken at 2hr and 
daily for 7 days after ACA to assess injury. Histopathology assessed CA1 hippocampal 
neuronal injury. DCS had no effect on neurological improvement but the ACA model 
produced significant brain injury in rats regardless of CA duration.
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C H A PTER  1 
G eneral Introduction to Excitotoxic Effects Resulting From  C erebral Ischem ia
1
1.1. Overview
This chapter will provide background on cerebral ischemia, cerebral ischemic 
subtypes (focal and global ischemia), and the excitotoxic mechanisms that occur during 
cerebral ischemic injury (e.g. membrane depolarization, hyperactivation of N-methyl-D- 
aspartate receptors [NMDAR], D-serine binding, etc.).
1.2. Cerebral Ischemia
Cerebral ischemia occurs in one of the following forms: focal ischemia (stroke), 
secondary injury ischemia following head trauma (TBI, traumatic brain injury), or as 
global cerebral ischemia (or cardiac arrest) (Rossi et al., 2 0 0 7 ). Cerebral ischemia 
involves highly complex mechanisms where the brain’s energy supply is compromised 
either focally (e.g. artery blockage in stroke) or globally (e.g. asphyxial cardiac arrest)— 
this results in severe brain damage which is the leading cause of death and long-term 
disability (Rossi et al., 2 0 0 7 ). Focal ischemia during stroke is the most common form of 
ischemia and occurs when there is an abrupt disruption of blood flow to one or more 
specific areas of the brain.
2Approximately 740,000 new cases of stroke occur annually in the U.S. (O'Neill 
and Clemens, 2 0 0 1 ). Ischemic stroke can result in speech impairment, postictal seizure, 
facial weakness, headache, hemiparetic or ataxic gait, hypoglycemia, and general 
weakness in half of the body, such as in the arm or leg. Stroke can be classified as 
ischemic stroke, subarachnoid hemorrhage, or intracerebral hemorrhage and is usually 
diagnosed through use of neuroimaging (computed tomography, CT or magnetic 
resonance imaging, M RI) used to detect the lesions and other pathological processes 
involved and vascular areas affected (Yew and Cheng, 2 0 0 9 ). Elevated intracranial 
pressure (ICP) and spontaneous intracerebral hemorrhage (ICH; accounting for 15-20% 
of all strokes) usually accompanies serious stroke injuries due to brain swelling from 
edema and results in poor prognosis or even fatality (Kimelberg, 1992, Hazell, 2 0 0 7 ).
Traumatic Brain Injury (TBI) involves secondary ischemic injury and consists of 
complex pathophysiological processes caused by a wide range of plausible injury causes 
thus affecting TBI impact. Approximately 2%  of the U.S. population will suffer long­
term disability following TBI. TBI can occur either directly (cerebral injury) or 
indirectly (supratentorial trauma to the cerebrum) which can result in tremors, impaired 
fine motor and balance skills, ataxia, sensory deficits, etc. (Potts et al., 2 0 0 9 ). Mortality 
increases even more in older patients when it can reach between 30-50% . Among people 
suffering TBI, 90%  are expected to die within 48 hours of onset due to uncontrolled 
intracranial pressure that usually builds up and causes brain stem herniation and neuronal 
death (Park et al., 2 0 0 8 ). Effective treatment for TBI remains a major problem
worldwide. The most effective treatments will require a multifactorial approach to 
prevent its rapid onset (Hazell, 2 0 0 7 ).
Global ischemia resulting from cardiopulmonary arrest (C A ) is the other form of 
ischemia. It remains one of the main causes of death in the U.S. even in light of fast 
emergency responses and improved defibrillation techniques. This type of ischemia 
affects the whole body including but not limited to the kidney, brain, and heart (Wang- 
Fischer, 2 0 0 8 ). Cardiac arrest is defined as a sudden termination of blood supply and 
cardiac output and can be subdivided into two main categories: primary and secondary. 
Primary CA involves arrhythmias (ventricular fibrillation, VF, or ventricular tachycardia, 
VT) and is caused by a number of factors such as myocardial infarction, electrocution, or 
drug overdose. Secondary CA involves various causes such as respiratory arrest, 
hypothermia, airway obstruction, severe hemorrhaging, electrolyte imbalances, etc. 
(Robinson, 2004 ) . Cardiac arrest (CA) affects over 300,000 people in the U.S. annually, 
in which only 70,000 are resuscitated and 42,000 die from the resulting brain injury 
(Krause et al., 1986 ). This injury results in either fatality or neurological impairment due 
to global cerebral ischemia (insufficient blood circulation to the entire brain). 
Neurological impairments include short-term memory loss, speech impediment, and 
impaired motor functions. Neurons continue to die from days to months after ischemia. 
Only 3-10%  of CA survivors resume normal function, therefore there is greater need for 
further development of novel therapies to lessen ischemic effects post-injury in order to 
improve overall survival and outcome (Krause et al., 19 86 ). The period of time occurring 
after CA injury and resuscitation (ROSC [“resumption/restoration of spontaneous
3
4circulation”] or “CPR”) is known as the post-cardiac arrest syndrome. This syndrome 
involves a myriad of pathophysiological processes including reperfusion brain injury, 
myocardial dysfunction, and systemic ischemia/reperfusion response, which cause the 
most damage to the brain and body (Neumar et al., 2 0 0 8 ).
Potential CA treatments include drug treatments (the use of agonists and 
antagonist blockers/enhancers such as to limit excitotoxic cellular load or counteract its 
effects), ischemic preconditioning (which occurs before onset of subsequent injury), and 
therapeutic hypothermia (Neumar et al., 2 0 0 8 ). However, there are barriers that prevent 
optimization and implementation of post-cardiac arrest care and treatment, including 
limited resources and/or requiring intensive care and monitoring; which are costly, and 
reliability and accuracy of early prognostication (<72hr after injury) remains limited and 
unclear (Neumar et al., 2 0 0 8 ).
1.3. Excitotoxicity
N-methyl-D-aspartate receptor (NMDAR) excitotoxicity resulting from excessive 
extracellular glutamate release plays a key role in producing neuronal damage (Rothman 
and Olney, 19 95 ). The glutamate hypothesis states that glutamate excitotoxicity leads to 
the development of several chronic neurodegenerative disorders (e.g. TBI, ischemia) 
caused by neuronal degeneration and dysfunction in response to CNS insult (Lau and 
Tymianski, 2 0 1 0 ). During ischemia a cascade of excitotoxic events occur simultaneously 
within seconds after onset of injury, e.g., failed ATP ion pump function [Na+/K+
ATPase], membrane depolarization (efflux of extracellular glutamate; sharp increase of 
intracellular Na+  and Ca2+ , and efflux of K+  and Mg2+ )  resulting in the opening of 
voltage-gated ion channels, and activation of a series of programmed cellular death
pathways (Kristian and Siesjo, 1997). Astrocytes might also be involved in the release of
2+ATP initiating the intercellular Ca propagated waves in neighboring cells by activating 
purinergic (P2Y ) receptors (Rossi et al., 2 0 0 7 ).
Excessive glutamate release plays a key role in excitotoxic neuronal death 
following brain ischemia and trauma by triggering NMDAR activation. When glutamate 
binds to the glutamate-gated NMDAR (Carroll and Zukin, 20 02 ) (with the endogenous
cofactor glycine and/or D-Serine, D-ser, present), the channel is opened, leading to
2+calcium influx into the cell and eventual decline in normal brain function. Ca influx
2+causes Ca dependent production of ROS (reactive oxygen species) from disruption of 
the mitochondrial electron-transport chain, and release of ‘free radicals’ (Dykens, 19 94 ). 
The time course of excitotoxic events can also differ between species such as rodents and 
humans. Previous microdialysis studies comparing TBI and stroke between humans and 
rats found that increases in glutamate only last a few minutes in rats but lasted anywhere 
from 6hr up to several days in humans (Biegon et al., 2 0 0 4 ). This key difference could 
potentially play a vital role in determining how to treat excitotoxic ischemic effects in 
humans, especially when using rodent animal models to mimic human clinical 
neuropathologies.
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61.4. NMDAR &  D-serine
NMDARs are comprised of NR1 and NR2 subunits consisting of coagonist 
(glycine, and D-serine) and agonist (glutamate) binding sites necessary for receptor
activation leading subsequently to 1.) Depolarization, 2 .) Intracellular electric current, 3.)
2+Ca influx, 4 .) Production of cGMP, 5.) Neurotransmitter release from vesicles, and after 
successive stimulation 6.) Neuron death (Nishikawa, 2 0 0 5 ). NMDARs require both 
glycine and glutamate receptor activation and can be distinguished from similar kainite 
and AMPA (a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptors by its 
need for simultaneous electrical and chemical stimulation through its ion channel 
(Furukawa and Gouaux, 2 0 0 3 ). The NMDAR is unique among most ligand-gated ion
channels since two different ligands must simultaneously be present on the receptor in
+  2+ order to conduct Na and Ca ions.
Glutamate-gated NMDARs are densely localized in the hippocampus (particularly 
the CA1 region) and activation of these receptors plays an important role in formation of 
memory and learning (Biegon et al., 2002, Biegon et al., 2 0 0 4 ). However, recent 
research indicates that NMDARs are also located on the myelin sheath of 
oligodendrocytes, glial cells producing the myelin sheath of axons in the brain; this is 
contrary to the belief that NMDARs were not involved in oligodendrocyte/myelin injury 
since they were not present here (Lipton, 2 0 0 6 ). NMDARs are usually involved in 
synaptic plasticity and in a number of diseases such as schizophrenia (Furukawa and 
Gouaux, 2 0 0 3 ).
Suppression of excitotoxic glutamate release, especially via inhibition of 
NMDAR activation using NMDAR antagonists, after ischemic insult can help reduce 
neuronal death and improve overall outcome (Biegon et al., 2 0 0 4 ). NMDAR antagonists 
have been found to be effective in improving outcome in focal ischemic models, yet have 
little effect on improving outcome in global ischemic models (Lau and Tymianski, 2 0 1 0 ). 
The problem with using NMDAR antagonists is that the effect is short-lived: antagonists 
only appear to be beneficial in a short time window given either before or immediately 
after injury and lose efficacy if  given over 30 min to 1hr or greater post-injury (Biegon et 
al., 2 0 0 4 ). Clinical trials of NMDAR antagonists developed to decrease brain injury have 
failed suggesting alternative types of treatment are necessary (Biegon et al., 2 0 0 4 ). 
Alternative treatments involving the use of NMDAR agonists have been shown to be 
neuroprotective; especially since NMDARs have a dual function in which they can either 
produce neuronal death or survival via receptor subunit modulation (Kingston et al.,
1999, Dos-Anjos et al., 2 0 0 9 ). Liu et al., (20 07 ) suggested neuroprotection after stroke 
insult is attributed to activation of NR2A-containing receptors. After 48hr post-injury, 
NR2A subunit expression in the hippocampus (an area highly vulnerable to ischemia) is 
reduced by half in comparison with NR1 and NR2B subunits which suggests that NR2A 
plays a critical role in regulating NMDAR expression (Dos-Anjos et al., 2 0 0 9 ). This 
effect points to a functional deficit and desensitization (“down-regulation”) of NMDARs 
rather than overstimulation as the main culprit for poor neuronal outcome following 
neuronal injury hours and days after injury, thus hinting at the need for alternative forms 
of treatment besides NMDAR antagonists (Biegon et al., 2 0 0 4 ).
7
8NMDAR coagonists can also provide neuroprotection. D-serine (D-ser), an 
endogenous NMDAR coagonist for NR1/NR2 subtypes; is densely concentrated 
throughout the brain, especially in higher brain function areas (Nishikawa, 2 0 0 5 ). D- 
cycloserine (DCS) (a positive modulator and partial NMDAR agonist) binds to the same 
glycine site of NMDARs to which D-ser normally binds (Nishikawa, 20 05 ) and plays an 
important role in recovery of cognitive function subsequent to brain injury (Temple and 
Hamm, 1996, Yaka et al., 2 0 0 7 ). DCS binding to the glycine site is characteristically 
seen as one of many primary effects that speed up NMDARs from further desensitization 
and repeated and prolonged activation mediates physiological response (Temple and 
Hamm, 19 96 ). DCS is already approved for antimicrobial use in humans and is 
considered to be a promising therapy for post-injury treatment of cognitive disorders like 
TBI (Temple and Hamm, 19 96 ). Since DCS binds to the same site as endogenous D- 
serine, DCS could be used as a potential therapeutic treatment option to restore activation 
of down-regulated NMDARs and improve memory deficits resulting from cerebral 
ischemia.
1.5. Conclusion
This thesis will focus on the following topics: i.) Implementation of an in vivo 
asphyxial cardiac arrest (ACA) rat model at the University of Alaska, Fairbanks (UAF) to 
reproduce cardiac arrest (C A ) and assess brain injury resulting from global cerebral 
ischemia pathology seen clinically in both perinatal and pediatric populations, and ii.)
9Test the hypothesis that a partial NMDAR drug agonist (D-cycloserine, DCS) would 
improve recovery from neuronal injury.
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C H A P T E R  2 
H e a lth  Im p lic a tio n s  an d  T ech n iq u e  A ssessm ent of A n A sphyxial C a rd ia c  
A rre s t  (A C A ) R a t M odel T ra n s fe rre d  to T he U n iv e rsity  of A lask a , 
F a irb a n k s  (U A F ) F ro m  T he U n iv ersity  of M iam i M ille r School of M edicine
2.1. Abstract
Cardiac arrest (CA) results in severe neurological impairments and death 
through excitotoxicity. Established animal models such as the four-vessel occlusion 
(4V O ) and two-vessel occlusion (2V O ) with hypotension have been used to study the 
pathology associated with CA. The asphyxial cardiac arrest (ACA) rat model has 
previously been established to reproduce reliable post-CA neurological injury and 
true global ischemia seen clinically in perinatal and pediatric populations. The ACA 
model includes surgical and post-operative care components allowing for long-term 
monitoring of neurological degradation compared to 2VO and 4VO animal models.
The ACA model is easier to implement and produces whole brain ischemia but can 
also be and time-consuming and result in low successful resuscitation rates with 
respect to surgical skill level.
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2.2. Asphyxiation Causes Cardiac Arrest
Asphyxiation is defined as oxygen deprivation caused by impaired respiration in 
which gas exchange required for normal cellular metabolism is disrupted (Elsner, 1983). 
Asphyxiation can lead to severe hypoxia (inadequate oxygenation supplied to specific 
tissues such as the lungs, heart, or brain) and often results in cardiac arrest, with 
subsequent global cerebral ischemia and brain damage. Asphyxial Cardiac Arrest (ACA) 
is clinically defined as the termination of mechanical activity by the heart caused by 
insufficient respiration (asphyxiation), lack of responsiveness, and the inability to 
generate a central pulse (Goldstein, 1982, Myerburg et al., 1982, Greene et al., 1989, 
Zaritsky et al., 1995, Manole et al., 20 08 ) and results in hypoxic brain injury (Moulaert et 
al., 2010). Approximately 50%  of all CA patients are successfully resuscitated with 10­
20%  of those patients making good recovery; most suffer severe disability (usually 
resulting in expensive ICU hospital costs sometimes up to $95,000 for comatose 
survivors (Gray et al., 1991 )) or death (Geraghty and Torbey, 2006). Some general 
causes of asphyxial cardiac arrest include but are not limited to the following factors: 
severe acute respiratory failure, obstruction of airway passages (e.g. foreign objects, 
tumors, etc.), acute asthma attacks, pneumonia, asphyxiation by hanging (suicide), and 
acute intoxication (Lah et al., 2011); other asphyxiation causes also include near- 
drowning, near-SIDS (sudden infant syndrome), hypoxemia (low blood oxygen), 
choking, and extrapyramidal side effects from drug use (e.g. antipsychotics &  dyskinesia) 
(Shannon and Kelly, 1982a, b, Macnab, 1995, Safar et. al., 1996, Robinson, 2004 ).
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This chapter will focus on several factors regarding ACA: incidence in different 
human populations (perinatal, pediatric, and adult), current treatment, previous animal 
models used to mimic ACA pathophysiology, and extensive detail regarding the ACA rat 
model (equipment, surgical procedure, and trouble-shooting). The ACA rat model 
produces CA and brain injury that closely matches pathophysiology seen clinically and 
potentially offers the best model option for testing future therapies.
2.3. Perinatal (Neonatal) Asphyxiation
Permanent neurological brain injuries such as mental retardation, blindness, 
deafness, cerebral palsy, epilepsy, and various learning disabilities (Robertson et al., 
2009 ) seen in children are commonly caused by hypoxia and ischemia during perinatal 
age (third gestation trimester through one month postnatal) (Scher, 2001, Berg et al., 
2008a, Robertson et al., 2009). Cerebral palsy (C P) usually results from either 
asphyxiation or some other pathology suffered during the antepartum (pre-labor) time 
period; <20%  of CP patients suffered brain injury exclusively from intrapartum (during 
labor) asphyxiation (Scher, 2001). Incidences of asphyxial injury in infants occur at a 
rate of 0.2 to 0.4%  of all full-term births and at even higher rates for low birth weight and 
preterm infants (Robertson et al., 2009). Asphyxia can also occur in brief stints during 
the delivery portion in all births resulting from various reasons such as inadequate 
oxygenation in arterial blood caused from compression of the umbilical cord or 
hypovolemic/hypotension heart failure compounded by respiration retraction (Elsner,
16
1983, Morley, 2005 ). Respiration can be depressed in new-born infants by central 
mechanisms such as hypoxia, and reflexively through stimulation of upper-airway 
receptors, and initial bradycardia during apnoeic episodes due to decreased pulmonary 
stretch receptor activity and loss of normal rhythmic central respiratory drive (Elsner, 
1983). Treatment against this effect should incorporate reversal of the hypoxic and 
apnoeic state by restoring adequate gas exchange (Elsner, 1983).
Intrapartum asphyxia and cerebral perfusion results in hypoxic ischemic- 
encephalopathy (HIE). HIE occurs approximately one in 12,500 live births with a steady 
decline over recent years, while the global CP rate is estimated to be approximately 1 to 2 
cases per 1,000 live births (Phelan et al., 2005). Neurological brain damage in neonates 
can be due to the presence or sometimes the absence of severe acidosis (e.g. umbilical 
artery pH < 7, and a base deficit > 12) which can occur at the time of birth and result in 
hypoxia and slower heart rate (<100 bpm) (Phelan et al., 2005). Fetuses try to counteract 
oxygen deprivation effects by diverting blood from less vital organs (kidney or liver) to 
more vital organs (brain, heart, and adrenal glands) speeding up red blood cell production 
and improving overall fetal oxygenation (Phelan et al., 2005).
2.4. Pediatric Asphyxiation
Nearly 60%  of all CA etiology seen in children is marked by an asphyxiation 
period occurring prior to loss of circulation (Manole et al., 2008, Robertson et al., 2009).
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Pediatric CA is typically caused from circulatory shock, respiratory failure, or a 
combination of both. Arrhythmogenic ventricular fibrillation (VF) arrests are seen more 
commonly in adults rather than in children (Nadkarni et al., 2006, Neumar et al., 2008). 
VF/VT (ventricular tachycardia) arrests occur in « about 10% of in-hospital CA and 5­
20%  of out-of-hospital pediatric CA (Neumar et al., 2008). In-hospital pediatric CA 
occurs in 2-6%  of all children admitted to pediatric intensive care units (PICUs) (Kuisma 
et al., 1995, Slonim et al., 1997, Suominen et al., 2000, Berg et al., 2008a) and in 4-6%  of 
children after cardiac surgery (Rhodes et al., 1999, Parra et al., 2000, Berg et al., 2008b). 
Out-of-hospital cardiac arrests (OHCAs) occur in approximately 8-20/100,000 children 
annually (Young et al., 2004, Donoghue et al., 2005, Berg et al., 2008a), with a 100-fold 
higher incidence for in-hospital cardiac arrests (IHCAs) (Morris and Nadkarni, 2003,
Berg et al., 2008a). About two-thirds of IHCA patients are successfully resuscitated 
(Parra et al., 2000, Reis et al., 2002, Meaney et al., 2006, Nadkarni et al., 2006, Samson 
et al., 20 06 ) with over 25%  survival to hospital release (Berg et al., 2008a).
The most common causes of CAs are asphyxiation due to acute hypoxia or 
hypercarbia, ischemia from inadequate blood flow to the heart (e.g. hypovolemic shock 
or myocardial dysfunction), and arrhythmias stemming from ventricular fibrillation, VF, 
or ventricular tachycardia, VT (Berg et al., 2008b). Asphyxial pediatric CA is usually 
caused by hypoxemia, hypercarbia, acidosis, and hypotension. Respiratory compromise 
is the most common cause of non-traumatic pediatric CA and can be secondary as well 
resulting in upper or lower airway constriction and/or obstruction leading to secretions,
18
aspiration, infection, suffocations, trauma, and/or depressed respiratory drive secondary 
to neurological impairment (Manole et al., 2008).
Drowning is a common cause of death where approximately 8,000 deaths occur 
annually in the U.S., caused either by asphyxiation alone or in combination with water 
intake (Elsner, 1983). Near-drowning is the third most common cause of death with a 
majority of victims under the age of 20 years. These drowning victims suffer anoxic 
encephalopathy, acute respiratory failure (ARF), or hypoxemia (defined as having Po2 60 
mmHg without supplemental O2) (Gregorakos et al., 2009). Drowning pathophysiology 
is caused by water aspiration into the lungs which leads to a multitude of fluctuating 
sympathetic and parasympathetic over-activity: blood pressure first increases followed by 
a gradual decline; excessive glucose, hypoxia and CO2 accumulate due to acidosis; and 
eventually circulatory failure occurs (Golden et al., 1997, Vaagenes et al., 1997). Near- 
drowning can also be paradoxically neuroprotective for children. The surface area to 
mass ratio and small body mass of young children in combination with immersion into 
cold water (hypothermia protection), improves survival due to the absence of higher brain 
(cortical) function and loss of voluntary muscle movement; especially if they are knocked 
unconscious prior to water submersion (Elsner, 1983).
Another cause of pediatric asphyxiation is Sudden Infant Death Syndrome 
(SIDS). SIDS is the third leading cause of infant mortality (~2300 infant deaths) in the 
United States annually and occurs in infants of 1 month to 1 year in age and of male 
gender) (Moon et al., 2007, Moon and Fu, 2012). Causes of SIDS range from various
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factors such as environmental, genetic, smoking exposure (usually during pregnancy), 
low birth weight, overheating, bedding material, negligence, sleeping position, and 
ethnicity (twice as many mortality rates [death/live births] for Alaska Native/American 
Indian infants [112/100,000] and African American infants [99/100,000] compared to 
Caucasian infants [55/100,000]) (Moon et al., 2007, Moon and Fu, 2012).
2.5. Adult Asphyxiation
Adult asphyxial CA can occur from various internal and external causes of either 
cardiac or non-cardiac etiology such as: non-traumatic bleeding, pulmonary embolism, 
intracranial processes, pneumonia, asthma, convulsions, malignancy, hemorrhagic 
pancreatitis, intoxication, trauma, near-drowning, choking, hanging [suicide], and carbon 
monoxide intoxication (Kuisma and Alaspaa, 1997). Ventricular fibrillations tend to be 
the main cause of adult CA versus asphyxia for pediatric/perinatal CA (Katz et al., 1995, 
Kochanek et al., 2009). Outcome from CA results in a reduction in the quality of life 
marked by cognitive impairments, fatigue, memory problems, post-traumatic stress, 
depression, and anxiety (Moulaert et al., 2010). In terms of drowning asphyxiation, 
survival rate was higher in drowning victims than for out-of-hospital primary cardiac 
arrest (OHPCA) patients (Grmec et al., 2009). In an cardiac arrest drowning study 
conducted from Feb. 1998 to Feb. 2007 in the town of Maribor (located in the European 
territory, Slovenia), 67%  (528/788) cardiac arrests with resuscitation were OHPCA, 
while 4%  (32/788) cardiac arrests with resuscitation were of drowning victims (Grmec et
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al., 2009). The survival rate among the drowning patients was significantly higher, 44%, 
compared to OHPCA patients at 22%  (Grmec et al., 2009).
Adult cardiac arrest usually occurs as a phenomenon called “Sudden cardiac 
arrest” . The onset of sudden cardiac arrest (SCA) usually has no real onset of symptoms 
prior to injury. Out-of-hospital cardiac arrests (OHCAs) are comprised of trauma, 
intoxication, near-drowning, non-traumatic bleeding, and pulmonary embolism.
Thirty percent of OHCAs are non-cardiac in origin and most SCAs happen to also 
tend to be non-cardiac in origin. The incidence of sudden OHCA of non-cardiac origin 
was 26/100,000 patients annually while trauma cases made up 20/100,000 patients 
annually, with an average age of about 49 years old (^6 5 %  male; 4%  under 16 years old) 
(Kuisma and Alaspaa, 1997).
Some plausible causes of SCA in adults include channelopathies (e.g. long QT 
syndromes and molecular anomalies [e.g. type 2 ryanodine receptor mutation]), genetic 
predisposition, coronary artery atherosclerosis which has accounted for 40%  and 65%  of 
major deaths in females and males respectively (coronary disease resulting in death was 
even seen in 15-49 year olds), lethal arrhythmia (ventricular fibrillation), acute coronary 
insufficiency in absence of coronary artery atherosclerosis (e.g. fibromuscular dysplasia, 
coronary artery narrowing), respiratory failure (e.g. sleep apnea, asthma), exercise 
exertion (e.g. anomalies found in coronary or pulmonary arteries), myocardial ischemia 
(myocarditis in young adults), side effects from psychotropic medication (typical and 
atypical antipsychotic drugs), anaphylaxis, viral infections, subarachnoid hemorrhage, 
esophageal/gastrointestinal causes of sudden death, etc. (Langlois, 2009).
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2.6. Post-Cardiac Arrest Syndrome And Brain Injury
The post-cardiac arrest (CA) syndrome characterizes the body’s response to 
whole-body ischemic/reperfusion effects occurring after successful cardiopulmonary 
resuscitation (CPR) due to cardiac arrest injury (Negovsky, 1972, Neumar et al., 2008). 
Post-CA brain injury results in eventual neuronal degradation hours to days after CA due 
to lack of oxygen supplied to the brain (Neumar et al., 2008). Clinical manifestations 
include hypotension, seizures, memory impairment, hypoxemia, a comatose state, 
myoclonus, impaired cerebrovascular autoregulation, and brain edema (Krumholz et al., 
1988, Pusswald et al., 2000, van Alem et al., 2004, Neumar et al., 2008). The brain’s
vulnerability to ischemia involves complex excitotoxic mechanisms including generation
2+of free radicals, disruption of Ca homeostasis, pathological protease cascades, and 
programmed apoptosis (Lipton, 1999, Neumar, 2000, Bano and Nicotera, 2007).
Children are particularly vulnerable to post-CA brain injury due to their poor survival 
outcome (Manole et al., 2008). Therefore, implementation of anti-excitotoxic therapies 
should be pursued as potentially beneficial treatment options in order to preserve cerebral 
metabolic demands.
2.7. Treatment
Treatment against asphyxia can be simply avoidance and prevention against 
things that may cause asphyxia in the first place or implementation of therapies aimed at
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restoring adequate cerebral blood flow either during or after CPR or ischemic insult if CA 
ensues. One such treatment is resuscitating newborns with room air rather than 100% 
oxygen to improve neurological outcome after CA since reactive oxygen and nitrogen 
species potentially worsen the outcomes of some neurological damage in animal models 
of CA (Manole et al., 2008). Another treatment option involves the use of 
neuroprotective drug therapies such as N-methyl-D-aspartate (NMDA)/a-amino-3- 
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/MK-801/Phencyclidine (PCP) 
antagonists, magnesium sulfate, and -aminobutyric (GABA) agonists (Aarts and 
Tymianski, 2005, Manole et al., 2008, Neumar et al., 2008).
Mild hypothermia has proven to be the most effective therapy against post-cardiac 
arrest injury (Hachimi-Idrissi et al., 2001, Hypothermia after Cardiac Arrest Study,
2002). Therapeutic hypothermia cools body temperature to between 32-34°C for 12-24 
hours to increase energy stores required by the brain (Nilsson et al., 1975). Oxygen 
consumption during hypothermia is reduced to approximately 5% per °C between 22- 
37°C (Yenari et al., 2008).
The benefits of hypothermia treatment have been observed in near-drowning victims. 
People who have ceased vital function from drowning were recovered as long as 40 min. 
from their initial submersion. It has also been reported that the heart can be restarted 
after two hours of water submersion (Harries, 1986). Deep hypothermia (<33°C ) has 
been shown, however, to cause such complications as bleeding, arrhythmia, sepsis, and 
even thrombosis but this effect has not been seen in infants with mild hypothermia
treatment (Hoehn et al., 2008). Hypothermia treatment for asphyxia newborns with 
encephalopathy did not improve survival or the condition of severely disabled infants but 
did have a significant impact on moderately affected infants (Hoehn et al., 2008).
In summary asphyxiation is a cause for cardiac arrest, especially in pediatric 
populations.
2.8. Animal Models of Global Cerebral Ischemia
Cardiac arrest leads to disability and death in part due to brain injury caused by 
global cerebral ischemia that ensues when cardiac function ceases. Several models have 
been developed to study global cerebral ischemia in animals. All of these models are 
limited by cardiovascular variables that differ from the clinical scenarios seen in humans.
2.8.1. Four-Vessel Occlusion (4VO)
The four-vessel occlusion (4VO) rat model is a model that reproduces global 
cerebral ischemia such as occurs during cardiac arrest in clinical situations by inducing 
transient forebrain ischemia. In this two-day procedure, permanent coagulation of the 
two vertebral arteries occurs first and then occlusion (via temporary ligation) of the two 
common carotid arteries occurs, allowing the hindbrain to still be partially perfused 
(Schmidt-Kastner et al., 1989). This effect allows for delayed cell death and reliable
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outcome (Schmidt-Kastner et al., 1989). The 4VO rat model is relatively inexpensive 
and useful for studying the unusual delayed cell death pattern after injury onset and for 
testing drugs for neuroprotection; however, there are also limitations with this model 
including chance of improper cauterization technique or rupture of vertebral arteries or 
insufficient blockage of carotid arteries resulting in excessive bleeding, spinal cord 
damage, severe neurological deficits prior to 4VO, loss of righting reflex, or even death 
(O'Neill and Clemens, 2001). For example, there is a chance of potential error when 
locating vertebral arteries for permanent occlusion using electrocauterization and/or 
possible tissue damage resulting from excessive heat use or muscle trauma leading to 
complications and fatality during surgery (Small and Buchan, 2000).
2.8.2. Two-Vessel Occlusion (2V O ) With Hypotension
Two-vessel occlusion (2V O ) with hypotension rat model (along with 4VO model) 
is one of the most frequently used for research into molecular mechanisms of global 
neuronal damage (Ginsberg and Busto, 1989, Wang-Fischer, 2008). 2VO produces 
reversible forebrain ischemia by employing bilateral common carotid artery occlusion 
combined with systemic hypotension (50  mmHg). Two main histopathological changes 
occur in this model: 1.) Selective neuronal variability (e.g. pyramidal neurons of the 
hippocampal cornu ammonus (CA) subregion [curved, U-shape lamina field of the 
hippocampus (Gondi et al., 20 10 )] and 2.) Delayed neuronal death (necrosis occurs 2-3 
days after reperfusion) (Raval et al., 2009). Reproducibility of ischemic damage is
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greater than 90%  and suitable for many research applications (neuroprotective agents, 
biochemical and molecular studies, etc.) (Raval et al., 2009). Although the 2VO with 
hypotension model is surgically easier to implement than the 4VO and allows for 
relatively easy monitoring of physiological variables, it can also produce overall 
variability in outcome (specifically, histopathology) which can result in profound 
variability beyond the experimenter’s control due to the need to induce hypotension 
(Small and Buchan, 2000).
2.8.3. Asphyxial Cardiac Arrest (ACA) Rat Model
The asphyxial cardiac arrest model (ACA) produces systemic hypoxia-ischemia, 
arterial hypotension, and circulatory arrest in tissues negatively impacting the entire body 
(Dave et al., 2009). The ACA model best approximates a true clinical scenario that leads 
to global cerebral ischemia. The ACA rat model is an already established model for 
neurological injury after cardiac arrest, reproducing many neurological deficits in humans 
(Callaway and Logue 2009). This model also adds additional variables to the CA 
pathology, which include but are not limited to: hypercapnia (excessive CO2 levels 
unable to expire out of the body), acidosis (lower pH in tissues), blood clots, lag in O2 
delivery from endotracheal intubation setbacks, etc. Some advantages to using this in 
vivo ACA model is that it can reproduce similar hypoxic and/or anoxic conditions that 
naturally occur in various brain diseases in humans and hopefully provide accessible 
ways to develop novel treatments by isolating specific mechanisms characteristic of this
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ischemic injury (Matsuoka et al., 1997). Another benefit of using the ACA model is that 
the biochemical pathways associated with ischemia can be studied within seconds or 
minutes after onset mimicking real time ischemia that occurs clinically; drug efficacy can 
also be assessed based on the knowledge of these pathways (Dave et al., 2009). Using 
small animals such as rodents in this model proves to be more cost effective over using 
larger animals and produces clear, consistent and reproducible injury in the hippocampus 
and posterior caudoputamen with 8-10 min duration of asphyxia (Traystman, 2003). 
Global cerebral ischemia models provide a more reliable way of quantifying and 
assessing neuronal damage and possible treatment from neuroprotective agents since the 
amount of variability in induction is significantly reduced especially in comparison with 
focal ischemia models (Small and Buchan, 2000). Advantages and disadvantages of this 
model are summarized in Table 2.1.
2.9. ACA Surgical Procedure
This section will look at all aspects involved with the asphyxial cardiac arrest 
rodent model, including step-by-step analysis of how to implement mechanical 
ventilation via endotracheal intubation, venous cannulation and IV (intravenous) paralytic 
administration, asphyxial cardiac arrest induction, resuscitation technique, and post­
operative care. Asphyxial cardiac arrest is achieved in mechanically ventilated animals. 
Paralysis is induced and mechanical ventilation is halted to achieve asphyxia. Asphyxia 
leads to a reproducible drop in both blood pressure and heart rate sufficient to produce
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global cerebral ischemia. Animals are then resuscitated by rapid manual chest 
compressions and immediate delivery of epinephrine followed by sodium bicarbonate to 
adjust pH after resuscitation. The most difficult aspects of the procedure involve 
intubation and mechanical compression that can lead to inflammation and/or obstruction 
of the trachea and pulmonary edema.
2.9.1. Induction &  Intubation
First, open pressure gauge pack and set up pressure transducer. Next, prepare 
injectables (see A ppendix D, “Asphyxial Cardiac Arrest Setup”) and fill two Tygon 
cannulae with heparinized-saline (hep-saline) using a 1cc syringe and 26ga luer stub 
adaptor. Fill one 10cc syringe with sterile saline. Leave sterile ends inside gas sterilized 
pack. Anesthetize with 5% isoflurane and a 30:70 mixture of O2 (400-500m L/m in) and 
N 2O (1L/min) via scavenger fluovac mask. This balance of N 2O ensures stable 
physiological levels for Po2, Pco2 and pH (Takeuchi et al., 1992).
Intubation procedure: Open sterile intubation pack. Place rat in a supine position 
while on rodent intubation stand (Hallowell EMC, Pittsfield, MA; Rodent Tilting Work 
Stand, Item No. 000A 3467, $484.21; www.hallowell.com) with teeth secured by incisor 
loop strap (Hallowell EMC, Pittsfield, MA; Incisor Loops, 5 pk, Item No. 210A 3490, 
$30.31; www.hallowell.com) sliding bars (optional) located on stand (animal will be off 
anesthesia mask during this procedure). Insert otoscope, with speculum (Henry Schein,
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Inc., Melville, NY; Welch-Allyn Otoscope Pneumatic w/specula, 3.5V [20200]; No. 
5662532, $186.99; Welch-Allyn Handle Rechargeable 3.5V [71000-A ], No. 5662474, 
$154.49; Welch-Allyn Battery Rechargeable Orange 3.5V [72300]; No. 5662828,
$45.79) attached and light turned on (Hallowell EMC, Pittsfield, MA; Rodent Tilting 
Work Stand, Item No. 000A 3467, $484.21; Rat Autoclaveable Specula, Item No. 
200A 3588, $38.59, www.hallowell.com), against the palate of the mouth (with the 
curved slide facing downward) while holding and deflecting the tongue to the side with 
your free hand.
Next, place a drop of lidocaine gel (Lidocaine Hydrochloride Jelly USP, 2%  R x; 
30 mL, NDC 17478-711-30 or equivalent) on the tip of the lidocaine applicator 
(Hallowell EMC, Lidocaine Applicator, Item No. 200A 3590, $24.26, 
www.hallowell.com) and apply it to the epiglottis (arch shaped and located just above the 
vocal cords) while still holding the otoscope and speculum against the palate of the 
animal’s mouth with the opposite hand. Lidocaine gel application should reduce 
epiglottis spasm as well as irritation in this sensitive region. Put animal back on 
anesthesia mask (rats 2-2.5%  Isoflurane) for 2 min. Next, place a drop of lidocaine gel 
(Lidocaine Hydrochloride Jelly USP, 2%  R x; 30 mL, NDC 17478-711-30 or equivalent) 
on the tip of the lidocaine applicator (Hallowell EMC, Lidocaine Applicator, Item No. 
200A 3590, $24.26, www.hallowell.com) and apply it to the epiglottis (arch shaped and 
located just above the vocal cords) while still holding the otoscope and speculum against 
the palate of the animal’s mouth with the opposite hand. Lidocaine gel application
should reduce epiglottis spasm as well as irritation in this sensitive region. Put animal 
back on anesthesia mask (rats 2-2.5%  Isoflurane) for 2 min.
Next, take animal off mask and reinsert otoscope/speculum unit as described 
previously. This time use the endotrachael catheter (14ga 1.75in; BD Insyte™ 
Autoguard™, Shielded IV Catheter, REF# 381467; guided with a bent, custom blunt 
biomedical 17ga x 4in. needle, 17TWx3, Popper &  Sons, New Hyden Park, NY #7427; 
blunt end can be made with a sanding tool) and insert it (with curved side facing up) into 
the trachea located via the opening between the two vocal cords. Movement of the vocal 
cords should be slowed down enough in order to facilitate this technique. Once the 
catheter is fully inside the trachea (only the orange hub should be sticking out of the 
mouth), quickly check if the catheter is truly in the trachea and not in the esophagus by 
holding a stainless steel instrument in front of the open end of the catheter (orange hub) 
so that condensation of respiratory moisture can be seen. If no moisture is visible, then it 
means that the catheter is in the esophagus. Repeat the aforementioned steps in order to 
reinsert endotracheal catheter into trachea. Discontinue surgery if more than two tries are 
needed to execute intubation. Return animal to home cage for at least 1 week before 
repeat attempt.
If an otoscope and endotracheal stand is unavailable for use, the trachea may be 
visualized to facilitate intubation. Clip the hair from the ventral neck and using a #10  or 
#15 blade or curved, blunt scissors make a 1-2cm incision along the ventral midline of 
the neck to expose the trachea and larynx. To prevent laryngospasm during oral
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intubation swab lidocaine onto laryngeal folds with a small cotton tip swab moistened 
with 2 drops of lidocaine. (Lidoject; lidocaine 2%  injectable, Butler Animal Health 
Supply, Dublin, OH 43107). Next, suture catheter to lip to avoid dislodging catheter 
during resuscitation.
To secure the catheter to the trachea, use a 3-0 silk suture (100 yds., waxed, USP 
3/0 black braided silk suture, Lot No. 6253) about 4 inches in length and place through 
slit opening of a cutting needle (W orld’ Precision Instruments, Inc.; cutting needle, 
Sarasota, FL; 5/16 Circle, 18mm cutting edge, spring eye, No. 501960, Lot No. 
1080297400; www.wpiinc.com). Place cutting suture with silk suture thread underneath 
the last round rung of the orange hub unit of the endotracheal catheter while it is placed 
inside the intubated animal (whom is connected to the ventilator at this point). With the 
only the orange hub sticking out of the animal’s mouth, make one throw around the last 
rung of the hub (so that the suture is secured to the catheter), lift up a small portion of the 
animal’s lip with forceps and pass the cutting suture through the lip (toward surgeon), 
make one throw (away from surgeon), grab the rest of the silk thread and pull it through 
in order to make a knot (make two knots total). Be sure not to tie too tight to the lip so 
that it is easier to remove later on and doesn’t damage the animal’s lip.
For a terminal, non-recovery procedure, a tracheotomy may be substituted for oral 
intubation. The trachea will be exposed and a small hole will be made between the 
cartilaginous rings in the trachea and the 14ga 1.75in; BD Insyte catheter will be inserted 
in that opening in the trachea.
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Shave throat (if  tracheotomy is planned), right groin, and (optional) dorsal surface 
of remaining legs (for ECG electrodes); scrub animal using 70%  isopropyl alcohol and 
100% betadine solution. First, start with betadine and then use alcohol. Alternate 
between betadine and alcohol for a total of three swabs betadine and two swabs 70%  
alcohol, ending with 70%  isopropyl alcohol. Use circular, inside-to-outside motions 
when scrubbing incision so as not to contaminate the innermost region. Record vitals: 
Cover eyes with sterile ophthalmic ointment for lubrication (e.g. Vetropolycin, neo-poly- 
bac, etc.), insert rectal thermometer (lubricated with K-Y), insert EKG leads 
subcutaneously (ground to hind leg; negative to left front leg, positive to right front leg) 
and secure both EKG leads and thermocouples/needles with surgical tape (Durapore™ 
Surgical Tape, 2.5cm x 9.1m [1 in. x 10 yd.] hypoallergenic; REF 1538-1, NDC 8333­
1538-01) monitor sO2 with pulse-oximeter if  applicable. Record values on surgery log 
and anesthesia record.
2.9.2. ACA Surgical Preparation
Don sterile gloves, drape and open surgical pack in a sterile field to arrange 
surgical instruments (6  week sterility for a double wrap pack and 3 week sterility for a 
single wrap pack) (see Table 2.2 for contents). Included in the surgical pack are: Small 
vessel scissors (protect tip with yellow pipette), 45o 5/45 sharp forceps (protect with tip 
of yellow pipette), Blunt; bent 16ga/2.5” needle (may bend, blunt and file needle from IV 
catheter used for endotracheal catheter) or purchase from Popper &  Sons, 17TWx3
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custom blunt popper biomedical needle (cat# 7427, http://popperandsons.com/index.asp); 
Fine, straight rat-toothed forceps (Miltex 6-106; ~1mm or 1/16” width x 5 inches long); 
90o curved hemostats (5.5 inch long; Roboz RS 7291), 2 x 8 inch smooth inner surface 
curved (~ 90o) forceps (for teasing apart and holding vessels, Paragon #4004-96 
http://www.paragonmedical.com/); Curved, blunt scissors for cutting skin and separating 
skin and muscle (Roboz; R S-6891), 4 inch curved forceps for holding cannula (smooth) 
(rough forceps will tear up surface of cannula) and 2 / “ forceps (rough), one needle 
holder, clear plastic drape with hole for throat and loin; (Optional)  Y-Luer adapter; used 
to connect both Epi and NaHCO3 to venous cannula line for immediate injection during 
resuscitation, group of 6 inch cotton tipped applicators (quantity based on surgeon’s 
preference), small scissors for cutting knots, / ” pile of gauze (Flush with saline, clean 
out blood clots, cover with saline wetted gauze), (Optional) Extra, 4 x 23ga blunt 
connectors, 6x 26ga luer stub adapters (for Tygon tubing), 1 silk needle w/suture (for 
securing endotracheal catheter to lip after intubation), 4-7 x 15 inch pieces of silk thread 
necessary for anchoring and tying off vessels during cannulation, 2-3 x 3-0 Prolene 
sutures for skin closure (3/8 19 mm; FS-2, 18” [45 cm] Non-absorbable), (Optional) 
retractor for throat if  doing tracheotomy; IV catheter (BD Insyte™ Autoguard™ Shielded 
IV Catheter; 14ga x 1.75 inch; 2.1 x 45mm [330 mL/min], REF 381467).
2.9.3. Arterial and Venous Femoral Cannulation
First cannulate the femoral vein followed by arterial cannulation. Flush with 
heparinized-saline (hep-sal; 0.2mL of 1000IU/mL/30mL vial saline or 6.7 IU/mL) and 
temporarily secure with sutures (see Fig. 2.3 &  Fig. 2.4). Gas sterilized catheters 
(Tygon®, flexible tubing; Saint-Gobain PPL Corp., 0.375-mm ID, 0.75-mm OD; length 
0.029” &  wall 0.014”; Norton, Akron, OH; AAQ041889; Lot No. 112046) will be 
introduced approximately 2 cm into the right femoral artery and vein for acute blood 
pressure recording, blood sampling, and drug infusion. First begin by making an initial 
skin incision by lifting skin up away from animal with forceps and carefully cutting skin 
with a smooth, curved blunt-end scissors approximately 2 cm medially and ~ 0.5cm distal 
to the inguinal crease (hint: start parallel to inguinal crease in the groin muscle area and 
directly across from the knee). Use blunt scissors and ‘blunt dissection’ technique to 
carefully stretch the skin longitudinally, no more than 1 inch long. Very carefully, 
separate fascia connective tissue with the blunt end of the scissors, keeping scissors 
closed and working caudally (in the direction toward the tail of the animal). Be careful 
as not to damage the portion of the femoral artery that runs on and along the muscle when 
first making the incision. Using blunt dissection, gently work along the crease of the 
muscle of the groin area and work underneath that muscle— gently use the forceps in the 
other hand to lift muscle up and away so that the femoral artery, vein, nerves, and 
inguinal ligament is revealed (the inguinal ligament is a shiny white band that runs 
directly above the femoral artery and vein; see Fig. 2.4b,c; also revealing the femoral 
sheath containing the femoral artery, vein, and nerve (Chen et al., 2008).
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Next, very carefully separate the femoral vein, artery, and nerve using fine tip, 
smooth inner surface, ~ 90° curved tip 8” forceps (Paragon #4004-96 
http://www.paragonmedical.com). Add sterile saline directly onto the femoral artery and 
vein to allow for easier separation and avoidance of desiccation. Avoid damaging the 
femoral nerves that run parallel and located on either side of the vein and artery— 
damaging the nerves will result in disabled animals when recovering further hindering 
their hindlimb movement and gait. It should take less than10 min to fully separate 
vessels.
Once vessels have been separated, look for any adjacent branching off vessel— it 
is best to place silk 3-0 thread tie below the branch so as to avoid any excess blood loss 
when inserting and tying off cannula. First begin with the femoral vein. Take the silk 3­
0 thread, fold in half to make a small loop at the bend, and using the fine tip forceps, 
grasp the loop, slip underneath vein (preferably underneath a branch) and pull through 
from the other side using forceps in the opposite hand. Stretch out the thread and make a 
loop around the vessel tied down close to but not actually on the vessel itself. Use curved 
hemostats to add tension to the thread by placing it on the very ends of the thread and 
allow it to hang over the animal’s knee located closest to the surgeon (hint: always start at 
the proximal end of the vessel when first tying off either the vein or artery). Now that the 
proximal tie has been completed, do the same exact step for the distal end of the vein.
Tie the 3-0 silk thread all the way down to the vessel until ‘snug’ (not tight). Make 
between 2-3 throws (knots) and hang over the adjacent knee using another pair of 
hemostats. Next, make a small, width-wise incision on the vein using small “vessel”
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scissors (FST 15000-00, www.finescience.com) or iris scissors or (make sure there is 
adequate tension on the vein using the silk ties and hemostats; inadequate tension results 
in blood loss during this step and/or vessel tearing). When making the same incision on 
the artery, the cut should not exceed 1/3 of the artery circumference in order to avoid 
tearing (Callaway and Logue 2009). Gently stretch the incision wide enough so that the 
cannula can fit through the opening ‘snugly’ and will not accidently slip back out (the 
vein is more flexible and prone to tearing compared to the artery). Also, periodically 
check for vessel desiccation and add sterile saline as needed. Carefully and gently insert 
the heparinized-saline filled cannula (primed) approximately 2cm into the vein (2cm 
should be indicated by a black mark on the cannula itself prior to sterilization). Cannula 
advancement should be stopped or adjusted based on blood flow resistance (this is very 
critical when cannulating the artery due to high blood pressure). Slip cannula as fully as 
possible into the vessel. It is fine if  the cannula is not inserted 2cm into the vessel, but 
enough so that the cannula will not slip out. While using one hand to hold the cannula in 
place with the fine tip forceps, use the other free hand to tie down the silk tie onto the 
vein containing the cannula (hint: use the thumb and index finger of the free hand to hold 
the thread and carefully stretch length-wise to the rat until “snug” fit). As soon as the tie 
is secured to the vein and cannula tubing, make at least 2-3 additional throws (knots) to 
secure cannula. Next, tie the proximal end of the cannula to the vein and make 2-3 
throws. Repeat the aforementioned steps for arterial cannulation with the exception of 
starting with the proximal end first. Be very careful of high blood pressure in the artery. 
If there is a lot of resistance, then carefully flush with hep-saline using one hand while
grasping the cannula with forceps. Once the artery has been cannulated, check for 
adequate blood flow with small hep-saline flush. Blood should flow back toward the 
hep-saline syringe (however, do not allow blood to flow back up the syringe or into the 
pressure transducer).
Mean arterial blood pressure (MABP) will be measured via an indwelling femoral 
arterial catheter connected to a pre-calibrated Statham pressure transducer and will be 
recorded continuously. Arterial blood gases and pH, and plasma glucose, will be 
measured in microsamples (75 -10 0^L ) (Total cumulative volume from repeated sampling 
not to exceed 1.5mL).
2.9.4. Induction of ACA and Positive End-Expiratory Pressure (PEEP)
Immediately paralyze rat after cannulation by injecting 0.3mL vecuronium 
(1mg/mL) IV and watch to see that animal stops breathing. Immediately connect 
endotracheal catheter to ventilator (Harvard Apparatus ‘6 8 3 ’ Model Small Animal 
Ventilator or UGO Basile 7025 Rodent Ventilator). Air is humidified with mucomist 
(10%  acetylcysteine; Roxane laboratories, Cincinnati, OH; NDC 0054-3027-02) with 
pressure dampener rebreathe bag attached and set approximately to 60 rpm, stroke 
volume (SV ) is adjusted based on body weight (1m L/100g up to 300g max) and typically 
set between 2.0-3.2m L— anything set over 3.2mL could potentially damage or rupture the 
lungs. SV < 2.0mL/min does not provide adequate expansion of the lung for efficient
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gas exchange. Immediately decrease isoflurane to 0.5%  and sample blood gas. Adjust 
blood gas values to within normal physiological values for Po 2 , Pco 2 , and pH: flow rate 
of O2 is typically between 450-500mL/min and N 2 O is 1L/min (a 30:70 mixture of 
O2/N2 O) while isoflurane is typically maintained between 1.2-1.8%  flow rate; Rat Pco2 : 
35-40 and Rat Po2 : 100-130. Monitor rectal and head temperature (T rec and T temporalis ) 
until between 36.5-37.5°C.
At least 10 min after previous injection of vecuronium, inject vec (0.3m L of 
1mg/mL, IV) and FLUSH immediately with 0.3mL hep-sal (6.7 IU/mL), 2 min later 
disconnect ventilator. OBSERVE THAT ANIMAL IS NOT BREATHING. If animal 
continues to breathe (>2 breaths) inject another 0.3mL of vec, wait 10min, and repeat this 
step. If animal is not breathing prepare to resuscitate . (Connect 2 way luer adapter 
primed with Epi (5ug/mL) and NaHCO 3 (8 .4% ) for immediately delivery; change BP 
scale to 0-50; turn off isoflurane vaporizer; turn N 2 O flow meter to 0 and increase O 2 to 
2L/min and respiratory rate to 80 bpm. Record the last vec injection and start of CA or 
sham procedure and Resuscitation in LabScribe in the marks entry.
2.9.5. Cardiopulmonary Resuscitation (CPR)
Resuscitate by reconnecting rat back to the ventilator, enter “Res” on LabScribe 
in the marks entry, and immediately inject 1mL/kg fresh Epi (5ug/kg or 10ug/kg; W est­
ward, Epinephrine Injection, USP). Apply rapid manual chest compressions at a rate of
200/min to the base of the heart (Fig. 2 .4 ) until BP is at least 50 mm Hg and is 
maintained by spontaneously beating heart for at least 10 sec. If not resuscitated after 1 
min, give a second Epi dose. Epi administration should help provide ventricular 
contraction via direct myocardial stimulation and increase heart rate (Westfall et. al., 
2006). Once heart rate (H R ) is spontaneous and MABP > 50 mm Hg, immediately inject 
0.9 cc NaHCO3 . Resuscitation is discontinued after 2 min if  animal fails to maintain a 
spontaneously beating heart. Squishing sounds from lung during manual compression is 
indication of lung injury and may be used as a basis for euthanasia.
Sample blood gases at 10 min of spontaneous circulation (ROSC). After 10 min 
of ROSC, decrease respiratory rate from 80 to approx. 60 bpm and % O2 from 100% to 
70%  in a mixture with N 2 O. Continue to sample arterial blood gases (with at least 10 
min. between sampling times) until animal maintains stable values for pH, Pco 2 , and Po 2  
within normal range for this species. Correct acid-base status with sodium bicarbonate 
and/or the ventilator settings. (Base excess should be >0; 5-10 is normal). If pH<7.3 
inject NaHCO3 to adjust pH. If pH is still too low, RR might need to be increased in 
order to blow off CO2 . Stroke volume must be >2mL, to achieve adequate lung 
expansion.
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2.9.6. Cannulation Removal and Extubation
Once blood gases are normal, remove arterial and venous catheters by tying off 
artery and vein with 3 throws of 3-0 silk suture. Use Close skin with 3-O prolene, simple 
interrupted stitch; at least 3 throws. Inject Sterile Saline (1mL/kg, intraperitoneally [IP]). 
Insert IPTT-300 temperature transponder tag (Bio Medic Data Systems, Inc. [BMDS], 
Seaford, Delaware; Reorder# IPTT-300) subcutaneously (SC) between the shoulder 
blades, if  not already present. Leave on ventilator until spontaneous breathing begins to 
fight ventilator. Maintain at 37.0°C (between 36.5 and 37.5°C) for at least 60 min. 
Animals not able to maintain 36-37.5°C body temperature without heat lamps are placed 
in a humidified neonatal incubator set at 29 .0oC for 12-24hr or until animals regain 
normal thermoregulation.
Place animal in postoperative cage (with underpad and water bottle provided) and 
put in neonatal incubator set to 29°C once animal spits out endotracheal catheter on their 
own (or with some help by the surgeon if catheter is still lodged in throat due to mucus 
secretions). For the next 8-16 hours directly after resuscitation, DO NOT FEED or 
PROVIDE ANY FOOD in the recovering animal’s cage as this can sometimes lead to 
accidental death (e.g. their face can be submerged in their food while trying to eat while 
in a very comatose state and result in an “accidental asphyxiation”). Dehydration will be 
prevented by giving an IP sterile saline injection (1mL/100g body weight [b.w .]) prior to 
placing recovering animal inside the incubator (this should be done before temperature
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transponder is implanted at the end of surgery) and by also placing a water bottle in their 
cage.
Copy and file anesthesia records, surgery logs, data sheets, animal care log sheets, 
and neurological deficit scores (NDS) sheets into IACUC animal quarters and vet 
services binders located in animal quarters office, B6. Enter blood gas data into Excel, 
back up LabScribe files to both laptop and designated external hard drive. Monitor a 
minimum of 3 times daily per post-op care below until animal shows signs of voluntary 
feeding, cleaning, and is able to easily move around in cage on their own. Record body 
temp daily and inspect/clean sutures daily up to 7 days and at regular intervals thereafter. 
Remove sutures at 10-12 days.
2.9.7. Post-Operative Care
Daily feeding, cleaning, and temperature checks will be done on post-operative 
animals for at least one week after surgery, if not more if doing a longer term study. 
Wounds are cleaned with diluted (tea colored) betadine and a piece of gauze once per day 
for 3 days and inspected thereafter. Between 8-16 hours after surgery, signs of distress 
are to be observed in the rat while they are housed in the neonatal incubator. Rats should 
also be fed a liquid diet at this time (and a minimum of 3 times per day for the first few 
days until animal can eat on their own and maintains a healthy weight) using a “spoon­
feeding” technique even if  they are somewhat able to eat on their own (sometimes seen in 
some 6 min CA animals). Food will consist of a ~50:50 mixture of ground rodent chow
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and sucrose (food grade) and dissolved in tap water to make a dilute solution, resulting in 
a liquid soup mixture that is placed in a small petri dish for their consumption—usually 
use the bottom lid of the petri dish in order to avoid any necessary spills during feeding 
(see Fig. 2.6). If unable to self-feed, animals will be then be fed by gavage (1mL/100g 
b.w.) a minimum of 3 times per day (stomach volume ~ 3 ml in a 300g rat and gastric 
emptying time is about 45-60 min). These animals will be fed the diluted chow soup 
mixture drawn into a 3 cc syringe using a curved gavage needle («  11 cm long, 16ga x 1 
^ ”, blunt-ended, with bulb diameter of 4.0 mm (Waynforth and Flecknell 1992)).
Caution should be given to avoid clogging the gavage needle by suctioning up the liquid 
portion of the chow soup and avoiding suctioning up food particulates. “Spoon-feeding” 
will be done for animals showing any “swallowing” response. Place the tip of the gavage 
needle in their mouth barely past their teeth, and gently push the liquid food contents 
down in their mouth while waiting for their “swallowing” response. Rats should only 
consume as much as food as they will swallow (usually a strong appetite response 
immediately after the 8-16hr post-operative period, but dependent on individual 
variation). Animals not consuming at least 3ml/100g are fed by gavage. Beginning at 8- 
16hr post-op body temperature is recorded and animals are monitored for neurological 
impairment and scored per “Neurological Deficit Scores (N D S)” daily for the first 7 days 
and at regular intervals thereafter (e.g. for 22-day studies, NDS done every 3 days after 
day 7: Day 10, Day 13, Day 16, Day 19, and Day 21).
Although the severity of brain damage is not expected to produce death, inter­
animal variation makes death a possibility. Animals will be monitored, fed by gavage
(1m L/100g b.w.) and given supportive care as needed at least 3 times per day. Severity 
of brain damage may be assessed from neurological examination. Animals showing 
severe neurological impairment including coma should not be euthanized because 
eliminating most severely affected individuals will bias final assessment of histology.
The number of animals that die will be noted, however, these animals are excluded from 
histological examination of tissue because death does not allow for in situ fixation of the 
tissue. Vet services should be contacted in case of complications encountered during 
regular work hours or during after-hour, weekend or holiday care (e.g. wound infection or 
unusual behavior by animal).
2.9.8. Neurological Deficit Assessment: Behavioral Scoring, Perfusion, &  Histology
A neurological deficit score (NDS) will be performed daily for 7 days (or up to 22 
days if  a long-term study) after global cerebral ischemia (see A ppendix E for NDS 
worksheet). The total NDS consists of five components: consciousness and respiration, 
cranial nerve function, motor function, sensory function and coordination (leg/tail 
movement, cleaning, depth perception, righting reflex) and for motor and sensory 
function as previously described (Katz et al., 1995). The NDS range is a scale between 0 
(normal function) to 100 (brain dead). To have consistency in results between animals, 
NDS scores should be done by one person. NDS scores may also be taken 1 or 2hr after 
resuscitation to assess acute impairment.
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Neurohistopathology requires a minimum of 3 days to develop and is more 
apparent 7 days after ROSC. Neuroscores are collected up until animals are euthanized 
and brains collected for histopathology. Brains are perfused in situ via the heart using 
filtered saline (0.9%  saline; 9g NaCl/1000mL diH2O) for 1 min. Saline is followed 
immediately by 19 min. of FAM (100m L of 36%  formaldehyde, 100mL of 99.5%  acetic 
acid-glacial, &  800mL 99.8%  methanol per 1 Liter of FAM solution). Briefly, animals 
are anesthetized with isoflurane (5%  mixed with 100% medical [Rx] grade O2 gas, 
delivered at 1.5L/min; and maintained at a surgical plane at approximately 3% 
isoflurane). The Thoracic cavity is opened, the descending aorta clamped, the right 
atrium is punctured, and solution is then delivered into the left ventricle using a peristaltic 
pump (MasterFlex® Economy Drive “Easy-Load®” Pump, Model# 77200-62; 
MasterFlex® Precision Tubing, Lot #  109548, Reorder #  06429-15) at a rate of « 
80mL/min for rats weighing between 250-350g.
After fixation is complete (20 min. total), animals are decapitated using a rodent 
sized guillotine and heads are placed in a jar containing FAM solution for 24hr at 4°C. 
After 24hr, heads are rinsed with distilled H 2O for 10-15 min (to relieve FAM odor and 
prepare for next solution), brains are carefully removed and placed into a 45 mL 
centrifuge tube containing approximately 25 mL of FAM for another 24hr at 4°C. Brains 
are placed in 70%  ethanol solution and stored indefinitely at 4°C until ready to be 
trimmed and sectioned into coronal brain blocks for paraffin embedding.
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Using a brain matrix apparatus (Braintree Scientific Inc., Braintree, MA; B5-A 
6000C ), the brain is trimmed into two 3 mm section blocks for the hippocampus and 
striatum regions (-3.80 mm from bregma; -1.80 to -0.80 mm from Bregma, respectively; 
Fig. 2.8). Coronal sections of 8p,m were stained with hematoxylin and eosin (see 
A ppendix H , I). Rat brain sections examined contained the hippocampus at 
approximately -3.8 mm posterior to bregma. Immediately placed into a cassette (for 
hippocampus placed caudal-side down and for striatum placed rostral-side down inside 
cassette), then into a jar filled with 70%  ethanol until ready for embedding. The 
embedding process is as follows: (30 min for each) 70%  isopropyl alcohol x 2, 80% 
isopropyl alcohol x 1, 95%  isopropyl alcohol x 2, 100% isopropyl alcohol x 3, Toluene x 
2 paraffin 56°C x 2, and 20 min in vacuum embedder. Slides are stained in Hematoxylin 
for 5 min. and in eosin for 1 min. (see A ppendix I). The whole cycle should take 
approximately 22 hours to complete.
2.10. ACA Troubleshooting
Table 2.3 provides a detailed list of various problems that can arise during the ACA 
surgical procedure and post-operative care. The most common problems that occur 
during ACA include the following: ineffective anesthesia, inadequate oxygenation after 
ROSC, difficulty inserting endotracheal catheter into trachea, swollen epiglottis/vocal 
cords during intubation, arterial/venous clotting during femoral cannulation, poor 
cannulation thread tension, inability to resuscitate animal, mucous in lungs after
44
45
resuscitation, too low/high temporalis/rectal temperatures, no ECG/MABP signal in 
LabScribe Acquisition software, excessive porphyrin secretion, wound infection of the 
cannulation site during post-care, etc.
2.11. Conclusion
In conclusion, the ACA rat model provides reproducible brain injury in a 
controlled laboratory setting and mimics neuronal injury seen clinically (especially in 
perinatal/pediatric populations). The ACA model is easier to implement than the 4VO 
and 2VO with hypotension animal models and provides a wider therapeutic window to 
investigate neuronal pathology. Although the ACA model is a great tool for studying the 
excitotoxic mechanisms of global cerebral ischemia, there are some disadvantages as 
well. The ACA model is a very laborious and time-consuming process from surgical 
implementation and technique to intensive post-operative animal care 1 week after CA 
injury.
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Table 2.1. Models o f Global Cerebral Ischemia
4 V O  A d v a n ta g e s
■ Reversible forebrain cerebral ischemia (rats)2.
■ Metabolic &  morphological studies
■ Can i mpleme nt o n awake, freely movi ng, o r anesthetized rats'*5.
■ 50-75% success rate2.
■ Useful to test drugs for neuroprotective activity.
■ Cell death closely mimics human ischemia2.
■ Opportunity to measure physiological without use of anesthesia or 
hypotension1'5.
4 V O  D isad va n tag es
■ Rat strain choice is critical (wistar preferred; not all strains 
adaptable)1AJ,
11 arder to i m pie ment (2-d ay proced u re)
■ H istopathology variability from proeedure, especially 
between animal strains and ischemia duration2'5,
■ Difficult to dete nn i ne vertebral artery' location a nd 
occlusion of these vessels are critical to outcome success2, 
U nsucoes s fu 1 outcome ooc urs i n 2 5% rats due to 
respiratory failure1-
Inconsistency between outcome yields; 50% survival to 
first-stage procedure even in best-ca.se scenario1.
2V O  w /hypa tension  A d van tag es 2 V O  w /hvpo  tension  D isad van tag es
Model of fore bra in ischemia2'4.
■ Suitable for chronic survival studies2.
Produces selective and delayed neuronal death and reliable injury' 
for behavioral and histological as.sesstment5.
■ 3 i m pie r s urgical preparationthan 4VCr.
Fast onset o f ischemia and reperfusion".
■ Sufficient forebrain ischemia from hypotension (50 mmHg via 
bleeding or hemorrhage J*.
Physiological variability' is expected from the procedure 
and beyond surgeon's control5.
Anesthesia and hy pote nsiondrug-inte taction canconfound 
data results2.
■ Minor fluctuations around 50mm Hg from reduced blood 
flow can produce variable neuropathological results1.
■ Outcome success dependent upon adequate hypotension 
production*.
■ 13eha vioral changes s ubseq ne nt of oec 1 usion ca nnot be 
assessed since this model cannot be used in awake 
animals1.
1. O'Neill M J, Clemens JA . Rodent models of global cerebral ischemia. Curr Protoc Neurosci. 2001;Chapter9:Unit9 5.
2. Traystman RJ, Animal models of focal and global cerebral ischemia, liar J, 2003;44(2):85-95,
3. Chen JX , ZaoC.; Xu, Xiao-Ming; and Zhang, John 1 i., editor. Animal Models of Acute Neurological Injuries2009.
4. Ginsberg MD, Busto R. Rodent models of cerebral ischemia. Stroke. 1989; 20( 12): 1627-42.
5. Small O l.. Buchan AM. Animal models, Br Med Bull, 2000;5d<2):307-17,
[ ‘ab le  2.1 C o n tin u e d ...
A ( ’A A d v a n t a g e s
■ Produces complete, 'true’ global ischemia in both brain and 
peripheral organs'.
■ Easy to  implement &  control physiologically,
■ Not necessary to monitor cerebral b lood flow,
■ Histological damage seen after several days from injury (first
appears 1-2 days after resuscitation up to 6 weeks later) ’.
Relatively cost-effective in terms small animal (rodent) use, supply, 
and duration of surgery2, J,
Minimally invasive.
■ Only about < \%of rats will develop ventricular fibrillation during 
cardiac arrest increasing CPR survival'.
■ Validated model in terms o f severe neurological deficit production 
similar to human disease resolved partially or completely over a 
couple of days5.
■ Reproducible &  reliable injury5,
■ Ac ute ti me i nvestigat io n of i nj my.
■ Able to use sophisticated neurosensory and motor behavior 
assessment as a measure of ischemic injury'outcome2.
■ M i m ics cl i n iea I sccna rios inhuman di seases (e.g.L bi rth asp by x ia1 , 
transient coma, sensorimotor deficits, hypoxemia, acidosis, 
choking, systemic inflammation, hyperglycemia, hypereorisolemia. 
near-drowning, and neut-SlDS)J,
A (’A D isad van tag es
■ I .abor inten sive (e.g. post-operati ve care); not for high- 
throughput studies5.
■ General animal welfare (paralytics and no analgesics) 
concerns.
■ Results vary depending on experience of surgeonJ.
■ Not clinically similar to ventricular fibrillation, the most 
common cause o f CA in adults.
■ Post-operative rats may be in a coma for several days after 
cardiac arrest'.
■ Progressi ve weight loss during 111 week o f post -operative 
care is expected despite careful monitoring and feeding5.
■ Swelling can occur from multiple intubation attempts f»2) 
leading to respiratory problems or even mortality 
(especially after extubation)5.
■ Heath s gene ra I ly occur bet ween 1 ■ 5 days a tier res uscitation 
(e.g. secretion build-up)5.
■ Individual variation occurs between surgeons and surgical 
preparation involves multiple-steps'.
1. O’Neill M J, Clemens JA . Rodent models o f global cerebral ischemia. Curr Protoc Neurosci. 2001;Chapter9;Unit9 5.
2. Traystman RJ. Animal models of focal and global cerebral ischemia. liar J. 2003:44{ 2):85-95.
3. ChenJX, XaoC.; Xu, Xiao-Ming; and Zhang, John H., editor. Animal Models of Acute Neurological Injuries2009.
4. Ginsberg MD, Busto R. Rodent models of cerebral ischemia. Stroke. 1989;20( 12): 162742.
5. Small DL, Buchan AM. Animal models. Br Med Bull. 2000;56(2):307-17.
Table 2,2, Setup and types of1 packs used during asphyxia! cardiac arrest surgery.
Early Setup__________________________________________________________________________________________________________________________
Color-coded svrinees Irir Lnieclahles: 5 x Icc sterile syripges |2 filled with beparLnL'ed-saline, I liar Vec, I forNaIICG.3, and I liar Epinephrine); I x 10 cc sterile 
syrmge 111 led with sterile sal me (see Append is Dl: e.g. of color-coding: red = Bp i, orange = hep-sal, green = sal me, yellow = vec, & white = sodium bicarbonate
□ I-1 Surgical Tape(Durapore™, I ”x IOyd [2.SanmS.Imj REF 1538-1}
□ Rodent Intubation, tilting workstand (www.hailowell .com; No, OOOA3467)____________________________________________________________________
liHiihaliun Pack (aufocln vet!)___________________________________________________________________________________________________________________
□ 2x15 " outturn sutures (fo rsecurmg catheter to lip alter mtilbatioji}
□ I x 4 ’ ’ straLgJit-edge forceps
Rat speculum tplastie), autocalveahle (www.hal lowed .conn No. 2 10 A3496) aitaclts to head o f otoscope)
□ Mouse lidooaine applicator (www.hallowvl Loom; No. 210A3496)
□ Needle Holder
Custom made Rl uni-end, hen i .5”  needle (may bend, blunt and. file needle from IV catheter used liir endotracheal catheter) or purchase tom  Popper &  Sons,
 17TWx3 custom blunt popper biomedioal needle (catf 7427, httpi.vpopperandsons.com/index.asp)___________________________________________________
t ’jiim ilu fiiin  I ' in k (ju lucluvcd and goes inxklr f ’A Hiiriiicul park)
2-3 x 3-1) Prole tie sutures (Bthiootl* 3-R, 19mm diameter, IR" [45cm] polypropylene culling suture: rS-2, R665: lionah.sorhahle) toptioilal: i f  expired, autoclave 
and place in packi i f  sterile can open during surgery)
□  4-0 x 3-1> (or 6-0) black silk suture tlircad (U iP  3/0 Silk Suture: Havel’s Inc; 100 yd waxed, 47-ASB-54; LOT: 6253); used f t *  tying cannula to vessel
Gardiac Arrest Surgical Tool PacMautoelaved)_____________________________________________________________________________________________
Adson-Browii Forcepts iwww.rmescienc.omn, FST 11627-12) lor bolding skin during initial cannulalion skin incision
□ Small “vessel" scissors (protect delicate tip with tip o f a smal I pipette; www.rmescience.cotn, FST 1501X1-(10)
"Dumont”  45s, #5(45 sharp, dumoxel std. tip forceps (protect with tip o f yellow pipette); (www.ruicscience.com: FST 11251-25); used to grasp delicate vessel 
while inserting cannula)
□ Fine, straight rat-toothed foroeps (Miltex 6-106; --Inun or 1/16" width x 5 inches long)
□ 90° curved hemostats (5.5 uidi loitg; Roboz R5 7291}
2 x FI inch smooth inner surface cld ved |-90°I forceps |ln r  leasing apart and holding vesselsi; t Paragon dE004-96 h t t p w w'w.panq’onmedical.coin.'I
□ Curved, hlunt-end scissors for cutting skin and separating skin and muscle (Roboz; RS-6891)
□ 4 inch rat tooth forceps for holding cannula and 2 'A”  forceps (rough)
I2” x l2 ”  clear, sterile plastic mouse drape (Sterile Boon-O-Fak111 . Gepco*' Reorder# 1212CPSTF); (not autoclaved with packdt added to pack prior when openuiE 
into sterile field)
□ (O pt tonal} Y-Lucr adapkT ( for qu ick del h w y  o f EpFNaHCO 3 during resuscitati ore WWW.qos ina.com, Qos ina 8 3016)
□ irile o f cotton tipped applicators (Puritan11’. 16”  [ I5cju|, RBF 806 -EX.': www.puntanmedproducts.coml 
Small, “ Iris”  scissors idelieate.strai pledge, 10.5cm; vvww.finescience.com; FST 14060-10) lor cutting knots
□ PiJe o f gauze sponges (8 Ply. Kendall Curity™, 2"x2"[5emx5cm), REF 2146, non-sterile, USP Type II Gauze)
2 x microscope handle covers (sterile stireical masks w/earloops work best: ’ 'DuPont1'" ' ’. Sierra® General Mask [’ ml No. 7 33-OE3L'-0(J-0 3001313. l_ot No. 
M00O75R0K}
Table 2.3. Troubleshooting guide for asphyxia! cardiac arresimodel.
A M F.ST IIF .S IA
l>iflKLult\ mmntammg or in d jd ig  a ‘’deep" ggough unes Unwin in rats,
• If  the rat is moving around or fits against the ventilator, then slightly increase anesthesia delivery, isoflurane should be set at the lowest 
possible delivery setting that causes the rat to be sedated (any where between 1.0-2. J%  isoflurane delivery on vaporizer unit works best 
to maintain anesthesia for 230-3(H)g rats). ] soflurane can even be increased to 2.5-3.0% to allow for ''deeper anesthesia’', but should not 
be set for longer than 2 minutes at a time because an overdose can accidently oeeur(it is imperative to watch for breathing patterns and 
consistency). ECG
Noisy Signals or m> ECU displayed on I, ah Scribe IhiLi A ii|uRilimi Software.
• Make sure ECG leads are placed subcutaneously in hind and tdrelimbs (and not in the muscle). Reinsert ECG leads in different spots 
until a signal is displayed (won’t get signal even if only one lead is wrongly positioned). Turnoff heat lamps prior to initial insertion of 
leads (lamps increase noise on ECG and interfere with LabScribe Data Acquisition software) there should still be a signal, albeit a
* noisy1 signal). Make sure the settings for “ECG transducer box" are set to 0.1 or I . I cads should be placed with little to no movement 
(be still as possible to avoid signal interference).
C A M M U LA TIO M
IHffictilG advancing eimnulii mdtle Lirtcruil u issvl.
• Carefully loosen tension of knots (it might be too tight): place smooth curved hemostats (45° angle) underneath knot just above cannula 
tubing (add saline to help loosen knot). This lightly loosens knot without risk of cannula slipping out from high HP, but enhances 
natural flow. Correct tension is CRUC IAL for obtaining a successful cannulation.
Difficult inserting cannula.
• C hec k te nsion of cann ula thread used to c rease a nd occl ude. Re adj ust te nsio n i f nece ssary, to ful ly occl ud e flow through cannula. A I so 
check the siye of vessel incision (hole)—should be large enough for cannula to fit through. Tip: bevel cannula end (cut at a slant angle) 
and insert cannula through hole with bevel tip facing toward opening. This should make it easier to insert cannula through vessel.
I liable to obtain any/egough blood from artery for blond lzlis ■-Lini|ile jjjflh  ■ok.
• Possible clot in artery flush with Hep arini/od-saline; check cannula tubing'pressure transducer for air bubbles and'dr leaks.
K F.SU SC fTA T IO M  (U O S Q
Rat tinriisponduL to C PR  i niniuml heart inusshlio) ns i nil i ruled mi LuhScrilx1 data iegujskmn software.
• Move temperature-controlled heat lamps s? 2-3 min, prior to resuscitation (prevents overheating of the heart &  more effective CPR; 
hypothermia is very protective against CA), Ensure proper index finger &  thumb placement directly on heart (not lungs). Readjust 
hand/finger placement until a ‘strong’ response (M ABP spikes) occurs during CPR. Minimize the distance between thumb and index 
finger on heart. Any lung damage will decrease outcome of survival.
\ cry low pi I friuii bjood ems sum pie.
• ] nject an additional NaHCOi (sodium bicarbonate) based off of I ml./kg (e.g. if rat weighs 280g, give 0 2 8  oc or mL o f  NlaHf’0-,) 
depending on blood gas pH value.
T F M P F R A T L JK F
Error message or "nlV* no O m ^ temp cun in ill i t s  won't turn mi.
• Temperature probes for that specific temp controller unit has "died" and needs to be replaced and recalibrated (Calibration: temperature 
and time controlled tests to ensure 0,1-0,2^ std, error b/w temporal is and rectal probes).
Low he ml gjid/or red a I (enireralui e readings.
• Temporalis probe for head temp should be placed correctly inside the temporalis muscle (not Subcutaneous ly). Rectal probe should be
placed approx, 3-4 cm inside the anus, Adj ust heat lamps and place closer to rat (no >(> in, so as to not bum skin).
Too hinh (hoi).
• Move lamps (and other heat sources) further away from body. Best to avoid overheating by constantly monitoring temp.
Tip: it is much easier and faster to warm a rat than it is to cool the rat down.
Table 2.3 Continued*..
labile 2 3  C o n tin u e d ...
IN T U BA T IO N
Difficulty iimiiniling Lininiul.
• IX ) NOT ATTEMPT TO INTUBATE MORE THAN TWICE (otherwise epiglottis will become swollen and be more likely to close up 
tighter due to irritation/ inflammat ion). Make sure rat is deeply anesthetized (e,g, most rats weighing 240-300g generally require 2 min, of 
Isoflurane set at 2-2.5%). If  a strong gag (uvula) re fie x occurs, then rat is not deeply anesthetized for proper intubation.
Syreljenness and/or bleeding around yocgjcords.
• Properly lubricate laryngeal folds surrounding epiglottis (and epiglottis too) prior to first intubation attempt so as to not easily irritate 
area—vocal cords are very sensitive and prone to agitation with repeated endotracheal catheter insertion. Use cotton swabs to gently stop 
bleeding. Reapply lubricate gel if necessary and avoid over-lubrication, which can block the animal's airway passage and cause hypoxia 
onset.
^ t u i i 'd iv 11 or sou n d s o ccu r  in m l d u r in g  [ntjjbgtijtn.
• "Squishy" or “gurgling" sounds occurring in rats while intubating generally means that their vocal chords and/or epiglottis has become 
irritated and/or intlamed (e,g, probably agitated from attempting to insert the endotracheal catheter). Make sure to put enough lidocaine gel 
on the lidocaine applicator BEFO RE applying to the laryngeal folds (the little whitish bands directly above the vocal chords). This should 
"numb1 the area enough so as to not cause a “ gagging reflex" in rat during intubation thus causing further trauma to the larynx area. If the 
rat is moving or has a "gagging reflex1 while you intubate, then slightly increase anesthesia delivery (2.0-2.5% isoflurane works best to 
maintain anesthesia in 23G-300g rats; 2.5-3.0% isoflurane works better for “deeper anesthesia” but do not set for longer than 2 minutes at a 
time because an overdose can occur). The rat should have consistently slow, even, and deep breaths to ensure a good intubation response.
f u  n u n s u c c e s s f u l  i n t u f r g t i o f  a t tg j lg M y  o c c u r .
• In order to increase the li kelihood of recovery from asphyx ial cardiac attest and resuscitation, it is best to only attempt two endotracheal
intubation attempts—moie than that increases the chances that the rat may not survive cardiac arrest and resuscitation. Another option is to
have two rats available for any given surgery-meaning that if you fail intubation with one rat after two tries, then you will have another rat
available to use. After two failed intubation attempts, the rat can be returned to its home cage (after it recovers from anesthesia, usually 
-10-15 min,) and allowed to recover in about 1-2 weeks so that it can be used forCA surgery again (the throat area should have healed 
within that period of time).
OnO
POST-OPERATIVE CARE
There i1* littlM In dark reddish urine am lnrtviir sekjreiir.iri.^  from e\es. iiuse. rnuuUi. and :nur that annuiir In hi? simijar jooklngjj)
Wood.
• These are ca I led porphyrins w hich have a " blood-1 i ke "a ppea ranee, but are not b  lood. Porphyri n production is a direct in dicuto r of 
physiological stress experienced by an animal. This generally occurs within the first 3 days or so o f recovery from cardiac arrest. He 
attentive to secretions and rat behavior during this time and give extra supportive care (e.g. use a wet gau/o to gently remove secretions 
from eyes, nose, mouth, and penis) as needed.
kill‘d hehiivinr K ygry uteri and jmtabje; u*n (Iiffie11] 1 <o handle w hik*“inoun-feedm»" usmg E?a>HE?e nvvrih1 (e.sr. ^nuiimi and
t'i-jh< sm il'd  feeding).
• I f rat i s ve ry ambu latory and tights d u ri ng hand I i ng a nd/or feed i ng, r his i s a good i nd icator that the rat appears to be "fee I i ng better” 
and doesn't need as much supportive care. Rat should be placed on a dry chow diet or given chow soup (5G:5Gchow: sugar mix in tap 
water) in a petri dish to administer self-feeding. If rat is unable to eat much on his own or fights a little bit, be sure to hold animal in a  
gentle but firm grip (e.g. place hands around and underneath rat's forelimbs famipits| tor a 'stronger' grip) and place the bulb o f the 
gavage needle into the mouth and let the rat "suck up’’ the liquid chow on their own, G EN TLY and SLOWLY release con tents into the 
mouth barely past the rat’s teeth and NOT DOWN THE THROAT (be sure to watch for anim al’s own swallowing reflex for clues 
when to increase or decrease amount o f  feedi ng).
InfeviiniL of suture area on cannujjjted {eg.
• ALWAYS check wound area and clean with dilute betadine solution ON LY  as often as possi ble, but at least once per day. If infection 
occurs, be sure to clean the area even more so with betadine. If the infection appears to be "glossy” and/or a darker color, then 
immediately consult with Vet Services as how to further proceed (Baytril, IP, may need to be given depending on severity' o f infection 
and veterinary' oversight).
Tabic 2.3 Continued*-*
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Figure 2.1. A comparison shown between focal (stroke) and global (asphyxial cardiac 
arrest) cerebral ischemia models. (A) Focal models: i.) Thrombotic or embolic stroke, or 
ii.) Hemorrhagic stroke. (B) Global ischemia models: i.) four vessel occlusion (4VO), ii.) 
two vessel occlusion with hypotension (2VO), and iii.) Asphyxial cardiac arrest (ACA).
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Figure 2.2. Cardiac arrest facility and equipment setup (a-f) shown. Instrumentation 
(a) includes a mechanical ventilator (b), a surgical microscope (c), tray for surgical 
instruments (d), an isoflurane vaporizer unit (e) and iSTAT analyzer (f).
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Figure 2.3. Rat intubation stand (a), endotracheal intubation tools and otoscope (b), and 
animal preparation for recording physiological vitals (ECG, temperature, and intubation) prior 
to induction of asphyxial cardiac arrest (c-d).
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Figure 2.4. Cannulation equipment, diagram, and procedure shown. Sterile tips are oriented 
towards the center of the sterile field (a). Orientation of femoral artery and nerves (b). Gentle 
removal of fascia connective tissue reveals the location of the right femoral artery and vein (c). 
Insertion of arterial cannula into the r. femoral arterial (d) using fine tip curved forceps (e). 
Completed femoral artery and vein cannulation (f) with tension applied using 3-0 silk suture 
thread to each vessel.
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Figure 2.5. Finger position and hand movement shown for the implementation of manual 
chest compressions during resuscitation of a rat. (A) Black marks indicate index finger and 
thumb position on rat heart for proper manual chest compressions. (B) (Optional) The left 
index finger and left thumb can also be used to support the direction of chest compressions 
made by the right hand. (C) Initial left hand and right hand index finger and thumb 
placement during CPR. The distance between the right thumb and right index finger on heart 
should be minimized in order to ensure the best CPR outcome. (D) Directional movement 
shown for effective chest compressions. The right index finger and right thumb should move 
in an “inward-outward” position followed by an “upward” motion starting at the base of the 
heart where the ventricle is to effectively pump blood back into the heart from the ventricles 
up through the atria. (E-F) Finger chest compression movement is shown. Right thumb and 
right index finger should move in an “upward-outward” sliding motion (E) starting at the 
apex of the heart (bottom left ventricle) and sliding towards the base of the heart (up to the 
atria) (F) to pump blood back into the atria of the heart.
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Figure 2.6. Post-operative care food and housing for rats recovering from post-cardiac 
arrest (CA) surgery. (A) Neonatal incubator used to house rats 24hr after resuscitation. 
(B) Post-op “recovery” cage consisting of a water bottle, an underpad, and cotton. (C) 
(Left) temperature and humidity monitor for neonatal incubator; (right) Rats unable to 
feed on their own and/or are unable to adequately consume enough food are fed a soupy 
mixture consisting of 50:50 dry rodent chow (finely grounded) and table sugar mixed 
with water. Chow soup is then placed in a petri dish for consumption. (D) Regular 
housing consisting of wood shavings for rats prior to cardiac arrest surgery and/or after 
recovery from CA once animal shows signs of normal self-care (e.g. self-feeding, 
grooming, hiding under padding, etc.).
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Figure 2.7. Perfusion equipment and procedure used to collect rat brains necessary for 
neurohistopathology assessment. (A) Perfusion Equipment: Biosafety hood with air 
filters, perfusion pump system (Master Flex Precision Tubing; Lot # 109548), and 
perfusion tray (9x13inch plastic pan with slits) which allows for drainage of blood and 
solutions (filtered saline solution [9g NaCl/1L diH2O]; ~ 3-4L of FAM solution [Per 1- 
liter: 100mL 36% Formaldehyde, 100mL 99.5% acetic acid glacial, 800mL 99.8% 
methanol]), and surgical tools (blunt-tip surgical scissors, 2 x hemostats, sharp-tip small 
iris scissors, rougeurs. (B) Perfusion Procedure: i.) Anesthetize with 5% isoflurane 
(<2min), ii.) Maintain rat on 2-3% isoflurane to ensure deep anesthesia (4-8min), iii.) Cut 
directly below xiphoid process & cut in a “V-shape” formation along the ribcage to 
expose the heart and lungs, iv.) Use a hemostat to clamp off descending aorta, v.) Insert 
18ga needle into left ventricle, vi.) Use iris scissors to cut a small hole in right atrium, 
vii.) Set perfusion pump to “2” & fix brain with saline for 2min ^  immediately fix with 
FAM (19min), viii.) Quickly decapitate rat with guillotine & use rougeurs to remove 
surrounding muscle near brain, ix.) Store head in FAM jar (24hr), x.) Carefully remove 
brain & store in FAM (24hr), xi.) Rinse brain w/diH2O & store in 70% ethanol until 
ready for trim & paraffin embedding.
69
Figure 2.8. Neurohistopathology hippocampus coronal brains sections of rat for neurological 
deficit severity assessment. A.) Schematic shown for quantifying cell counts in a rat brain 
(hippocampus, HPC). B.) Sample of “healthy” neurons in a naive rat versus “ischemic”
(pyknotic) neurons in a cardiac arrest rat in the CA1 region of the hippocampus in rat brain.
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Figure 2.9. Microscope equipment assessment of histopathology (neuronal deficit expressed 
as the number of “healthy” [normal] hippocampal neurons per mm of CA1). A.) Computer, 
Nikon Eclipse 80i Upright microscope, and MetaMorph Software version 7.1.2.0 used for 
neuronal cell count analysis of rat neurons. B.) Close-up view of CA1 hippocampal “healthy 
(normal)” neurons in rats. C.) CA1 HPC neuron counts shown in red.
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C H A P T E R  3
D -cycloserine (D C S ) A c tiv atio n  of N -m e th y l-D -a sp a rta te  R ecep to rs  
(N M D A R ) 24  &  4 8 h r  A fte r A sphyxial C a rd ia c  A rre s t  (A C A ) H as No 
E ffect on H ip p o c am p a l CA1 N eu ro lo g ical D e fic its1
3.1. Abstract
Cardiac arrest (CA) results in severe neurological impairments and death 
through excitotoxicity, especially via hyperactivation of N-methyl-D-aspartate receptors 
(NMDAR). Partial NMDAR activation, however, can actually restore hippocampal 
synaptic plasticity by strengthening glutamatergic synapses, thus improving spatial 
learning and memory. We hypothesized that NMDAR channels were down-regulated 
from hours to days after resuscitation (ROSC, restoration of spontaneous circulation) 
from CA in Sprague dawley male rats (250-330g). Low dose D-cycloserine (DCS) 
(10mg/kg, IP), a partial NMDAR agonist, was administered in rats 24 and 48hr after 
6 or 8-min of asphyxial CA. Heart rate and blood pressure (mean, systolic, and 
diastolic) all showed a similar decline after 3-4min of CA regardless of duration. 
Neurological deficit scores (NDS) (at 2hr and daily for 7 days after CA) for 6 or 8-
1 Combs, Velva M., Crispell, Heather and Drew, Kelly L. (2013). D-cycloserine 
(DCS) Activation of N-methyl-D-aspartate Receptors (NMDAR) 24 &  48hr After 
Asphyxial Cardiac Arrest (ACA) Has No Effect on Hippocampal CA1 Neurological 
Deficits. Prepared for submission to the Journal o f Neurochemistry.
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min CA were significantly higher during the first 3 days of scoring (P<0.05, Tukey) 
and eventually declined near “0” . DCS had no effect on NDS. DCS also had no 
effect on normal CA1 hippocampal cell counts (P>0.05, Tukey). Although DCS 
showed no neurological improvement, further research on the specific NMDAR 
activation window post-CA injury could potentially offer clinical insight into CA 
treatment options.
3.2. Introduction
Recovery after cardiac arrest (CA) is generally very poor and usually results 
in death or severe neurological impairment due to global cerebral ischemia (restricted 
blood flow to the entire brain) and its hypoxic excitotoxic effects. Over 300,000 
people annually are affected by CA in the United States, whereby only 13,800 (4.6% ) 
survive, 42,000/70,000 (60 % ) of patients that are resuscitated die from brain injury, 
and only 2,100-7,000/70,000 (3-10% ) resume a somewhat normal lifestyle (Krause et 
al., 1986, Hypothermia after Cardiac Arrest Study, 2002, Nichol et al., 2 0 0 8 ). 
Neurological impairments include short-term memory loss (primarily affecting the 
CA1 hippocampus region of the brain), speech impairments, and motor and cognitive 
dysfunction. Hyperactivation of N-methyl-D-aspartate receptors (NMDAR) plays a 
major role in excitotoxic neuronal injury and has led to the need to use NMDAR 
antagonists in order to slow down or stop the rate of excitotoxic neuronal loss (Yaka
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et al., 2 0 0 7 ). Previous traumatic brain injury (TBI) research held the belief that 
blockage of NMDAR hyperactivation after injury would decrease neuronal death and 
improve recovery; however, clinical trials have failed to show any actual benefit of 
blocking NMDAR (Biegon et al., 2 0 0 4 ). There are three main reasons why these 
clinical trials may have failed in the past: 1) Hyperactivation of glutamate-gated 
NMDAR only occurs for a very short period of time (<1hr after injury), but its effects 
on neuronal injury actually last much longer (usually >7 days after initial injury), 2 ) 
There is a short therapeutic time window (<30m in after injury) in which NMDAR 
antagonists prove to be most efficacious and lose their effectiveness if given after this 
point, and 3 ) Re-stimulation of NMDAR after injury may actually contribute to the 
regeneration of new synapses (improve synaptic plasticity) in order to compensate for 
the initial loss of synapses due to injury (Biegon et al., 2 0 0 4 ). Biegon et al., 2004 has 
shown that NMDAR are “down-regulated” in the hippocampus as early as 8hr to as 
late as 7 days after closed head injury (CHI) in mice from its initial hyperactivation 
15min within initial injury (Biegon et al., 2 0 0 4 ).
Previous literature (Yaka et. al., 20 07 ) has shown that D-cycloserine (DCS), a 
partial and selective agonist of NMDAR at the glycine site, improved neurological 
outcome in mice subjected to CHI and stimulated hippocampal LTP (long-term 
potentiation), a form of synaptic plasticity, in the previously damaged CA1 brain 
region (Yaka et al., 2 0 0 7 ). DCS is thought to play a role in increasing the rate of 
NMDAR channel opening, which results in higher spatial learning performances
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(Pitkanen et al., 1995a). No study (to our knowledge) has yet addressed if  NMDAR 
stimulation from hours to days after global cerebral ischemia will improve 
neurological outcome from asphyxial cardiac arrest (ACA) in rats. Partial activation 
of NMDAR is hypothesized to improve outcome following global cerebral ischemia 
caused by ACA.
We hypothesized that NMDAR channels were down-regulated from hours to 
days after resuscitation (ROSC, restoration of spontaneous circulation) and that re­
stimulation of these receptors would improve neurological outcome in male Sprague 
dawley rats (250-330g). Our goal was to improve neurological recovery by restoring 
NMDAR activity back to baseline levels without over stimulating receptors and 
initiating another excitotoxic cascade. In this study, we induced global cerebral 
ischemia in rats via 6 or 8-min of ACA. We resuscitated animals within 2min. after 
ACA, and then administered a low dose (10mg/kg, intraperitoneally [IP ]) of DCS at 
24 and 48hr after ROSC. Neurological deficit scores (NDS) were taken 2hr after 
ROSC and daily during a 7 day period after ROSC in order to assess neurological 
severity. CA1 hippocampal cell counts were also measured to determine any 
neuronal cell loss resulting from ischemia. Our results showed no effect of DCS on 
neurological improvement, but did show a significant effect of increasing CA 
duration on neurological impairment as indicated by higher NDS during the first three 
days after ROSC.
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3.3. Methods
3.3.1. Animals
All animal procedures were performed in accordance with the Guide for the 
Care and Use o f Laboratory Animals published by the National Institutes of Health 
and approved by the Institutional Animal Care and Use Committee (IACUC) of the 
University of Alaska Fairbanks (UAF) (A ppendix K). Male Sprague-Dawley rats 
were purchased from Simonsen Labs (Gilroy, CA). Female rats were not used for the 
present study because of possible neuroprotective interference with neurological 
assessment and/or drug-interaction due to estrous cycles. Rats were group-housed 
initially prior to quarantine for 1 week and transferred after quarantine to a procedure 
area where they were housed in pairs and allowed to acclimate for 2-3 weeks prior to 
use. Rats were housed 21-23°C on a 12:12-hour light/dark cycle. Food and water 
was available ad libitum prior to experimentation and during recovery (1 week) after 
cardiac arrest, except that rats were fasted 24hr prior to surgery. Experiments 
consisted of four groups of animals where 6 or 8-min ACA was followed by coded 
treatment with D-cycloserine (DCS) or vehicle (saline). A group of naive animals 
were also included for comparison. All rats used for this study weighed between 25 0­
330g.
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All animal experiments were conducted from November 2008 through 
December 2009. The surgical procedure was performed as described previously 
(Katz et al., 1995; Dave et al., 2006; Ch. 2). Animals were induced with 5% 
isoflurane and a 30:70 mixture of oxygen and nitrous oxide followed by endotracheal 
intubation. Anesthesia was maintained between 1-2% isoflurane. Head and rectal 
temperatures were maintained between 36.5-37.5°C using temperature controlled 
heating lamps and Omega (Stamford, CT) T-CSC32 temperature controllers 
throughout the procedure and for 60min post-ROSC. A three lead electrocardiogram 
(ECG) was attached to the fore and hind limbs to monitor heart rate. The femoral 
vein was cannulated using a single lumen (Tygon® flexible tubing; Saint-Gobain PPL 
Corp., 0.375-mm ID, 0.75-mm OD; length 0.029” &  wall 0.014”; Norton, Akron,
OH; AAQ041889; Lot No. 112046) catheter and advanced ~ 2 cm towards the heart. 
The femoral artery was cannulated using the same type of tubing for continuous 
blood pressure monitoring and blood gas analysis. After cannulation vecuronium 
(0.3mL, approximately 1 mg/kg) (Gensia Sicor pharmaceuticals, Irvine, CA) was 
injected intravenously followed by mechanical ventilation (60  breaths per min or 
bpm) and isoflurane was lowered to 0.5%.
Blood gases were continually sampled (with at least 10min intervals between 
sampling) until physiological levels were normalized for CA induction. Arterial 
blood gases, including, Pco2, Po2, pH, HCO3- and ABE were analyzed (iSTAT
3.3.2. Cardiac Arrest Procedure
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analyzer with GC8+ cartridges; Abbott Laboratories, Abbott Park, IL) and maintained 
within normal limits by adjusting respiratory rate (60rpm ) and tidal volume (stroke 
volume 2.0mL-3.2mL/min). MABP and ECG were also continuously monitored 
using an AMP 6600 blood pressure amplifier, and an AMP 6600 bioelectric amplifier 
(Gould Instrument Systems, Valley View, OH).
Asphyxial CA was induced by disconnecting the ventilator from the 
endotracheal tube for 6 or 8-min of asphyxiation. Positive End Expiratory Pressure 
(“PEEP”; 5cm column of water) was implemented during CPR. Resuscitation was 
attempted for 2min or less following epinephrine (10ug/kg, i.v.) injection followed 
immediately by bicarbonate (NaCHO3, 0.9cc, i.v.) injection to reduce acidosis. Ten 
minutes after ROSC, blood gases were sampled again. Immediately following blood 
gas sampling, ventilator rate was decreased from 80 to 60 rpm and oxygen lowered 
from 100% to 30%  in a mixture with N 2O. IPTT-300 temperature transponder tags 
(Biomedic Data Systems [BMDS] Inc., Seaford, DE) were implanted subcutaneously 
[SC] at the end of surgery.
3.3.3. Post-Operative Care
Post-operative (post-op) rats were placed in a neonatal incubator set to 29.0°C 
overnight with water provided. Saline (0.9% , IP) was administered in a volume of 
1mL/100g body weight at the end of surgery to prevent dehydration. After 8-16hr
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animals were fed, weighed, cleaned, and assessed for neurological deficit scores 
(NDS). This was repeated daily for 7 days (Note: NDS were also assessed 2hr post- 
ROSC). Rats were fed a 50:50 mix of rodent chow and sugar mixed with water to 
create a liquid “soupy” chow mixture which was placed in small petri dishes to allow 
animals to self-feed. Animals that were unable to feed themselves were assisted via 
“spoon-feeding”. A gavage needle («  11 cm long, 16ga x 1 U”, blunt-ended, with 
bulb diameter of 4.0 mm ) and a 3cc syringe were used to deliver liquid soup material 
into the animal’s mouth. Animals were fed until they no longer swallowed in 
response to food delivery into the mouth. Most rats were spoon-fed and consumed 
the entire 3cc volume. Rats would feed themselves by consuming dry rodent chow 
on subsequent days. Wounds were cleaned once per day with dilute betadine to 
prevent risk of infection. Exclusion criteria: only animals resuscitated within 2 
minutes post-ACA were included in data analyses.
3.3.4. Drug Administration
D-cycloserine (DCS) was purchased from Sigma-Aldrich (St. Louis, MO; 
C 6880-1G ) and dissolved in saline and delivered intraperitoneally (IP) at 10mg/kg in 
a volume of 1.0mL/kg. This DCS dose improved acquisition of spatial memory tasks 
without inducing concurrent side effects (Lelong et al., 2 0 0 1 ). Vehicle consisted of 
sterile saline (0.9%  NaCl, 1.0mL/kg, IP). DCS and Vehicle were sterilized by
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filtering through a 0.2pm  filter (Pall Corporation, Ann Arbor, MI; PN 41 92 ) into a 
sterile red top vacutainer test tube. Both solutions were freshly prepared on the first 
day of injection (24hr after resuscitation) and given to rats 24 and 48hr after CA.
DCS or vehicle was administered and NDS assessed by an observer unaware of 
treatment. Adverse DCS symptoms were not seen nor reported in previous literature 
(Yaka et al., 2 0 0 7 ).
3.3.5. Neurological Deficit Scoring Assessment
Neurological deficit scores (NDS) were taken at 2hr after ROSC and daily for 
7 days after CA (see A ppendix E for NDS worksheet). Total NDS assessed five 
components: consciousness and respiration, cranial nerve function, motor function, 
sensory function and coordination (Katz et al., 19 95 ). The NDS scale ranged between 
“0” (no neurological deficiency; normal function) to “ 100” (maximum neurological 
deficiency). To maintain consistency between NDS animal results, NDS was 
performed by a single observer. NDS was collected through day 7 until animals were 
euthanized and brains collected for histopathology 8 days after ROSC.
80
On day 8 following ROSC, rats were perfused with FAM solution (100m L of 
36%  formaldehyde, 100mL 99.5%  glacial acetic acid, and 800mL 99.8%  methanol 
per 1L solution; 1:1:8 by volume) for 19min after a 1-min initial perfusion with 
physiological saline (see A ppendix G ). The perfusate is delivered at a constant rate 
~ 80mL/min of into the left ventricle of the heart (C h. 2.3 ) with the descending aorta 
clamped. The rat was decapitated and the head was immersed in FAM at 4°C for 
24hr. After an initial RO-H2O wash for 10-15min, brains were carefully removed 
from the skull and stored in fresh FAM for another 24hr at 4°C. Finally, brains were 
placed in 70%  ethanol solution until trimmed and sectioned into coronal brain blocks 
for paraffin embedding. Coronal sections of 8pm were stained with hematoxylin and 
eosin (see A ppendix H , I). Rat brain sections examined contained the hippocampus 
at approximately-3.8 mm posterior to bregma. Normal (“healthy”, non-pyknotic) 
neuronal counts were made within a section of the CA1 region of hippocampus by an 
investigator blinded to the experimental conditions and the counts are expressed as 
number of normal neurons present per mm of CA1 (at 40X  magnification). Normal 
neurons were defined as having a well-defined cellular membrane and distinct 
cellular nucleus. MetaMorph 7.0 software was used to record cell counts.
3.3.6. Histology
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Data are expressed as mean ± SD with the exception of NDS data which is 
expressed as median and quartile values. Statistical evaluation was performed using 
MANOVA with repeated-measures over time followed by a Tukey multiple- 
comparison post-hoc test used to measure differences between group means (SAS 
v9.1 software; SAS Institute Inc., Cary, NC, USA) or t-test where indicated; P <0.05 
was considered significant. ANOVA single factor statistical test was used for CA1 
hippocampal cell counts. Five rats were excluded from data analysis which included 
rats not surviving to 48hr post-ROSC (n=1), had poor brain tissue fixation (n=3), or 
did not have hippocampal brain tissue trimmed -3.80mm from bregma (n=1).
3.4. Results
3.4.1. Physiology
Physiological parameters (age, body weight, Po2, Pco2, pH, acid base excess 
(ABE), hematocrit (HCT), plasma glucose, HCO3 , mean arterial blood pressure 
[MABP], and temporalis/rectal temperatures) were monitored before as well as after 
CA to explore if experimental groups differed before or after treatments. Age, body 
weight, HCT, and plasma glucose (mg/dL) did not differ between experimental 
animal groups. pH, HCO3-, and ABE all significantly increased after CA while
3.3.7. Statistics
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MABP decreased from baseline values after CA (T able 3.1; P<0.05, MANOVA, 
main effect of time for each variable). MABP values overall were lower in 8-min than 
in 6-min rats (T able 3.1; P=0.0016, MANOVA main effect of duration). 8-min CA 
rats had significantly lower Po 2  than 6-min both before and after CA regardless of 
drug treatment (P=0.0294, MANOVA, main effect of duration). Tbrain and Trec 
values were overall slightly higher in 8-min rats than 6-min CA rats which had lower 
Tbrain values, but all within the 36.5-37.5°C range (T able 3.1; P=0.0220 [Tbrain], 
P=0.00033 [T rec]; MANOVA, main effect of duration). Trec values in all groups were 
slightly higher “After CA”, but were all within 36.5-37.5°C (T able 3.1; P=0.0141, 
main effect of time). There were no differences between physiological parameters 
prior to drug treatment.
3.4.2. Asphyxial CA
Heart rate (H R) and blood pressure (MABP, systolic [SBP], and [D BP]) were 
compared before, during, and after CA between experimental groups. For the most 
part groups showed similar severity of CA with declines in heart rate and blood 
pressure over time (P<0.0001 for HR, P<0.0001 for MABP, P<0.0001 SBP;
P<0.0001 DBP; MANOVA, main effects of time). However, for heart rate, MABP, 
SBP, and DBP there were some statistical differences between 6 and 8-min CA 
groups at some time points (Fig. 3.1 ) (For HR, P<0.0001, MANOVA, time x duration
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of CA; for MABP P=0.0030, main effect of duration, P<0.001 time x duration of CA; 
for SBP P=0.0035, main effect of duration; P=0.0016, time x duration; for DBP, 
P=0.0048, main effect of duration; P=0.0021, time x duration). No differences in 
heart rate or blood pressure were seen in groups subsequently treated with DCS or 
saline (Fig. 3.2). Immediately after induction of asphyxiation, bradycardia (~ >60%  
HR reduction) and hypotension (<50mmHg) was observed in all animals starting 
around 2min of CA. For 6 or 8-min CA rats, HR and MABP slightly decreased 
within 1min of CA and significantly decreased within 2-4min of CA with values near 
0 mmHg by 4min of CA (see Fig. 3.1). CA duration time intervals of “Before CA” 
(2min prior to CA induction), “ 1-2min”, and “2-3min” significantly differed between 
both 6-min and 8-min CA rat groups (P<0.05, Tukey). DCS and vehicle saline 
groups had similar declines in HR and MABP and systolic and diastolic blood 
pressures during CA (Fig. 3.2, P>0.05).
3.4.3. Neurological Deficit Scores (NDS)
To assess the extent of injury caused by CA or therapeutic effects of DCS we 
compared NDS between experimental groups. NDS scores were not normally 
distributed, however, transformations failed to improve normal distribution of 
residuals. Therefore data were analyzed using ANOVA and are shown as median and 
the first and third quartiles. Note that when data are not normally distributed medians
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and quartiles are a more accurate measurement of ‘central tendency’ than mean ± 
SEM. CA produced significant neurological deficit (indicated by higher NDS values) 
as shown in Total NDS that spontaneously recovered over time (a majority of rats 
eventually had a NDS of “0” or “near 0” by the end of the 7-day assessment) 
(P<0.0001, MANOVA, main effect of time; Fig. 3.3). Rats exposed to 8-min CA 
showed greater and prolonged injury (especially during the first three days of scoring) 
which slowed down recovery time as opposed to 6-min CA rats which had faster 
recovery times and less neuronal injury (Fig. 3.33a, b; P=0.0026, main effect of 
duration; P=0.0003, time x duration). DCS treatment had no effect on Total NDS 
(Fig. 3.3c, d). Categorical NDS was also analyzed within the following categories: 
General Behavioral, Cranial Nerve Reflexes, Motor, Sensory, and Coordination. All 
categorical NDS showed significant differences between 6 and 8-min CA rats over 
time (NDS Days 1-3) (P<0.0001, main effect of time; Fig. 3.4). 8-min CA also 
produced significant injury in rats for both Total and Categorical NDS (Motor NDS 
P=0.0039, main effect of duration; P=0.0058, time x duration; Fig. 3.4a; Sensory 
NDS P=0.0008 main effect of duration; P=0.0004, time x duration; Fig. 3.4b; and 
Coordination NDS P=0.0023, main effect of duration; P=0.0003, time x duration;
Fig. 3.4c; General P=0.0242, main effect of duration; P=0.0021, time x duration; Fig. 
3.4d; Cranial P =0.0167, time x duration; Fig. 3.4e) which contributed to slower 
recovery. Overall, DCS did not produce a significant effect on Total or Categorical 
(Motor, Coordination, and Sensory) NDS; slight differences between DCS and saline 
rats were seen for General (NDS Day 5, P<0.05, Tukey; Fig. 3 .5a) and Cranial (NDS
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Days 5 &  6, P<0.05, Tukey; Fig. 3 .5b ) NDS, respectively. DCS has no significant 
effect on NDS.
3.4.4. Histopathology of CA1 Hippocampus
All CA treated rats showed a significant reduction in the number of healthy 
CA1 neurons in the hippocampus when compared with naive rats; (Fig. 3.6). Mean ± 
SD for CA and naive rats were as follows: 180.8 ± 27.6 naive (n=5) vs. 46.3 ± 33.8 
[all CA groups, n=27]; (P= 7.12x10-5, two-sample unequal variances t-test). There 
was no significant differences seen in CA1 neuron counts for 6 and 8-min CA rats 
and DCS had no significant effect on cell counts (Fig. 3.6). Ischemic neurons 
(shrunken “pyknotic” cells with darkened triangular-shaped nuclei, and eosinophilic 
nucleolus and cytoplasm) were also present in the CA1 region of all CA treated rats; 
especially in 8-min CA DCS rats, but were not counted for histopathological analysis 
(Fig. 3.7).
3.5. Discussion
The aim of this study was to determine if activation of down-regulated 
NMDAR function by DCS after ischemic injury could improve neuronal outcome 
subsequent to asphyxial CA. Our results showed that DCS had no significant effect
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on neurological improvement from asphyxial CA in either 6 or 8-min CA rats as 
assessed by NDS and histopathology. These results fail to support our initial 
hypothesis that DCS would improve neurological outcome after CA. Our NDS 
results showed greater injury and slower recovery time for 8-min CA rats while 
histopathology results showed a severe reduction of healthy hippocampal CA1 
neurons in CA rats compared to naive rats, in rats subject to 6 or 8-min of CA. These 
results suggest that 6-min CA injures the ischemic vulnerable CA1 region to a 
maximal degree.
DCS ineffectiveness in improving brain injury could be attributed to four 
possible main factors. First, DCS treatment possibly did not coincide with NMDAR 
down-regulation. NMDAR down-regulation only occurs for a limited period of time 
(Bickler and Buck, 1998, Biegon et al., 20 04 ) and DCS could have been administered 
at a time point in which its efficacy may have no longer proved to be effective. It has 
been hypothesized that long-term suppression of NMDAR function exacerbates 
progressive brain injury following cardiac arrest as described for traumatic brain 
injury (Yaka et al., 2 0 0 7 ), however NMDAR down-regulation after CA has not been 
studied. In fact, the exact duration of NMDAR hyperactivation (generally, <1hr) post 
ischemic/TBI injury still remains unknown; NMDAR hypofunction occurs a few 
hours after injury and lasts for 24hr or more (>7days) (Biegon et al., 2 0 0 4 ). Second, 
the severity of injury may have been too great to see improvement. 6-min CA may 
have already produced maximal neuronal injury and any attempt of alleviating injury
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at this point (or at 8-min CA) would not be seen. This possibility is supported by the 
observation that 6 and 8 min of CA produced the same decrease in the number of 
healthy neurons in the CA1 region suggesting that a maximal degree of CA1 injury 
was sustained by 6 min of CA. Third, DCS drug dosage could have been too low or 
too high to show any therapeutic effect. DCS dosage was chosen based on improved 
outcome following TBI in mice (Yaka et al., 2 0 0 7 ); however, the dose-response 
relationship may depend on the time course of NMDAR down-regulation as well as 
the species and severity of brain injury. At high doses, DCS generally produces an 
antagonistic effect which competes with other agonists for the same NMDAR binding 
sites while at moderate doses, DCS produces a partial agonistic effect which 
facilitates glutamatergic NMDAR transmission (Horio et al., 2 0 1 2 ). Fourth, 
histopathology and NDS assessment may not have been sensitive enough to detect 
more subtle differences in hippocampal function and histopathology did not allow for 
study of the time course of hippocampal injury. Measure of hippocampal dependent 
cognitive dysfunction (e.g. Morris water maze, radial arm maze, contextual fear 
conditioning, or fear-extinction conditioning behavioral tests) could be used to assess 
the time course of CA1 hippocampal deficiency (Kesslak et al., 1998, Hall et al.,
2000, Mizuno et al., 2000, Cunha et al., 2 0 1 0 ). Poor recovery from CA is now 
understood to be attributed to progressive neuronal death over a period of days to 
months after injury so assessment of the time course of hippocampal function is 
warranted (Dave et al., 2 0 0 6 ).
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Physiological parameters were consistent among DCS and saline treated 
groups so it is unlikely that a difference in the severity of CA confounded the effects 
of DCS. pH, HCO3 -, and ABE all increased significantly after CA probably in 
response to the HCO3 - flush which occurs immediately after successful resuscitation 
in order to control for acidosis. Longer CA duration caused significantly lower Po 2 
and MABP. These differences are consistent with what is expected from longer 
duration of CA and with the worse outcome observed after the longer duration of CA. 
CA generally results in lower pH in tissues, arterial hypotension, and hypercapnia 
clinically in prenatal, pediatric, and some adult populations (Katz et al., 2 0 0 2 ). The 
asphyxial CA rat model produced neuronal injury that is consistent with previous CA 
literature (Katz et al., 1995, Dave et al., 20 06 ) by which HR and BP decreased within 
3-4 min of CA onset. Results show statistically different declines in HR and BP over 
time in 6 and 8-min CA rats. The decline in BP was slightly faster in rats 
subsequently exposed to 8-min of asphyxia. No differences were seen between DCS 
and saline (both declined at similar rates). Another important factor to note is the 
elevated Tbrain in 8-min CA rats. Slower recovery time in 8-min CA rats could have 
been attributed to overall higher Tbrain, or to slightly more severe decreases in BP 
during 1-3min of asphyxia.
It was somewhat unexpected for DCS to not have any effect, especially in 
histopathology analyses. Previous studies have shown that DCS improves recovery 
after closed head injury (Yaka et al., 20 07 ) and that DCS facilitates changes in
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hippocampus-and-amygdala dependent learning (Monahan et al., 1989, Flood et al., 
1992, Thompson et al., 1992, Kuriyama et al., 2 0 1 1 ). Past human preclinical DCS 
trials have even shown elevation of activity in the CA1 region of the hippocampus 
compared to placebo groups (Grunwald et al., 19 99 ). This effect occurs indirectly by 
increasing the learning efficiency through which upregulation of glutamate signaling 
in NMDAR above normal threshold levels occurs (Onur et al., 2 0 1 0 ). In the brain, 
DCS has a higher selective affinity for the glycine site of NMDAR where granule 
cells are potentiated; DCS stimulates NMDAR-mediated transmission by freely 
entering into the blood brain barrier (BBB) and has been shown to enhance field 
potentials in the hippocampus, typically seen in highly concentrated NMDAR areas 
of the brain like the CA1 region of dorsal hippocampus and the dentate gyrus 
(Pitkanen et al., 1995b).
The main caveat regarding this study is that the exact NMDAR down-regulation 
time course remains unknown for the ACA injury model. Another caveat is that the 
mechanism for neuroprotection via DCS in TBI remains unclear. Other studies have 
shown that restoration of NMDAR channel activity increases brain-derived 
neurotropic growth factors (BDNF) levels, which can cause a positive feedback loop 
effect to further enhance hippocampal function. In fact, the hippocampus has the 
highest levels of BDNF mRNA and BDNF gene receptor, trkB, which play a vital 
role in synaptic plasticity (Hofer et al., 1990, Klein et al., 1990, Ma et al., 19 98 ). One 
big disadvantage to this approach, however, is that there is a critical time window
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involved whereby restoring NMDAR back to normal levels is only beneficial in the 
subacute post-injury phase. Also, overstimulation of NMDAR can cause the same 
excitotoxic effects that were originally initiated by the ischemic injury. Thus, more 
work is needed before dismissing the potential for a NMDAR partial agonist to 
improve outcome after global cerebral ischemia.
3.6. Conclusion
DCS had no significant effect on neurological improvement following 
asphyxial CA. Asphyxial CA duration (6 and 8-min) played a significantly larger 
role in affecting neurological outcome as expressed in NDS and CA1 neuron counts 
than DCS treatment. Additional research is needed to further evaluate the therapeutic 
effectiveness of NMDAR activation after excitotoxic ischemic injury in animal 
models when NMDAR are expected to be down-regulated.
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Table 3.1. Physiological parameters measured before and after asphyxial cardiac arrest (CA) In rats
Physio log ical Parameters for 6 min C A  rats.
Ischem ia (6 min)
Before After Before After
croup Variable D-cyclosenne (DCS) Vehicle (Saline)
DCS Rats (n = 10) Age (days) 68.9*4,3 6 8 5 *5 .5
Vehicle Rats (n = 8) Body Weight (g) 284.7 ± 107 283.7 *  17.6
pH 7.46 ± 0.03 7.50 *  0 07 7 44 ± 0 02 7.46 ± 0 02
Pcoi(mmHg) 38,0 *  2,3 37.8 *  22 38.8* 1.7 41.1* 3.0
Po: (mm Hg) 119 ±7.1 135 *44 122 *  7.3 1 28 *14
H C 03' (mmot/l) 2 7 3 *  1 8 29 8 *4 .2 2 6 2 *1 .5  2 9 1 * 2 5
Base Excess 35  ±2.1 6 .7 *5 3 2 . 1 * 1 6  5 .3 *2  6
HCT 48 2 * 2 0 48.5* 1.5
MABP (mm Hg) 120* 16 9 6 *  14 116 *  9.5 9 3 *  17
I * * ,  r c ) 36.6 i  0 2 36.7 *  0.2 36 7 ± 0 2 36 6 *  0 4
T * ( ’C) 36 8 *  0 2 37.0 *  0.3 36 8 *  0 2 36 8 *  0 5
Plasma glucose (mg/dL) 144* 16 143 ± 22
Note: One 6-min CA rat is missing "After" ischemia physiological values for all vanables
Physio log ical Parameters for 8 min C A  rats.
Ischem ia (8 min)
Before After Before After
Group Variable D-cycloserine (DCS) Vehicle (Saline)
D CS Rats (n = 7) Age (days) 7 4 0 * 6 4 60.8 ±6.1
Vehicle Rats (n = 6) Body weight (g) 299 2 *  24 3 275.4 *  16.5
PH 7 45*0.01 7.48 *  0.04 7 44 *  0.03 7.50 ± 0 0
PM f<mm Hg) 37.9 *  1.1 38.1*1.8 36.3 ±2.7 331 ± 2 0
P0i (mm Hg) 112* 10 0 116*34,11 119* 10 102*2.5
HCOj' (mmot/L) 2 6 3 *  1 2 28.0 *  2.9 25.8 ± 1.3 30.0 ±2.1
Base Excess 2 1 *1 .3 5 1 ±3,6 1.7* 1.5 6 8 * 2 4
HCT 47 8 * 3  5 46 6 *0 .07
MABP (mm Hg) 109* 10.9 72.4* 10.5 106 *30 74 ± 17
Tbjjn |‘C) 36.9 ± 0 3 36.9*0.4 36 .8 *0  3 36.8 i  0.2
T i« [‘C) 36 9 ± 0 4 37.1 ± 0.3 37.0 ±0.1 37.4 ± 0.4
Plasma glucose (mg/dL) 144 *24 124 ± 16
All data are expressed as mean i  SD  N = 30-31 rats total
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Figure 3.1. LabScribe Values for (a) heart rate (HR), (b) mean arterial blood pressure 
(MABP), (c) systolic blood pressure (SBP), & (d) diastolic blood pressure (DBP) before, 
during, and after induction of asphyxial cardiac arrest (6 or 8-min CA). The decrease in BP 
was slightly faster in rats subjected to 8-min CA; *P<0.05, Tukey.
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Figure 3.2. LabScribe Values for heart rate (HR) (a), mean arterial blood pressure (MABP) 
(b), systolic blood pressure (SBP) (c), &  diastolic blood pressure (DBP) (d) before, during, 
and after induction of asphyxial cardiac arrest (6 or 8-min) in control (vehicle saline) or 
experimental (D-cycloserine, DCS) rats. Drug was administered IP in rats 24 & 48hr post­
resuscitation.
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Figure 3.3. Total Neurological Deficit Scores (NDS) shown for 8-min cardiac arrest (CA) (a), 
6-min CA (b), D-cycloserine (DCS) (c), &  Vehicle (Saline) (d) treated rats. NDS scores were 
significantly higher during the first 3 days of testing in both 6 and 8-min CA rats and 
eventually decreased to near 0 over time; however, there were no significant differences 
observed in NDS scores for DCS and saline treated rats. *P<0.05, Tukey, 6 vs. 8-min, n=6-10.
100
Q o£
i lZ T3
S
E■
8-min vs. 6-min CA Cranial Nerve Reflexes 
NDS Median & Quartile Values
"  "  8  m in  CAC3Q]
6 -m in  CA 
(3Q I
•  8 -m in  CA 
(med)
•  1 6 -m in  CA(med)
— *  -  8 -m in  CA
(1Q1
“  *  “  6 -m in  CA(1QJ
d
v%
!flI
E
8-min vs. 6-min CA Coordination 
NDS Median & Quartile Values
Day Day
Figure 3.4. Categorical Neurological Deficit Scores (NDS) consisting of (a) motor, (b) 
sensory, (c) coordination, (d) general, and (e) cranial components are shown for both 6-min 
and 8-min cardiac arrest (CA) rats. NDS scores were significantly decreased in both 6 and 8- 
min CA rats with respect to recovery time. *P<0.05, 6 vs. 8-min, n=6-10.
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Figure 3.5. Categorical Neurological Deficit Scores (NDS) consisting of (a) motor, (b) sensory, 
(c) cranial, (d) coordination, and (e) general components are shown for both DCS and saline 
cardiac arrest (CA) rats.
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Figure 3.6. Number of healthy normal neurons per mm of CA1 hippocampal (HPC) region in 
CA duration (6-min CA or 8-min CA) and experimental drug (control: Vehicle Saline; 
experimental: D-cycloserine, DCS) treated rats 8 days post-ischemic injury and resuscitation. 
No significant differences were seen for CA1 neuronal cell counts in either 6 or 8-min CA and 
DCS or saline rats, but all CA groups differed from naive rats. *P<0.05 CA vs. naive, n=5-10, 
t-test.
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Figure 3.7. Representative images (at 40X magnification) showing histopathology of pyknotic 
(ischemic) and healthy neurons in the CA1 hippocampal region of drug (D-cycloserine, DCS, or 
Vehicle, saline) treated rats 8 days after 6 or 8-min asphyxial CA. Scale bar = 100pm.
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C H A PTER  4 
G eneral Conclusion
The goal of this thesis was to transfer the clinically relevant asphyxial cardiac 
arrest (ACA) rat model technique already established at the University of Miami (UM ) 
into the laboratory setting at the University of Alaska Fairbanks (UAF). I also used the 
model to test the hypothesis that stimulation of NMDAR hours-to-days after cardiac 
arrest would improve outcome. Since NMDAR (N-methyl-D-aspartate receptor) channels 
are believed to be down-regulated within hours-to-days immediately following 
reperfusion, I hypothesized that re-stimulation of NMDAR channels back to (or similar 
to) baseline levels prior to ischemic injury could possibly lead to neuronal improvement. 
Therefore, I predicted that D-cycloserine (DCS) administration would lead to neuronal 
improvement by re-stimulating down-regulated NMDAR channels back to (or at least 
similar to) baseline levels prior to ischemic injury.
Results showed that administration of DCS 24 and 48hr after ROSC (restoration 
of spontaneous circulation; resuscitation) did not improve neurological outcome in male 
Sprague dawley rats subjected to either 6 or 8-min CA as based on 1 week Neurological 
Deficit Scoring (NDS) and neurohistopathology (healthy CA1 hippocampal neuron 
counts) assessments. However, results did show that implementation of the ACA model 
was very effective at reproducing clinically relevant brain damage (as seen in prenatal 
and pediatric asphyxia) in rats into the lab setting and can help in the development of 
future neuroprotective therapies for humans, especially regarding prenatal and pediatric
asphyxial CA.
Further investigation into NMDAR down-regulation time window can potentially 
offer insight into the effectiveness of various therapeutic agents such as NMDAR 
antagonists and agonists. Studies on DCS efficacy including dosage and therapeutic time 
window optimization, and insight into how DCS activation of NMDAR provides 
neuroprotection can provide new treatment options for various cognitive impairments. 
ACA rat model improvements involve brain region specific quantification methods for 
assessment of neurohistopathology after brain injury. For example, use of behavioral 
assays that specifically test hippocampal function, such as the Morris water maze, may 
provide better brain injury assessment with greater sensitivity for detecting spatial 
memory deficits. In addition, the ACA model will be used to investigate the 
neuroprotective effects of mild therapeutic hypothermia.
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A ppendix A 
Surgery Log
SURGERY LOG
Date:_____________ **IACUC#:
I D ______________  SEX:_
** An IACUC a u x c e  f r s x  a aurem A iiu rix s o f  Animal C ar* f r o x x u s t b e  in the log.
All procsdufss must have be*n approved and the inrseonidentified to the IACUC
Surgeon:_______________________________ Assistant:
A ssistant: Assistant:
A N E S T H E S IA  :{ you must attach anesthesia monitoring forms to the surgery log)
________________AGENT_________ DOSE (mg)__________ ROUTE_________ TIME____________COMMENTS
Pre-medication:
Anesthesia:
Anesthesia is induced and maintained with isoflurane mixed with 70/30 N 20 02  delivered at 1.5 
L min.
Post-Op medication:
vPon-Op xedi:atiaa inchid« all antiiepti:,antibiotic, aaalsesic.ECT/
S U R G IC A L  PR O C ED U RE: (detail surgical site, site preparation, draping, size ofincision, scalpel blade size, blunt 
and or sharp dissection, describe manipulation and or implants, describe samples collected including amount, describe closure 
including suture material, size and knots, detail all complications encountered during procedure, etc.).
S T A R T  T I M E ______________ E N D  T I M E _________________
L ocation  o f  su rgery :__________________________________________________________
Table and stereotax w ere w iped  w ith  N olvasan solution. Surgical instrum ents and  screws w ere 
autoclaved or gas sterilized and sterilized w ith  Instrucal lubricant milk betw een animals. 
Tem perature probes w ere inserted into bo th  the  rectum  and th e  le ft tem poralis muscle, and 
separate heating lamps or heating lamp and circulating w ater blanket w ere used  to  m aintain 
rectal tem perature and tem poralis m uscle tem perature at 36.5°C to  37.5°C. Surgical site w as 
prepared by  clipping o f  th e  hair using a clipper b lade and disinfecting o f  the  sldn by using 
alternate scrubs o f  beginning w ith betad ine and alternating w ith  70% isopropyl alcohol for 3 
tim es and finishing by  painting site w ith  full strength betadine.
SPECIES
WEIGHT:
Figure A-1. “Surgery Log” form page 1. This form records physiological data from rats during 
cardiac arrest surgery.
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{Steps are copied from  D rew  lab cardiac arrest protocol; set up  fo r  CA revised  O ctober 23,
2009 w ith  changes implemented'):
Notes
1. Open pressure gauge p a c t  and set up pressure 
transducer.
2. Prepa re iujectables(seepg. 10) and  fill two cannulae 
v/hep-5aline w/1 cc syringe a n d 23 ga. luer stub adapter 
(B e cton Dickinson: re o rd a  i  42 7 5 65) for PE-50: 26ga luer 
stub forTygon. Fill one 1 Occ syringe w /sterile saline. 
L eave sterile en d sin p ack .
3. Ane s the tize with 5% iso flurane and a 3 0:70 mixture o f  
Ot (40D-500mL m in)andN rO (lL  m in)via scavenger 
iluovacm ask. This insures stable phvsiologicallevels for 
PQr, PCOt andpH . ' ' '
4. Begin endotracheal intubation first i f  using rats {skip 
this step & step ;  i f  using AGS; see step 10 for AGS 
intubation): Open sterile intubation pack. First tak e  
anim al o ff  anesthesia mask, insert otoscope (with 
speculum atlachedandlight tum edon)against thepalate 
o f  the m outh  (with the curved slide facing downward) 
while holding and deflecting the tongue to the side. Next, 
pla ce a drop o f  lido c aine gel to the tip o f  the lido c aine 
applicatorand apply ittheep ig lo ttis(archshapedand  
located  ju s t above the vocal cords) while still holding the 
otoscope and speculum against the palate o f  the animal's 
m outh  with the opp osite hand. L idocainegelapplication 
should re due e epiglottis sp a sm a s well a s init ation t o this 
sensitiv e region. Put anim al b ack on anesthe sia m ask (rats 
2.5% Iso; AGS 3 -3.5% I so) for 2 min.
5. Take animal off mask and reinsert otoscope/speculum 
unit as described earlier. T histim eusethe endotrachael 
catheter (14ga 1.75in: BD Insyte Auto guard, shielded iv 
catheter,ref$3S1467 guided with a bent, custam blunt 
biomedical 17gax4 in needle. 17TWx3. Popper & Sons, 
New H yden Park. NY£742 7) and try to insert it (with 
curv ed s id efac in g u p )in to th e trach ea lo ca ted v ia th e  
openingbetw eenthetw ovocalcords. M ovem ento fthe  
vocal cords should be slowed down enough in order to 
m aneuver this techni que. One ethecathe teris ftilly inside 
the trachea (only the orange hub should be sticking out o f 
m outh), quickly check if  the catheter is truly in the trachea 
and not in the esophagus by holding a stainless steel 
instrument in front, o f  the open end o f  the c atheter (orange 
hub) so th a t condensation o f  respiratory moisture canbe 
seen. I f  no moisture is visible, then  it m eans tha t the 
catheter is in the esophagus. Repeat aforementioned steps 
in order to reinsert endotracheal catheter into trachea. 
Discontinue surgery if  more th a n  2 tries are needed to 
execute intubation Return animal to home cage for at
□
Figure A-2. “Surgery Log” form page 2. Shows anesthesia induction and intubation 
preparation.
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least 1 w eek be fore rep ea t attempt. I f  necessary, tra chea 
m ay  be visualized to  facilitate intubation Clip the hair 
from  the ventral neck  an d u s in g a#  ID or#  15 b lade or 
curved, b lun t scissors m ake a l-2cm incision along the 
ven tra l midline o f  the neck  to  expose the trachea and 
la rynx . T o p revent laryngo spasm during oral intub ation 
swab lido caine onto laryngeal folds n ith  a sm all co tton  tip 
swab m o is te n e d ^ ith i drops o f  lido caine (Lidoject; 
lido c aine 2 ? a inj e ctable, Butler Animal H e alth Supplv; 
Dublin. OH 43 107). C lo se^ ith  Prolene, 3-D suture, 
simple interrupted stitch.
Suture catheter to  lip to avoid  dislodging catheter during 
resuscitation. Close ^ i th  3 - 0 prolene. simple interrupted 
stitch, a t least 3 throws).
For term inal, non-recova y  procedures a tr a <±16010:1™ 'may 
b e sub stitute d for oral intub ation. The tra chea T\ill b e 
exp 0 se d a s de scrib ed abov e. A small hole nill b e m a de 
betw een the cartilaginous lings in the tra chea and the 14ga 
1.7 5 in; BD Insyte cathet er ^ ill b e inserte d. The c atheter 
n l  be secure d in  the tra chea ^ i th l  or 2 sutures using 3-0 
silk. '
S. Shave thro a t (if  tracheotom y is planned), right groin, and 
(optional; dorsal surface 0 f  remaining legs (for EC G 
elecuodes); scrub animal using 70%  alcohol and  100%  
betad ineso lu tionbe ginning sh th  b etadine and  
alternatingTtith 70% isopropyl alcohol for 3 tim es (three 
swabs beta  dine and two swabs 70%  alcohol), ending 
ssith lD 0% betadine. Use circular, inside-to-outside 
m otions ishen scrubbing incision so a s n o t to 
cont aminat e the innerm ost re gion.
7. R eco rd  vitals: Cover eyes with sterile ophthalmic
ointm ent for lubric ation(e .g. v euop  oly cin, ne o-p olv-b ac, 
etc.), insert re ctal therm om eter (lubricated ^ i th  K-Y), 
insert E K G leads subcutaneously (ground to hindleg; 
negative to left front leg. positive to right front leg) and 
securebo th  EKG leads andtherm oc ouple srte e die s \sith 
surgical tape ; monitor s02  T \ithpulse-oxim etH if 
applicable. R ecord values on surgery log and  anesthesia 
record.
S. Don sterile gloves, drape and open pack1 and arrange 
surgical instrum emte.
*Nbte I f  tra che at omv is p lum ed:
□ IV  catheter (same for ra ts  and AGS; BD/Insvte; 
H 3124A ; 14gax 1.7 5 inch; 2.1 x 45m m ) '
□ 3 -D Prolene (when closing)
Figure A-3. “Surgery Log” form page 3. Intubation and surgical preparation setup shown.
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9. C annul ate femoral vein and then  artery. flush with saline 
and  clo se t emp orarily with suture s. Poly ethylene c athetffs 
(Ty gon tubing; 0 3  7 5 -mm 10,0.75 -m m  OD; Norton. Akron. 
OH or PE-50 c atheter for vein and a r tsy ) , will be intro due ed~  
2 cm into the right femoral artery andvein  for a cute blood 
pressure recording, blood sampling, and drug infusion: or 6 cm 
for chronic c annula pla c ement . Me an arterial bio o d pr e ssure 
(MABP) will bem easuredvia anindwelling femoral arterial 
c atheter c onne c ted to a p re  calibrate d St athanipr e ssure 
transducer and will b e re c orde d c ontinuously. Arteri al bio o d 
ga se s and  p H, andpla sma glue o se. will b e me a sure din 
micro samples (7 5-1 DO pL). (Total volum e no t to exceed 1.5mL
10, Intubation (for AGS only endotrachael intubation must
f oil o w v e no us c a nnul a tio ii b e c ause v e cur oniumm ust b e 
a dminist ere dimmediately a ft er intub ation or AGS bre athe 
against the endotrachael caftreter): See step 4 above.
11 . P a  ralyze: AGS m ust b e p aralyzed immediately after 
inserting endotrachael catheter. Inj ect 0..3 mL Vecuronium 
(lm g  m L)iv. W atch to see that animal stops breathing.
C onnect v  entilator (humidifte dwith rnuc omist ( 1.4m L " QmL 
H 20); pressure dampene dwith rebreathe bag at, approximately 
53 rpm. SV2.0mL). Im m e diatdy decrease isoflurane to 0.5%.
12. Sample and adjust blood gases; adjust stroke volume, SV. 
(typic ally b etwe en 2 — 3 m L) and  % 02 (typic ally b etwe en 4 50 
and  50 QmL min) toad justb loodgases (AGS PC 0 2 :3 0- 
S4m m H g;P02 41-73 mmHg[PC02 of60m m H gandPO 2 o f 
6 OmmHg is typical for AGS]; R a t P C 0 2 :3 5AO; P 02  100-110 
[110-130 is acceptable]1
1J . Mo ni to r 1™ a nd Tamper nt until b etwe en 3 6 .5 and3 7.5 DC_
14. At least 10 mill afterprevious injection of vecuronium.
in je c tv e c (0 .3 m L o fl m g m L iv)andFLU SH  imm e diatdy 
w ith0.3m L hep-sal (6 .7 IU mL), 2 m in later disconnect 
ventilator. OBSERVE THAT ANIMAL IS NOT BREATING.
I f  animal c ontinue s t o bre athe p>2 bre aths) inj e ct another 03mL 
o f vec, wait lOmin. and rep eat this step. I f  animal is not 
breathing prep are to resuscitate1. (Connect 2 wav luer adapter 
prim edw ith Epi (5ug m L) andN aH C 03 (S.4%) for 
immediately delivery; change BP scale to 0-50: turn  off 
isoflurane vaporizer: tu m N 2 0  flow m eter to 0 and  increase 02 
to 2L m in and respiratory rate to  30 b p m  NOTE last vec 
inj ection and  start o f CA or sham procedure and Resuscitation 
in Lab Scribe.
15. Re s us ci ta te by re c onne cting v entilat or. imme diatdy inj e ct 
1 m L  kg ire sh Epi (5ug kg or 1 Oug kg). Im m e diatdy inj e ct Epi 
and  apply rapid manual chest compressions a t a rate o f200 min 
to base o fthe  heart until BP is at least 50 m m  Ha and is
□
Figure A-4. “Surgery Log” form page 4. Cannulation, blood gas sampling, cardiac arrest 
induction, and resuscitation step-by-step procedures shown.
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m aintained by spontaneouriv beating he art for > 10 tec. I f  n o t 
re suscitated after 1 min, give a second Epi dose. Once H R is 
sp ont aneous and M A B P > 5 0 m m  Hg, im m e diately inj ect 0 9  cc 
N a H C 0 3 . Resuscitation is discontinued after 2 m in if  anim al 
fails t o m ain t ain a sp ontaneously b e ating he art. S quishing 
sounds from  lung during m anual com pression is indication  o f  
lung injuiv a n d m av b e  used  as a basis for euthanasia.
16, Im me diately  sam ple blood gases once animal m aintains 
stable M A BP afte r restoration o f  spontaneous circulation 
(ROSC). A fter 10 m inutes ofR O SC , decrease respiratory ra te  
from  SO to approx. 6 0 b p m a n d % 0 2  from  100% to 7 0 % in a  
m ixture s tith N 2 0 . A gain sam ple arterial b lood  gases.
17. Correct acid-base status stith sodium bicarbonate 
and/or the ventilator settings. (B ase excess shou ldbe> 0 ; 5- 
10 is norm al). I fp H < 7 3  inj ec tN aH C 03  to adjustpH . M ay 
need  to  increase R R to b lo w o ffC 0 2 ifp H is lo w , in  AGS C 02  
is o ft en >6 0. Stroke volum e m ust be >2 mL.
IS. Once b iood gasesare  normal, remove arterial and
v e no us c a the te rs by tying o f f  arterv and v  ein ivith 3 throw s o f  
3-0 silk suture. Close sk in ^ ith  3 -0  prolene. simple interrupted 
stitch; a t lea st 3 throws. Inject Sterile Saline (i.p. lm L/kg).  
Or. i f  clironic cannula is needed  go to chronic arterial-venous 
cannulation SSOP.
19. Insert IP T T  tag. if  not present.
20 .L eave  on ventilator until spontaneous breathing begins to 
fight ventilator.
21. Maintain a t37°C  (between 36.5 and37-5°C)for at least  
60 min. A nim als n o t able to  m aintain 3 6 -3 7.5&Cbody 
tem perature w ithout he at lam ps are placed in  a hum idified 
ne onat al incub atcr set a t 29°C for 12 -24h or until animal; 
re aain norm al therm ore aulati on
2 2 .Place animal in  postoperative cage (with underpad and 
waterbottle provided) and put in neonatal incubator set to
29°C once anim al spits out endotracheal catheter own their ostn 
(o riv ith  som e help by the surge on i f  catheter is still lodge d in  
th ro a t due to  m ucus secretions). Do n o t provide any food in  the 
cage a s th is  can  som etim eslead to  accidental dea th
23. Copy an d  file anesthesia re cords, surgeiy logs, d a ta  sheets,, 
anim al care log sheets, an d  neurological deficit scores (NDS) 
sheetsin to  appropriate binders andlo  cations. Enter b lood  gas 
da ta  into Excel, b ac k u p  LabScribe files to  b o th  laptop and 
designated external h a rd d n v e .
2 4 .M onitor a minimum o f3  times daily per post-op care 
below until anim al shows signs o f  voluntary feeding, cleaning, 
an d  is able to  easily m ove around incage on their own.
2 5 .Record body temp daily andinspect/dean  sutures daily
u p t o 7  days and atregular intervals there after. Remove sutures 
a t 10-12 dav&-
Figure A-5. “Surgery Log” form page 5. Post-ROSC (resuscitation) steps outlined for cardiac 
arrest surgery.
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POST-OPERATT\"E CAKE: (describecare and monitoring procedures. you m ust note the times that the animal regains 
righting reflex and becomes ambulatory)
Post-op care: A nim al will be m ain ta ined  in a neonata l incubato r set to 29.0°C  fo r 24hr 
a fte r surgery. A nim al will be p laced  in  a clean., stainless steel cage w ith an underpad  
p rov ided  and wrater bottle, b u t N O  W'ood shav ings. I f  an im al is am bu latory and  
unaffected by su rgery, anim al w ill be fed fresh  carrots and apples, rodent chow , and 
w a ter and returned to its hom e room .
Pe rsonn el approved for post-operative care and m onitoring w ill participate in:
f. N a m e(s)
Post-Op Care Note Date, Time &  Observations
Daily cleaning and inspection of wounds. Wounds are cleaned 
with dilute (tea colored) bet a dine once per day for 3 days and 
insp ected there after.
8- 16 h post-op. animals are observed forsigns o f distress and 
fedrodent chow soup mixture placedin a petri dish. If not able 
to eat at all on their own. animals are fed by gavage (1ml 'kg 
body weight) 3 times per day: (The stomach volume is about3 
ml in about 300 grat andgastric emptying time about 45 -60  
min. Sucrose (i.e., table sugar from grocery store)ismixed 
~50:50 with chow and dissolved withtap watertomake a dilute 
solution that canbe drawn into a 3 cc syringe using a gavage 
needle without clogging the needle). Animals that respond and 
swallow are fedbv placing the tip o f the gavage needle into the 
mouth andallowedto consume more than lm L  kg. Animalsnot 
consuming at least3mL kg are fedbv gavage.
Beginningat S-16hpost-op body temperatureisrecordedand 
animals are monitored for neurological impairment andscored 
per "Neurological Deficit Scores (NDS)” daily for the first 7 
days and at regular intervals thereafter.
Vet serviceswill becontactedincaseofcomplications 
encountered during regular work hours or during a fter-hour. 
weekend or holiday care (e.g. wound infection or unusual 
behavior by animal).
Although the severity o f  brain damage is not exp ected to produce 
death, inter-animal variationmakes death a possibility. Animals 
will be monitored, fed by gavage (lmL/lOOg body w eight) 
and given supportive care as needed at least 3 times per day.
Severity o f  brain damage maybe assessed fromnetrological 
examination Animals showing severe neurological impairment 
including coma will not be euthanized because elirmnatmgmost 
severely affected individuals will bias final assessmentof 
histology. The number o f  animals that die will be noted, 
however, these animals are excluded fromhistological 
examination o f tissue because death does not allow forin situ 
fixation o f  the tissue. Deposit dead animals in refrigerator in AQ 
o ffice. leave a note that the carcass is in the re fiigerator, and a s 
always, up date record on AQ disposition log andinlab animal 
inventory notebook.
*NOTE:Use back of page if  necessary. Any mortality or complication must be submitted to Veterinary 
necropsy.
Figure A-6. “Surgery Log” form page 6. Post-operative care procedure outlined for rats 
recovering from cardiac arrest surgeries 8-16hr post-resuscitation.
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Asphyxial Cardiac Arresl Data Sheet (revised October 23 ,2009} Page 1 rpm st.vol
Date: Food removed: IACUC #: Before CA
ID/Sex/Strain: Age or DOB: During Resus
Experiment: Days acclimatized: 10' A fter Resus.
Body weight (g): Delivery Date: Glucose (mgydL) Hcrpq
Com puter tim e = T1; Timer = T2 Start: End:
Clack
Time
(T1)
Clock
Time
(T2) V Event
Tree
TO
Tbraini
TO pH
R: 35-4D ags: 
30-84 PCD; 
(mmHg)
R: 1DO-130 
ags: 41-73 
POijfrimhg)
MABP
{mmHg)
HCOb' ABE
(mmol/L)
ksoTU
NjWOj
0:00 Anesthetize, intubate, camulatfi; lower Isoflu rare to -1.5% (rats), 2.514 (AGS) inj vec immediately aler intubating
Turn o ff heating pad; p repare blood gas and glucose machines
Vec iD.SniLof Ima/mLi: MOT BREATHING? mech. '^nt rate= 60; lower iso to -0.5% trals)~1%iAGSi Aiso in let to ventilator.
STXSe-; Connect head and rectal probes, ECG needles, calibrate and connect tar BP rear(GND) R(+)L(-)
To ran reach 1 
33.5C Sample all
Type "vec" in LabScribe
Inject vee as 1 
needed Sample g asses
Always w ait 
10 rrin Sample g asses
Vec (1mUkg) FLU SH  w/hep-sal; note ’Last vec' in LabScribe; l Iso to 0%; wait 2 min Off
Prepare for CA 2 t  min Type "start CA" in LabScribe; set T2 to 8 'or ' countdown; set BP ranqe 0-50 mmHq
_ Disconnect ventilator from endotracheal t i ie ;  IF>2breaths inject another Q.3mL vec (Ing/nnL); wait 10 min
Prepare to 
resusilate Type "Res" in LabScribe; setN;0 to 0; O2 I0  2Umin; t rpmto SO; prime for epi and NaHCOs"
U Resuscitation; connect to ventlator; quickly inject epi (1mL/kg); start CPR; when 6P=50 inject NaHCOs"
+10 Sample gasses
Sample gasses
Sample passes
Conect pH (adjust SV or if necessaiy inject NaHC03; Base excess (ABE) should lie >0 (5-10 normal)
Sample gases
Remove catheters
Put back on mask (no iso if unconsious)
Disconnect vent lator and check for spon breathing; cut thread, but leave in endotrachtube
to
A
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Figure 
B-2. 
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Asphyxial Cardiac Arrest Data Sheet (revised October 23, 2009) Paqe 2
Date: Animal ID #:
Maintain atTbat 37.0°C for 60' min
Checklist Task
NOTESGvei.p. 1mL7kg Sterle Saline (non-heparan ized)
Put in humidified incubator at 29C°C overnight
Clock time □ate Next morning: feed 3mL suqar water chow mix 3 times /da/
am feeding
noon feeding
evening feeding
Record T,=c Daily °c Bodywt (g)
24-hr post resus
48-hr post nesuB
72-hr post resus
Pertiise for histology
1'Saline -»10T FAM 1 Head in FAM br24hr Head rinsed wr'RO H ;0 & Srain in FAM 2.4hn Brain in 70% EtOH until ready for trim
Dissect out brain and put into FAM at 43C at least ovemitjrt; store at A C  in FAM until parafn embedding
Embedded
Additional Time Points
Clock Clock 
Time Time 
(T1) (T2) V Event
Tree
ra
Tbran
ra pH
R: 35-10 ags: 
3D-B4 FCOj 
(mmHgt
R: 100-130 
ags: 41-73 
P p ; (mmHfl)
MABP
(mmHg)
HCOa'
(mmol/L)
ABE
[mmol/L)
Iso %l
n2o/o2
114
Anesthesia Log
A ppendix C
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Figure C-1. “Anesthesia Log” form shown. This form records physiological parameters of 
anesthetized rats during cardiac arrest surgery.
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A ppendix D 
Asphyxial C ardiac A rrest Setup
Asphyxial C ardiac A rrest Setup 
M arch 13, 2007
O rder
□ (±) Epinephrine HCl (Epinephrine injection, 1mg/mL, Butler Columbus Ohio, cat 
#W A B 10310) (store at 4°C)
o  Dilute 1:50 to make 0.05 mg/mL: To red top tube add 0.5 mL of 1mg/mL 
epi + 9.5 mL saline to make 0.05 mg/mL (50 ug/mL) 
o  Dilute 1:10 to make 0.005 mg/mL: To red top tube add 1.0 mL of 0.05 
mg/mL + 9.0 mL sterile saline.
□ CG8+ iSTAT Cartridges (3 mon shelf life) 
http://www.abbottpointofcare.com/istat/www/products/cartridges.htm, Abbott 
Laboratories. Abbott Park, Illinois
□ Contact Abbott labs to order blood gas standards (Calibration solutions are 
contained within each cartridge, but it is best to confirm accuracy with known 
standard especially if  cartridges are near or exceed shelf life).
Gas sterilize (2 4 h r p rio r to surgery; aerate overnight) for survival or acute surgery. 
Assemble pressure transducer using sterile technique, fill with sterile saline and use 
for up to 1 week or until contam inated. Replace line to arterial cannula daily with 
gas sterilized line.
O r Cold sterilize for acute surgery:
□ 2, x~20 cm PE-50 or Tygon tubing (0 .375-m m  ID, 0.75-m m  OD; Norton,
Akron, OH; special o rder) cannulae (marked 1 inch at one end and 2-3inches 
from other end) with blunt stainless steel fittings (23ga for PE-50; 26ga for Tygon 
tubing);
□ Pressure gauge and PE-90 x 50-70 cm tube with connectors to connect 10cc 
syringe and to arterial line for BP monitoring
Autoclave: Double wrapped pack1 (see below)
Fast rats and AGS 20-24h r before surgery by moving anim al to clean, food free 
cage 20-24h r prior to procedure
Set out:
□ Injectables (see below) with color coded syringes for 2x-HEP sal, Vec, NaHCO3 
and Epi
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□ 10mL syringe filled with sterile saline and bottle of sterile saline
□ Sterile 10 cc syringe (to fill with hep-sal and connect to pressure gauge)
□ 2 x 5 inch curved hemostats with Tygon on tips
□ Water blanket covered with towel or absorbent blue pad-Warm up
□ Clippers
□ Balance for weighing animal
□ Curved forceps for grapping tongue
□ Filled isoflurane vaporizer; Flow meter for N 2O and O2; tanks of N 2O and 
medical grade O2 with jar or box for inducing anesthesia
□ 2 lamps with 60-75 W bulbs; each connected to Omega (CSC32 temp controllers; 
calibrated with thermocouples to be used for experiment with Omega HH41 
digital thermometer and ON-403-PP thermocouple)
□ Needle thermocouple
□ Rectal thermocouple and lubricant
□ ECG needles (Platinum; F-EZ; 12 inch; 10/box)
□ DSI transducers (bioelectric for ECG set to 0.1; transducer for BP; output (0-1V;
set to 100) connected to gas sterilized pressure gauge; 10 cc syringe filled with
hep-sal and 50-70 cm inlet (o f same tubing as cannula) with blunt luer connector 
to connect to BP transducer and blunt stainless steel adapter to connect to arterial 
line for BP monitoring
□ Ring stand for holding pressure gauge
□ Pressure meter (such as physicians use for BP monitoring)
□ Computer with I-works A-D converter and software
□ Ventilator \Recommended ventilator: UGO Basile Rodent Ventilator, Stoelting Cat# 50095, $4850. Harvard ventilator does not provide reliable volume. CO2 may gradually increase and be difficult to regulate] (set to appropriate stroke 
volume and rpm with 0.5L bag ( Csharkey@vital-signs.com) in loop to serve as 
pulse dampener for lungs); connected to 250 mL humidifier (Scienceware, 
www.belart.com, cat#110300000) filled with 25mL H 2O + 20uL mucomist 
(acetylcysteine 10%; Roxane laboratories, Cincinnati, OH; NDC 0054-3027-02). 
Cylinder is capped with 2-holed rubber stopper. Hard Teflon, ~1/4in ID inlet 
tube with 90o bend reaches into fluid at bottom. Similar, but shorter outlet tube 
feeds humidified air into ~1/4 in ID Tygon. Outlet connects to inlet on 
ventilator. Ventilator outlet connects to ~1/8 in ID T that connects to 
endotracheal luer lock hub and ventilator inlet to complete circuit of humidified 
air. O2 and N 2O tanks to flow meter to isoflurane vaporizer to humidifier to 
fluovac inlet (clamp 2nd inlet for 2nd line) to animal. When animal is on ventilator 
inlet from humidifier goes to inlet on ventilator. Outlet from ventilator goes to 
Omnicon f/air canister or for UGO Basil ventilator fluovac mask fits in hole for 
ventilator output and suction scavenges output.
□ Fluovac or other scavenger and mask
□ 2-3 sets of sterile surgical gloves
□ Betadine (full strength) and 70%  isopropyl alcohol for scrubbing
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□ Gauze for scrubbing
□ Q-tips for scrubbing
□ Data sheet, post-op recovery sheet or tissue collection sheet; and, UAF (surgery 
log; anesthesia record); UM (protocol sheet and animal ID number recorded in lab 
log)
□ Surgical microscope or magnifying glasses
□ Blood gas machine and blood glucose machine or iSTAT machine with cartridges 
for blood gases and glucose and hematocrit centrifuge
□ UM (500uL vials for glucose; clay capillary tubes for HCT; long capillary tube
and 2 caps for blood gases); UAF (capillary tubes and putty for HCT; same
capillary tubes for blood gases and glucose via iSTAT), AND 500uL heparinized 
microfuge tubes to collect 500uL blood, spin and freeze plasma for hormone 
analysis.
Procedure:
1. Open pressure gauge pack and set up pressure transducer.
2. P rep are  injectables (see list near end of this document) and fill two cannulae 
w/hep-saline w/1cc syringe and 23ga. luer stub adapter (Becton Dickinson; reorder # 
4 27565 ) for PE-50; 26ga luer stub for Tygon. Fill one 10cc syringe w/sterile saline. 
Leave sterile ends in pack.
3. Anesthetize with 5% isoflurane and a 30:70 mixture of O2 (400-500m L/m in) and 
N 2O (1L/min) to insure physiological levels for PO2, PCO2 and pH.
4. Shave throat, right groin, and dorsal surface of remaining legs (for ECG electrodes); 
scrub animal.
5. R ecord vitals: Cover eyes with lubricant, insert rectal thermometer (lubricated with 
K-Y), insert EKG leads subcutaneously (ground to hind leg; negative to left front leg, 
positive to right front leg), monitor sO2 with pulse-oximeter. Record values on 
anesthesia record.
6. Don sterile gloves, drape and open pack1 and arrange surgical instrum ents.
1(double wrap is sterile for 6 weeks; single wrap is sterile for 3 weeks)
□ Small vessel scissors (protect with tip of yellow pipette)
□ 45o 5/45 sharp forceps (protect with tip of yellow pipette)
□ Blunt; bent 16ga/2.5” needle (may bend, blunt and file needle from IV catheter used 
for endotracheal catheter) or purchase from Popper &  Sons, 17TWx3 custom blunt 
popper biomedical needle (cat# 7427, http://popperandsons.com/index.asp)
□ Fine, straight rat-toothed forceps (Miltex 6-106; ~1mm or 1/16” width x 5 inches 
long)
□ 90o curved hemostats (5.5 inch long; Roboz RS 7291)
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□ 2 x 8 inch smooth inner surface curved (~ 90o) curved forceps (for teasing apart and 
holding vessels) Paragon #4004-96 http://www.paragonmedical.com/
□ Curved, blunt scissors for cutting skin and separating skin and muscle (Roboz; RS- 
6891)
□ 4 inch curved forceps for holding cannula (smooth, I used rough at UM, but tear up 
surface of cannula) and 2 forceps (rough)
□ Needle holder
□ Clear plastic drape with hole for throat and loin
□ Y-Luer adapter
□ Whole pack of cotton tipped applicators wrapped in tin foil
□ Retractor for throat
□ Small scissors for cutting knots
□ ^ ” pile of gauze wrapped in tin foil (Flush with saline, clean out blood clots, cover 
with saline wetted gauze)
□ Extra, 4 x 23ga blunt connectors, 6 x 23ga. Luer stub adapters (for PE-50) 6x 26ga 
luer stub adapters (for Tygon tubing)
□ 1 razor blade per pack
□ 1 silk needle w/suture
□ 4 x 15 inch pieces of silk thread
□ Glass slide covered w/foil
□ Follow procedure on Excel data sheet
7. Open into sterile field
□ IV catheter (same for rats and AGS; BD/Insyte; H3124A; 14ga x 1.75 inch; 2.1 x 
45m m )
□ 3-0 Prolene (when closing)
8. C annulate femoral vein and then artery, flush with saline and close temporarily with 
sutures. Polyethylene catheters (Tygon tubing; 0.375-mm ID, 0.75-mm OD; Norton, 
Akron, OH or PE-50 catheter for vein and artery), will be introduced ~ 2 cm into the 
right femoral artery and vein for blood pressure recording, blood sampling, and drug 
infusion. Mean arterial blood pressure (M ABP) will be measured via an indwelling 
femoral arterial catheter connected to a pre-calibrated Statham pressure transducer 
and will be recorded continuously. Arterial blood gases and pH, and plasma glucose, 
will be measured in microsamples (75^L ).
9. In tubate  with endotrachael catheter (14ga 1.75in; BD Insyte Autoguard, Shielded IV 
Catheter, ref# 381467 guided with a bent, custom made blunt biomedical 17ga x 4in 
needle, 17TWx3, Popper &  Sons, New Hyden Park, NY #7427). If necessary, clip 
the hair from the ventral neck and using a #10  or #15 blade or curved, blunt scissors 
make a 1-2cm incision along the ventral midline of the neck to expose the trachea and 
larynx. To prevent laryngospasm during oral intubation swab lidocaine onto 
laryngeal folds with a small cotton tip swab moistened with 2 drops of lidocaine
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(Lidoject; lidocaine 2%  injectable, Butler Animal Health Supply, Dublin, OH 43107). 
For survival surgery, suture the catheter to the lip to avoid dislodging catheter during 
resuscitation CPR. Close with 3-O prolene, simple interrupted stitch, at least 3 
throws).
For terminal, non-recovery procedures, a tracheotomy may be substituted for oral 
intubation. The trachea will be exposed as described above. A small hole will be 
made between the cartilaginous rings in the trachea and the 14ga 1.75in; BD Insyte 
catheter will be inserted. The catheter will be secured in the trachea with1 or 2 
sutures using 3-0 silk.
10. Paralyze AGS must be paralyzed immediately after inserting endotrachael catheter. 
Inject 0.3cc Vecuronium (1mg/mL) IV. Watch to see that animal stops breathing. 
Connect ventilator (humidified with mucomist (1.4mL/70mL H 2 O); pressure 
dampened with rebreath bag at, 60 rpm, SV 2.5mL). Decrease isoflurane to 0.5%.
11. Sample and adjust blood gases; adjust stroke volume, SV, (typically between 2 -  3 
mL) and % O 2 (typically between 250 and 600mL/min) to adjust blood gases (AGS 
PCO 2 : 30-84mmHg; PO 2 41-73mmHg \PCO2 of 60mmHg and PO 2 of 60mmHg is 
typical]; Rat PCO 2 : 35-40; PO 2 100-110 [110-130 is acceptable]1.
12. M onitor T rec and T temporaiis until between 36.5°C and 37.5°C.
13. A t least 10 min after previous injection of vecuronium , inject vec (0.3m L of 
1mg/mL, IV) and FLUSH immediately with 0.3mL hep-sal (6.7 IU/mL), 2 min later 
disconnect ventilator. OBSERVE THAT ANIMAL IS NOT BREATHING. If 
animal continues to breathe (>2 breaths), inject another 0.3mL of vec, wait 10min, 
and repeat this step. If animal is not breathing prepare to resuscitate . (Connect 2 
way luer adapter primed with Epi (5ug/mL) and NaHCO3 (8 .4% ) for immediately 
delivery; change BP scale to 0-50; turn off isoflurane vaporizer; turn N 2 O flow 
meter to “0” and increase O2 to 2L/min and respiratory rate to 80 bpm. NOTE “last 
vec” injection and “start of CA” or “sham” procedure and “res” (resuscitation) in 
LabScribe. Setup “PEEP” (Positive End-Expiratory Pressure) if  applicable— place 
the expiratory end of ventilator tubing against the bottom of a container filled with 5 
cm of H 2 O).
14. Resuscitate by connecting ventilator, inject 1mL/kg fresh Epi (5ug/kg). Pull back 
on NaHCO3 plunger when injecting Epi; apply rapid heart message until BP is at 
least 50 and HR is spontaneous (for at least 10 sec). Immediately inject 0.9 cc 
NaHCO3 . Resuscitation is discontinued after 2 min if  animal fails to maintain a 
spontaneously beating heart.
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15. After 10 minutes of restoration of spontaneous circulation (ROSC), decrease 
respiratory rate from 80 to 60 bpm and % O 2 from 100% to 70%  in a mixture with 
N 2 O. Sample arterial blood gases.
16. Correct acid-base status with sodium bicarbonate and/or the ventilator settings.
(Base excess should be >0; 5-10 is normal). If pH<7.3 inject NaHCO3 to adjust pH. 
May need to increase RR to blow off CO2 if  pH is low, in AGS CO2 is often >60.
17. Once blood gases are normal, remove arterial and venous catheters by tying off 
artery and vein with 3 throws of 3-0 silk suture. Close skin with 3-O prolene, simple 
interrupted stitch; at least 3 throws.
18. Leave on ventilator until spontaneous breathing begins to fight ventilator.
19. Maintain at 37.0°C (between 36.5°C and 37.5°C ) for 60 min.
20. Monitor until ambulatory.
21. Return to home cage.
22. Record body temp and inspect sutures every 24hr for 3 days.
23. File anesthesia records, surgery logs and data sheets.
24. Enter blood gas data into Excel.
25. Back up LabScribe files on laptop and to an external hard drive.
Post-op Care:
Personnel approved for post-operative care and monitoring will participate in the
following:
1. Daily cleaning and inspection of wounds. Wounds are cleaned with dilute (tea 
colored) betadine once per day for 3 days and inspected thereafter.
2. 8-16hr post-op, animals are observed for signs of voluntary feeding. If not 
eating, animals are fed by gavage (1mL/kg body weight) 3 times per day: (The 
stomach volume is about 3mL in about 300g rat and gastric emptying time about 
45-60min. Sucrose (i.e., table sugar from grocery store) is mixed ~50:50 with 
chow and dissolved with tap water to make a dilute solution that can be drawn 
into a 3 cc syringe using a gavage needle without clogging the needle).
3. 8-16hr post-op and again at 24hr intervals for 7 days, body temperature is 
recorded and animals are monitored for neurological impairment and scored per 
“Neurological scores data sheet.doc”.
4. Vet services will be contacted in case of complications encountered during 
regular work hours or during after-hour, weekend or holiday care.
5. Although the severity of brain damage is not expected to produce death, inter­
animal variation makes death a possibility. Animals will be monitored, fed by 
gavage (1m L/100g body weight) and given supportive care as needed up to 3 
times per day. Severity of brain damage may be assessed from neurological 
examination. Animals showing severe neurological impairment including coma 
will not be euthanized because eliminating most severely affected individuals will 
bias final assessment of histology. Death must therefore be used as an endpoint. 
The number of animals that die will be noted, however, these animals are 
excluded from histological examination of tissue because death does not allow for 
in situ fixation of the tissue. Deposit dead animals in refrigerator in the Animal
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Q u a r t e r s  ( A Q )  o f f i c e ,  l e a v e  a  n o t e  t h a t  t h e  c a r c a s s  i s  i n  t h e  r e f r i g e r a t o r ,  a n d  a s  
a l w a y s ,  u p d a t e  r e c o r d  o n  A Q  d i s p o s i t i o n  l o g  a n d  i n  l a b  a n i m a l  i n v e n t o r y  
n o t e b o o k .
N o t e s :
1 V e n t i l a t o r y  v o l u m e  w i l l  t y p i c a l l y  b e  2 . 5 m L  a n d  v e n t i l a t o r y  r a t e  w i l l  b e  6 0  b p m  p r i o r  t o  
C A  a n d  8 0  b p m  a f t e r  r e s u s c i t a t i o n .  H o w e v e r  r a t e  a n d  v o l u m e  m a y  v a r y  a s  n e c e s s a r y  t o  
a d j u s t  b l o o d  g a s e s  a n d  p H .  V o l u m e  a n d  r a t e  w i l l  g e n e r a l l y  v a r y  b e t w e e n  2 . 5 m L  ± 1 . 0  
m L  a n d  6 0  ± 1 0 b p m  ( p r i o r  t o  C A ) ;  8 0  ± 1 0  a f t e r  r e s u s c i t a t i o n .  H o w e v e r  b o t h  r a t e  a n d  
v o l u m e  m a y  e x c e e d  t h e s e  p a r a m e t e r s  i f  n e c e s s a r y  t o  a d j u s t  b l o o d  g a s e s  a n d  p H .
- A n  i m m e d i a t e  b r a d y c a r d i a  i s  t y p i c a l l y  o b s e r v e d  f o l l o w e d  b y  h y p o t e n s i o n  t o  5 0 m m H g .  
W i t h i n  a p p r o x i m a t e l y  t h r e e  m i n u t e s ,  M A P  d e c r e a s e s  t o  z e r o  m m H g  a n d  t h e  h e a r t  r a t e  i s  
f u r t h e r  d e c r e a s e d .  B e t w e e n  6  a n d  8  m i n u t e s  o f  a s p h y x i a ,  t h e r e  i s  m i n i m a l  E C G  a c t i v i t y .  
E i g h t  m i n u t e s  ( o r  l o n g e r  d e p e n d i n g  o n  e x p e r i m e n t a l  p r o t o c o l )  a f t e r  a s p h y x i a ,  
r e s u s c i t a t i o n  w i l l  b e  i n i t i a t e d .  A f t e r  1 0  m i n u t e s  o f  r e s t o r a t i o n  o f  s p o n t a n e o u s  c i r c u l a t i o n  
( R O S C ) ,  t h e  v e n t i l a t o r  r a t e  w i l l  b e  d e c r e a s e d  t o  6 0  b p m  a n d  t h e  o x y g e n  w i l l  b e  l o w e r e d  
t o  7 0 %  i n  a  m i x t u r e  w i t h  N 2 O .  A r t e r i a l  b l o o d  g a s e s  w i l l  t h e n  b e  d e t e r m i n e d  a n d  i f  a n y  
c o r r e c t i o n s  i n  a c i d - b a s e  s t a t u s  a r e  n e c e s s a r y ,  s o d i u m  b i c a r b o n a t e  w i l l  b e  a d m i n i s t e r e d ,  
a n d / o r  t h e  v e n t i l a t o r  s e t t i n g s  w i l l  b e  a d j u s t e d .
LabScribe (Softw are) D ata Acquisition:
S tart LabScribe
1. Load program:
S e t t i n g s / l o a d  I W X 1 1 8 - E C G M A P - C A - K D
2. Select program:
S e t t i n g s / S e l e c t  I W X 1 1 8 - E C G M A P - C A - K D
3. Place electrodes (subcutaneously, SC); GND to back leg; (+) to R  front leg; (-) to 
left front leg.
4. Set Bioelectric transducer to 2.5 (full scale), In  LabScribe click on S tart and Full 
Scale in channel 1 (E C G ) to acquire. I f  noisy change mV to V
5. C alibrate pressure transducer once per day: F i l l  w i t h  s t e r i l e  H e p - S a l  ( 0 . 2 m L  o f  
1 0 0 0 I U / m L / 3 0 m L  v i a l  s a l i n e  o r  6 . 7  I U / m L )  a n d  b l e e d  a i r  f r o m  s y s t e m .  I N  L a b S c r i b e /  
E d i t / p r e f e r e n c e s  V a l u e s  p r i n t e d  b e l o w  s h o u l d  b e  s e e n  i n  I W X 1 1 8 - E C G M A P - C A - K D
122
Open transducer to atmosphere; Press Shunt CAL, Press Auto Bal. LabScribe screen 
should read ~0 (+/- 1mmHg). If auto bal does not stabilize at 0, air is in line. Flush air. 
May need to adjust CALIB knob if first time combining pressure transducer with Gould 
transducer box. Connect stethoscope pressure gauge to outlet on pressure transducer 
and increase pressure to 50, 100, 150; adjust CALIB knob on transducer to correct 
reading on LabScribe.
6. M onitor BP: Connect to arterial catheter; Clamp catheter with hemostats protected 
with Silastic tubing when BP is not being monitored; Close transducer to air, close to 
syringe, open to artery. Check readout on LabScribe. Must be connected to 
transducer with luer LOCK. Arterial pressure will cause blood to bleed into line and 
transducer if  any leak in system.
Omega T em perature C ontroller:(Refer to O m ega C N 9300 Temp C ontroller users
guide.pdf at http://www.om ega.com /M anuals/m anualpdf/M 2897.pdf)
F or model CSC32 (T  type)
Omega.com
Program  settings
>  Retain or change to factory settings (level 3; rS E t)
>  hold a  and v keys together for 3 sec to enter program  mode
>  Scroll through program  options w ith a  or v key until LEV EL appears
>  Scroll through level #  with a  or v key
1. Level 1: Set Autotune (tune) to OFF
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2. Level 1: Set Integral time (Int.t) to OFF
3. Level 1: Set SP1 Prop band(gain)/hyst (bAnd) to 0.1
4. Level 1: Set Cycle time or on/off (CYC.t) to ON.OFF
5. Level 2: Set Select display units (unit) to oC
6. Level 2: Set Select input sensor (I nPt) to tc t
7. Level 2: Set Display resolution (diSP) to 0.1 degree
8. To lock: Level 3: scroll to (uEr) and press a  and v  keys together for 10 sec until
display switches to LoC4. Press * and scroll through a  to select ALL
If you get lost in program mode, press a  and v  keys together for 3 sec to return to 
display mode. check the INSTRUMENTS ADJUSTMENTS above and try again.
When in program mode, after 60 sec of key inactivity the display will revert to either 
(I nPt) none or, if  the initial configuration has been completed, the measured value. 
Any settings already complete will be retained.
C alibrate at s tart of each new set of experim ents and every time a different 
therm ocouple is attached to a tem perature  controller. C alibrate a t 3 points or 
more (such as 25, 37, 42 ) using +/- 0.1oC Hg therm om eter or Omega digital 
calibration therm om eter.
C on tro ller
g  (°L )
C ontroller
1 and  
R ectal 
p robe (°C)
2 and 
need le  
th e n n o co u  
p l e f C ) D iffe ren ce -1 D iffereuce-2 %  Err o r -1 %  E rror-2
41.5 39.7 39.6 1.8 1.9 4.337349 4.578313
39.5 37.7 37.9 1.8 1.6 4.556962 4.050633
32.2 30.6 30.7 1.6 1.5 4.968944 4.658385
27.3 25.7 25.8 1.6 1.5 5.860806 5.494505
25.9 24.5 24.5 1.4 1.4 5.405405 5.405405
25.2 23.8 23.9 1.4 1.3 5.555556 5.15873
a m : 1.6 1.5 5.11417 4.890995
1. UNLOCK: Level 3: scroll to (uEr) and press a  and v  keys together for 10 sec 
until display switches to LoC4. Press * and scroll through a  to select nonE
2. Level 3: Set (Zero) to difference (+ i f  controller is low; - i f  controller is high)
3. Lock as in 8 above
4. Check that lamps turn off at 37.5oC and on at 37.0 or higher. Note one output 
plug is for heating and the other is for cooling. If lamp does not turn off, move 
plug to other output.
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M echanical Ventilators:
R. Busto says Harvard is not a good model. Best is the UGO Basile (Italian company 
has booth at SFN) model. UGO Basile is more reliable and able to make fine 
adjustments. If Harvard ventilator goes bad we will be unable to control CO2. CO2 will 
tend to increase because of error in expiratory volume.
BP and EK G
EKG bioelectric lead: plug electrodes into top pin in house shaped plug :
Bioelectric transducer/E C G  Lead Instructions:
1.) Try to make electrodes and wire harness as still and immobile as possible.
2.) Insert electrodes into animal using surgical tape if necessary.
3 .) Turn on ECG box to “full scale” setting #1.
4.) Turn low cut filter to 10 and high cut filter to 30.
5.) Start LabScribe and click on the “autoscale” button.
6.) If ECG box is making a “clicking” sound, it is trying to figure stuff out. Give it some 
time to stabilize and try to keep electrodes and wire harness as immobile as possible. 
It may take a few minutes to stop clicking and show an ECG signal.
7.) If there is no signal or a weak signal, turn each filter (both low and high filters) to 10 
Hz. Then turn the full scale” knob down to a lower value (should probably see 
something at 0.1).
Injectables:
1. Epinephrine (5 ug/mL if  fresh (<6 mo); 10ug/mL if  old (>6mo; will have pinkish 
color); lmL/kg for 5 or 10 ug/kg; (bring to room temp before filling syringe)
E p i 1 00X  Stock ill H 2 Q _____________500 ug/inL______________________ 1000 ug/inL_____________________
(Weigh out 5-10mg: pour into 5-10mg/10-20mL 5-10mg/5-10mL
scintillation vial and add
appropriate vol o f  H20 . Pipette into
500inL aliquots. Store at -20°C
or -80°C).
Epi Ready for Injection____________5ug inL_________________________lOug/mL_________________________
lOOuL Stock + 9900 uL saline. lOOuL 500ug/mL Stock + 9900 100 uL lOOOug/mL stock + 9900
Filter into sterile red top tube uL (9.9inL) saline. uL (9.9niL) saline
through 0.2mn syringe filter.
Store at 4°C. m apped in foil. Bring
2. Vecuronium
(1mg/mL; 1mL/kg for 1mg/kg)
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Reconstitute 20mg with 20mL sterile H 2O (Sicor Pharmaceuticals, Irvine, CA NDC 
070302925-01 )
3. H EP Saline
0.2mL of 1000IU/mL/30mL vial saline or 6.7 IU/mL (note for chronic cannulation at 
of AGS at UAF, we fill lines with 30 IU/mL hep saline, but are careful to not overfill 
cannulae and deliver high hep to animal).
4. N aH C O 3
NOTE at UM we always gave 0.9mL NaHCO3 to rat and AGS regardless of animal 
weight; (1cc syringe for rats; 3 cc syringe for AGS); 8.4%; 1 mEq/mL; 3mL/kg for 3 
mEq/kg) Hosira, Lake Forest, IL; NDC 0409-6625-02
5. Sterile Saline
Non injectable:
M ucomist
(1mL/500mL H 2O; 0.125 mL/1.67 mL H 2O; fill 250m L graduated cylinder with 20mL 
H 2O and add 40uL mucomist (acetylcysteine 10%; Roxane laboratories, Cincinnati, OH; 
NDC 0054-3027-02)
A rterial cannulation
Bevel slightly (best to not bevel because artery can close on bevel and give inaccurate 
BP reading). If artery breaks: remove silastic tubing from hemostats; rinse with saline 
until artery clamps and stops bleeding. Grab end with hemostats. Slide tied loop of 
suture over hemostat and tie off onto artery. Open other leg and cannulate other artery.
It is ok to have vein and artery on opposite sides.
Resuscitation
If epi solution is pink, make fresh or animal will not resuscitate.
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A ppendix E 
Neurological Deficit Scores (NDS) Form s
Neurological Scores:
A neurological deficit score (NDS) will be performed daily for 7 days after global cerebral ischemia The total NDS consists of 
five components: consciousness and respiration, cranial nerve function, motor function, sensory function and coordination 
(leg/tail movement, cleaning, depth perception, righting reflex) and for motor and sensory function as previously described [ 
Katz et al. J Cereb Blood Flow Metab. 1995. 15. 1032-1039], The NDS ranges from 0 (normal) to 100 (brain dead).
Page 1
A nim al ND score
D ate Started On:_________________
Anim al #_____    G roup/condition_____________________
No Condition Score
Guideline
Score obtained by animal each day 
(12:00 PM to 2:00 PM)
*2 hr 1 ‘J i 4 IS
1 General
behavioral
deficit 
(worst, 40 
points)
Consciousness Attempt to explore 
spontaneously
0
No attempt to explore 
spontaneously 
(comatose)
20
Respiration Normal 0
Abnormal 20
2 Cranial 
nerve 
re flexes 
deficit 
(worst. 70 
points)
Olfactory 
(sniffing food)
Present 0
Absent 5
Vision (follows 
hand)
Present 0
Absent 5
Comeal Present 0
Absent 5
Whisker
movement
Present 0
Absent 5
3 Motor 
deficit 
(worst. 10 
points)
Legs/tail
movement
Normal 0
Stiff 5
Paralyzed 10
4 Sensory 
deficit 
(worst. 10 
points)
Legs/tail (on 
pinching)
Present 0
Absent 10
5 Coordination 
deficit 
[worst. 20 
points)
Righting reflex 
(attempting to 
right self when 
placed on back)
Present 0
Absent 10
Self-feeding Present 0
Absent 5
Self-cleaning
(grooming)
Present 0
Absent 5
Total 0-100
* Denotes NDS taken 2 hours after resuscitation
Figure E-1. “Neurological Deficit Scores (NDS)” form page 1. This form assesses neurological 
severity 2hr and 7-22 days post cardiac arrest injury.
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N eurological S co res:
A neurological deficit scone (NDS) will be performed daily for 7 days (or up no 211. days i f  a long-term study) 
after global cerebral ischemia.. The total NDS consists o f five components: consciousness and respiration. 
cranial nerve function, motor function, sensory7 function and coordination (leg/tail movement, cleaning, depth 
perception, righting reflex} and for motor and sensory function as previously described [Katz et al. J  Cereb 
Blood Plow Metab, 1935. 15. 1032-10)9], The NDS range is a scale between 6 (normal function) Do 100 (brain 
dead).
Page 2
A niinnl XD score
Date Started On:________________
A n un til #____________________ ___________________  G ro u p  c o u d itio n ________________________
N
0
Condition Score
Guideline
Score obrained by auiinal each
dav
(12:00 PM  to 2:00 PAT)
7 10 13 16 10 22
1 General 
behavioral 
deficit 
(worst 40 
points)
Consciousnes
s
Attempt to explore 
spontaneously'
0
No attempt to 
explore 
spontaneously 
(comatose)
20
Respiration Normal 0
Abnormal 20
2 Cranial
nerve
reflexes
deficit
(worst 20
points)
Olfactory
(sniffing
food)
Present 0
Absent 5
Vision
(follows
hand)
Present 0
Absent 5
Comeal Present 0
Absent 5
Whisker
movement
Present 0
Absent 5
3 Motor 
deficit 
(worst 10 
points)
Legs/tail
movement
Normal 0
Stiff 5
Paralyzed 10
4 Sensory7 
deficit 
(worst 10 
points)
Legs/tail {on 
pinching}
Present 0
Absent 10
5 Coordinati 
an deficit 
(worst 20 
points)
Righting
reflex
(attempting to 
right self 
when placed 
on back)
Present 0
Absent 10
Self-feedina Present 0
Absent 5
Self-cleanins
(grooming)
Present 0
Absent 5
Total 0-100
* Denotes NDS taken 2 hours after resuscitation.
Figure E-2. “Neurological Deficit Scores (NDS)” form page 2. This form assesses 
neurological severity 2hr and 7-22 days post cardiac arrest injury.
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A ppendix F  
Animal Post-operative C are Log
Animal Post operative Care Log
AniiiLil
ED#
Check
time
Dute Weight
te)
Bodv 
temp (:Q
Ambient
tempCQ
Fee dins 
G=Gavage 
S=Self
C— mmii 'Tnili ii
Figure F-1. “Animal Post-operative Care Log” form shown. This form is used to monitor rat 
behavior (including any pathological changes) and recovery after cardiac arrest surgery.
129
A ppendix G  
R at B rain  Perfusion Protocol
R at In tracard ia l Perfusion Procedure
Making Perfusion Solutions:
• Filtered Saline:
-  Dissolve 9g NaCl into 1000mL of fresh Milli-Q water and filter solution 
using filter paper, vacuum tubing, and a glass funnel.
-  Each animal needs 1000mL saline (prepare 1000mL but may only use 
about 500-600m L).
• 1000 mL of FAM, mix following solvents:
-  100 mL 36 % formaldehyde
-  100 mL acetic acid, glacial (99.5 % )
-  800 mL methanol (99 .8% )
Anesthetize Rat (use isoflurane vaporizer near hood):
• Induce at 5%  halothane or isoflurane (at 1.5LO2/min) for ~ 2 min. Make sure rat 
is surgically anesthetized (does not respond to multiple toe pinches).
• Maintain on nose cone between 2-3%  for rats.
• Proceed with the perfusion.
Position animal for collection of perfusion fluid:
• Set animal on plastic or wire grid above 9x13 inch pan or larger.
• Fluid will run into pan
• When finished pour fluid into waste jar. Label with contents (biohazard, rat blood 
and FAM, [100m L 36%  formaldehyde, 100mL 99.5%  acetic acid glacial, &  800 
mL 99.8%  methanol]) and call risk management for pick up.
Perfusion Technique:
1.) Use blunt-end surgical scissors to cut a “V” in the squirrel’s chest. Begin by using 
forceps to hold the xiphoid process of the sternum which is at the point of the “V” . 
(N ote: the sternum  is a flat, dagger shaped bone located in the m iddle of the
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chest. The xiphoid process, also called the "tip", is located on the bottom  of the 
sternum . I t  is often cartilaginous, but does become bony in later years.)
A.   B.   C.
2.) Carefully cut a hole in the chest below the xiphoid process with the surgical 
scissors being careful not to hit any organs. Poke the lower blade of the scissors 
through the hole to cut the sides of the “V” in the animal’s chest through the ribs 
and diaphragm. Use large forceps to hold the flap back.
3.) Using a hem ostat clamp off the descending aorta. To do this you will have to push 
the organs aside and look for a large artery attached to the side of the body cavity 
near the spine. This artery is the descending aorta (directly superior to the thoracic aorta and inferior to the apex of the ventricle of the heart).
D. E.
4.) As shown in the above diagram (d ), clamping the descending aorta at the green 
arrow (e) diverts the perfusion solution to only go to the upper body (e.g.. brain). 
The red lines are the arteries which bring blood to the body, the blue are veins that 
return blood to the heart.
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7.) (Optional) Insert the 18ga needle attached to the perfusion tubing into the left 
ventricle (f, yellow arrow). Be careful not to insert the needle too deep and 
puncture the left ventricle (f, yellow curve). If you can see the needle tip it is not 
in the heart it is only in the pericardial sac. You must be sure it goes through the 
heart’s muscle wall but not so far as to puncture the right ventricle. After the 
needle is inserted into the left ventricle, cut a small hole (yellow line) in the right 
atrium with iris scissors to let the blood out. Then turn on the pump to begin 
perfusing. The perfusion solution will enter through the left ventricle go to the 
upper body via the ascending aorta and push the blood out via the hole in the right 
atrium. After a couple of minutes, you will begin to see solution exiting the body 
via the hole in the right atrium.
8.) Perfusion of Solutions
• The first solution to be perfused is the saline which should be pumped for 1 min 
(set pum p to “2 ” = ~80m L/m in)
• Then the pump is shut down and the solution end of the tubing moved to the 
FAM solution before the pump is turned on again.
• The FAM  solution should pum p for 19 min w ith pum p set to “2 ” . It is 
normal for the rat’s arms to move and stiffen as they are fixed during the first 2 ­
3 min of the FAM fix. If this does not occur, then the fix may be a poor one 
(only want “alive” neurons to be fixed; if  poor fix then cannot use that perfused 
animal for neurohistopathology analysis).
• Watch the level of FAM solution in the container because you need enough left 
to fill your tissue collection jar (sometimes best to fill tissue collection jar with 
FAM prior to fixation).
(Use an 18ga needle).
Dial setting------------ Flow mL/min
 1------------------------- 34
 2---------------------------------- 79.5
 3------------------------- 122
4------------------------- 160
 5..................................201
 6----------------------------------245
 7------------------------------------------------------------------------ 312
 8---------------------------------- 335
Perfusion Pump: “MasterFlex®” L/S™ Economy Drive.
“Easy-Load® II": Model #  77200-62.
Perfusion Tubing: Cole-Pahner, “MasterFlex®” Precision Tubing.
Lot #  109548, Reorder #  06429-15. '
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9.) Brain Collection
• Using a guillotine or a pair of large scissors cut off the animal’s head.
• Use a razor blade to cut the scalp and expose the skull.
• Using rougeurs pull bits of bone away around the head stage if  the animal has 
one.
-  (Note: head should be stored in FAM  at 4°C for 2 4 h r ^  H ead rinsed
with diH 2O, brain  removed &  placed in FAM  at 4°C for 2 4 h r ^
B rain placed in 7 0 %  ethanol until fixed and ready for paraffin 
em bedding).
-  Always carefully side the rougeur between the skull and brain carefully
and pull up so the brain is not damaged.
• When all the bone is pulled away around the head stage, slowly pull on it 
straight up to remove the cannulae from the brain.
• Pull off any remaining pieces of skull that may impede removing the brain.
• Turn the head upside-down over the fixative and use a spatula to loosen the 
brain from the skull touching only the edges of the brain.
• The dura (outer connective tissue) and the optical nerves of the brain will need 
to be teased away from the skull with the spatula periodically to allow the brain 
to slip out.
• Using a scalpel-type spatula, scoop out the pituitary gland at the base of the 
skull and place it in the fixative.
• Discard head in biohazard bag.
10.) After perfusion
• Take care of the brain: The brain is stored in fresh FAM until paraffin 
embedding.
• Dispose of all fluids collected during perfusion in a waste jar. Fill out 
Hazardous Waste form and label waste containers. Call risk management (Haz- 
M at) for pick-up (R ichard  Deck at 474-5617).
• Unused FAM can be saved for future use.
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A ppendix H 
Histology R at B rain Trim m ing Instructions
You will need the following items in o rder to trim  ra t brain  into 3 mm slices:
• 1-2 full packs of clean/new razor blades; 3 clean/new razor blades are to be
used per ra t brain  (use 3 new razor blades to cut coronal brain sections/slices 
every time you trim—this method avoids cross contamination and ensures a 
sharp cut every time).
• 1 clean, ra t brain  m atrix  (make sure that each slit on matrix = 1 mm sections)
• 1 clean petri dish lid (either top or bottom  lid will w ork fine) and 1 
dropper/plastic pipet; use of either the top lid or bottom  container of petri 
dish does not m atter (you will place the brain matrix containing your upside- 
down loaded brain on top of the petri dish; the petri dish lid acts as a waste 
container [or “alcohol reservoir”] so that you can pour 70%  ethanol onto the 
brain so as to avoid tissue desiccation while trimming).
• A bout 500-1000 mL of 70 %  ethanol solution (maybe more if  trimming many 
brains at once).
• 1 x 250 mL beaker and 1 x 600 mL beaker to act as additional 70%  EtO H  
storage containers. You can use these beakers to also pour alcohol onto the 
brain while trimming and/or to fill up any brain cassette storage containers filled 
with 70%  EtOH.
• 1 clean plastic forceps (to carefully pick up brain and place it upside-down 
inside brain matrix and to carefully transfer brain slices into cassettes after 
trimming).
• A container/rat brain  ja r  filled about half-way w ith 70%  ethanol (you will 
place your cassettes containing freshly trimmed brain slices in this container for 
indefinite storage until ready for paraffin embedding).
• 1 spatula; used to adjust brain  position inside m atrix  and for anything else.
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• Histology tissue cassettes (2  cassettes per animal: one cassette for “H PC ”, 
hippocam pus, and another cassette for “ STR”, striatum ); each cassette 
should be appropriately labeled as follows: “Species &  Anim al ID # and 
specific brain  region (H PC /STR)” indicated on the front p a rt of the cassette, 
and “cassette num ber or anim al ID #” indicated on the side portion of the 
cassette.
Actual Trimming Process:
1) M ake sure all supplies are cleaned, labeled, and ready for trim m ing. B rain 
tissue is especially prone to desiccation, so this process should be prom pt.
2 ) Carefully place the brain  upside-down (so that the optic chiasm, white bands 
“crossed together” lies superior to hypothalamus; e.g. “facing toward you”) 
inside the brain  m atrix  using plastic forceps. Make sure to place the brain 
matrix (with the brain inside it) on top of a petri dish lid. This acts as a reservoir 
for 7 0 %  ethanol (E tO H ) which you will use to consistently lubricate the brain 
to avoid desiccation while trimming.
3 ) There will be slight variations (e.g. size of brain, shape) between anim al 
brains. Try to be consistent while putting brains into the matrix (e.g.. push the 
frontal part of the brain towards the edge of the matrix; you may have to trim off 
part of the brain stem  in order to ensure proper brain placement inside the 
matrix).
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Figure 2. Shows how to load brain into brain matrix, target brain regions for shoes (HPC, STR), and target shoe.
4) W ith the brain  m oisturized with 70%  EtO H , place all 3 razor blades in the
stfollowing order: i.) Place the 1 razor blade ju s t under ( “ inferior to”) the 
optic chiasm  and press down slightly so th a t the blade is securely placed into 
the brain  but not all the way down so as to initiate a full cut); ii.) Next, place 
a 2nd razor 3 mm above (“superior to”) the 1st blade and press down in the 
same way; iii.) Lastly, place a 3 rd blade 3 mm below (“ inferior to”) the 1st 
blade (m iddle blade) in the same w ay as the first two blades. The 1st blade 
should be a ‘dem arcation point’ separating the rostral (striatum, STR) and 
caudal (hippocampus, HPC) slices from  one another. M ake sure th a t the 
razor blades are placed against the wall of the brain  m atrix  slit to ensure a 
straight cut. Also, m ake sure to routinely m oisturize the brain  w ith 70%  
E tO H  during this process to avoid desiccation.
5) Once all 3 razor blades have been securely placed in the brain  and the brain  
moisturized w ith 7 0 %  EtO H , carefully flip the brain  over to a right-side-up
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position (do this step w ith the brain  still inside the brain m atrix and 
containing all 3 razor blades).
6) Gently lift up the brain  m atrix  while carefully pressing all 3 razor blades 
down so as to release them  from  the brain  m atrix. M ake sure to get a 
straight, even cut while trim m ing brain  for slices w ith the brain  m atrix.
Crooked slices (even slightly crooked) will result in blocks that will have to be 
‘matched’ (meaning that both sides of the slice have to be retrimmed until both 
sides are in the same plane/region of target brain region, e.g. right and left side 
HPC). Uneven slices take longer to process, and thus can result in increased 
charges per slide.
7) Once the brain  m atrix  is fully off, carefully and gently transfer the H PC 
slice into the appropriately  labeled “H PC ” cassette and vice versa for the 
“ STR” slice. W hen loading the H PC slice into the cassette, ALW AYS place
CAUDAL SIDE DOWN (sometimes this leads to the slice being upside down 
from the right-side-up position, but it shouldn’t matter as long as its placed 
caudal side down) and ALWAYS place the STR slice ROSTRAL side up in 
the appropriately labeled “ STR” cassette. You should have two slices per 
brain.
8) Im m ediately place cassettes w ith H PC/STR brain  slices into a container 
filled w ith 7 0 %  E tO H  so as to avoid desiccation and preserve tissue 
integrity. Store cassettes (containing both the HPC and STR brain slices and 
properly labeled with pencil) in a container (e.g. the same FAM Head 
containers work great for storing multiple cassettes too) filled w ith 7 0 %  EtO H  
indefinitely until ready for paraffin  embedding. Based off of previous 
experience, 5-m in hem atoxylin staining and 1-min eosin staining times will be 
used. Brain slices sectioned from blocks take a total of 22-h r cycle to set ( ‘dry’) 
on a microscope slide after they have been trimmed into 7-8 ^m  “serial” 
sections/slices with the micro-vibratome (this process is done by Rhonda Swor, 
474-6054 from  UAF Vet Services).
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9) UAF Vet Services Costs for Histology Embedding/Slide P re p :
"Serial" sections (unstained, general tissue sections) = $3 per slide. 
“Hematoxylin/Eosin” rat brain staining (or similar demanding work) = $13 per 
slide.
*F o r norm al easy to section tissues H & E  stain is $12/slide.
*F o r h ard  to section tissues H & E  stain is $14/slide.
(Sometimes discounts are given if  specific supplies are provided, e.g. clearing 
agent and alcohol for processing.) *Costs subject to change annually.
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A ppendix I 
Histology Staining Protocol 
H &  E Staining Protocol for Histology Slides B ird Room 109B
A. Prepare staining racks, replenishing any low or discolored alcohol baths. Levels 
may be just above where tissues located on slides.
B. Filter hematoxylin.
C. First stain bath is in lower left hand corner. Proceed from left to right along front
rack of baths, then move back to upper right bath &  proceed from right to left along
back rack of baths.
D. After staining 100 -  200 slides, change all baths. Xylenes must be put in discard 
bottle. Alcohols, eosin &  hematoxylin must be put into waste containers as well.
All wastes are picked up from EH&S.
3-4 minutes Xylene bath for a total of 10 minutes
1. Clear rite or Xylene bath
2. Clear rite or Xylene bath
3. Clear rite or Xylene bath
30 seconds or 20-30 dips for each of the following alcohol baths
4. 100% isopropyl alcohol bath
5. 100% isopropyl alcohol bath
6. 100% isopropyl alcohol bath
7. 95%  isopropyl alcohol bath
8. 80%  isopropyl alcohol bath
9. 70%  isopropyl alcohol bath
Total 1 minute gently running distilled water bath (black sink setup)
10. Distilled water
11. Distilled water
12. 5 minutes in filtered Hematoxylin
Total 5 minutes gently running distilled water bath (in hood) (Hematoxylin will continue 
to stain even in water, so watch this time very carefully)
30 Seconds or 20-30 dips for the following alcohol bath
13. 80%  isopropyl alcohol bath
14. Total 1 minute in Eosin, blot rack  after pulling from  stain bath
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30 seconds or 20-30 dips for each of the following alcohol baths
15. 95%  isopropyl alcohol bath
16. 95%  isopropyl alcohol bath
17. 100% isopropyl alcohol bath
18. 100% isopropyl alcohol bath
19. 100% isopropyl alcohol bath
20. 100% isopropyl alcohol bath
30 Seconds or 20-30 dips for each of the following Xylene baths
21. Xylene bath
22. Xylene bath
23. Xylene bath
24. Coverslip (Use Richard-Allan medium with Clear rite or Cytoseal with Xylene)
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A ppendix J  
C ardiac A rrest Supply List
Table J-l. Cardiac A rrest Supply List
Vendor/Supplier QTY Description
Catalogue/ 
Reorder No. Price
ABAXIS. INC. 1 I-STAT CG8+ FINAL PACK (25 ct) 600-9001-25 $374.50
Accurate Surgical 
& Scientific 
Instrument; 2 Fine tip. smooth inner surface 8" forcepts FRC15EM8 $286.00
AliMed.Inc. 2 SILK SUTURE SPOOL. 100 YD. 3-0 98SUT244 $13.75
AliMed.Inc. 2 3-0 BLACK SILK SUTURE SPOOL 100YD 98SUT24-4 $27.50
American Power 
Conversion Corp 1
APC Replacement Battery- Cartridge #2 (for UPC 
Upgrade Selector Surge Protector/Battery Unit) RBC2 $39.99
ApogeeKit; 1 Magnifying Glasses w/LED Light MA-016 MA-016 $18.95
Astro-Med 1 12” Electrode Subdermal Platinum Needle Electrodes F-E2-12 $214.00
Bit
1
14 G x 1.75 in. BD Insyte™ Autoguard™ 
shielded IV catheter (2.1 mm x 45 mm) made of 
BD Vialon™ biomatenal. (200'c a) 381467 $507.00
Bel-Art Product; 1 Gas Washing Bottle WTritware® Dispersion Disc 110300000 $42.00
Bickford 20 Omnicon fair 80120 $155.00
Bickford 20 Omnicon fair 80120 $155.00
BioMedic Data
System; 1 Implantable Programmable Temperature Transponders IPTT-300 $995.00
BMDS 1 IPTT-300 Temperature Transponder IPTT-300 $875.00
Braintree Scientific 1 Acrylic (Rat Brain) Matrice. 1mm Coronal BS-A 6000C $190.00
Braintree Scientific 1 Large Rodent Intubation Stand (400-500g) RIS-200 $255.00
Braintree Scientific 1 Large Rat Kit for Rats 200+ grams LR-Kit $320.00
Cascade 1 Lidocaine HC1 Injectable $60.00
Cole Parmer
1
EW-47355-24 
Cart with outlet strip and drawer, two shelf. 
8” x 3” casters 47355-24 $679.00
Cole-Parmer 1 Masterflex Tygon LFL tubing US 15ft EW-06429-15 $90.00
DRE Medical 1 AIR-SHIELD C-100 QT Incubator N/A $1,750.00
DRE Medical N/A AIR-SHIELD C-100 QT Incubator Shipping fee N/A $560.00
eBulb. Inc.
10
USfflO FCR 100W 12V Bipin Halogen Lamp 
(GY6.35 Bipin): Rated Life 50hr: for Nikon 80i 
Histology Microscope Lamphouse Umt 1000490-M $30.02
Erlah. Inr 1 Captair Filters (2 each) F4F $1,130.00
Ei lab Inc 1 PrefilteTS (2 each) F4PF1 $48.00
eSuture; 2 3-0 Silk 8 x 18" SH taper. CR 8 C013 $14.00
eSutute; Ed 3-0 Surgipro blue 18" DX-19 cutting (3/8 circle. 19mm) XPS632 $2.00
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Table J-l Continued.
Yendor/Supphei <?ty Description
Catalogue/ 
Reorder No. Price
eSutures
25
3-0 Surgipro blue 18" P-12 cutting (Prolene 8687) 
(expires 01/2010 or later) SP56S7 52.00
Fine Science Took 1 Dumont #5/45 forcepts - Dumoxel Standard Tip 11251-35 535.50
Fine Science Took 1 Vannas Spring Scissors-3mm blades straight 15000-00 5312.00
Fine Science Took 2 Micro-mosquito hemostat curved 12cm 13011-12 513600
Fine Science Took 1 his scissors delicate straight 10.5cm 14060-10 561.75
Fine Science Took 1 Olsen-Hegar needle holder 14cm 12002-14 596.75
Fine Science Took 2 Adson-brown forcepts shark teeth 12cm 11627-12 511400
Fine Science Took 1 Graefe forcepts O.Smm tips straight 11050-10 548.25
Fine Science Took 1 Dumont **5/45 Forcepts - Dumoxel Standard Tip 11251-35 535.50
Fine Science Took 1 Vannas Spring Scissors-1mm Blades Straight 15000-00 5312 00
Fine Science Took 1 Ins Scissors - Delicate Straight 10.5cm 14060-10 564.25
Fisher 1 Acetic Acid, Glacial, 2.5 L RABA001025D 57195
Fisher Reusable Polydome w/out Diaphragm NC9554766 522.00
Fisher 1 Black Permanent Markers 23400-451 530.36
Fisher 1 Red Permanent Markers 02-681440 530.61
Fisher 1 lOuL Micro Tips 02-707-134 5353.50
Fisher 1 200uL Large Orafice Tips 21-3S1-SA 5317.50
Fisher 1 200uL Low Retention Tips 22-282-202 5642.50
Fisher 1 lmL Tip 13-676-10K 580.50
Fisher 1 25mL pipettes (individual) SCGPU05RE 5205.11
Fisher 1 500mL Stericup Filter Units SCGPU10RE 5138.00
Fisher 1 1 OOOmL Stencup Filter Umts 5194 00
Fisher Science 
Education
1
Simport* MultiRack* Tube Racks 18 x 50mL 
centrifuge tubes (25-30mmdiameter): Autoclavable, 
Orange. Acetal Polymer. & Cap 18; Case of 10
05-407-113; Simport 
Plastics: 
No.:S600-300 5179 54
Fisher Scientific 1 XDCR BD P23XL BP TRANSDUCER NC9789695 52,000.00
Fisher Scientific 1 3.5 VOLT NUMATTC PNEU OTOSCOPE NC9200700 5245.70
Fisher Scientific
1 Welch Allvn Rechargeable Handle NC9085106 5214.20
Fisher Scientific 1 WELCH ALLYN BATTERIES # 72300 NC9555019 556.04
Grass 1 Female SAFELEAD to Binding Post Adaptor DF-215-BP 555.00
ELaDowtH EMC 1 Incisor Loops (Pack of 5) 210A3490A 530.31
Halo well EMC 1 Lidocaine Applicator 200A3590 524.26
Hallo well EMC 1 Rat ET Tube Introducer 210A3492 548 51
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Table J-l Continued
Vendor/Supplier VTY Description
Catalogue'' 
Reorder No. Price
Hallowell EMC 1 Rat Specula. Autoelaveable 200A35S8 838.59
Hallowell EMC 1 Rodent. Tilting Work Stand 000A3467 $484.21
Hallowell EMC 1 Mouse Lidocaine Applicator 210A3496 825.47
Hallowell EMC 1 Rat Specula. Autoelaveable 200A35S8 839.75
Hallowell EMC 1 Rodent. Tilting Work Stand 000A3467 $532.63
Harvard Apparatus 1 IMS Fluosoiber Filter Canister 340415 $244.00
Harvard Apparatus 1 Christolube Prod. # 5000047 817.00
Harvard Apparatus 1 Fluovac 240 VAC. 50Hz 340387 $2)215.00
Henry Schein 1
Welch-Allyn Otoscope Pneumatic w specula.
3.5V (20200) ' 5662532 $186.99
Henry Schein 1
Welch-Allyn Handle Rechargeable. 
3.5V (71000-A) 5662474 $154.49
Henry Schein 1
Welch-Allyn Battery Rechargeable Orange.
3.5V (72300) ' 5662828 845.79
Heska 1 iSTAT Cartridges 25 per box CAT 5110-CG8+ $368.50
Heska 2 iSTAT Cartridges 25 per box CAT 5110-CG8+ $727.00
Heska 1 iSTAT Cartridges 25 per box CAT 5110-CG8+ $363.50
Heska 2 CG8+ iSTAT Cartridges (25 per pack) CAT 5110-CG8+ $727.00
Heska 2 CG8+ iSTAT Cartridges (25 per pack) CAT 5110-CG8+ $727.00
Heska 1 CG4+ iSTAT Cartridges (25 per pack) 5110-CG4+ $359.00
Heska 2 rSTAT CG4+ 25pack of cartridges 5110-CG4+ $732.00
Heska 1 CG8+ iSTAT Cartridges (25 per pack) CAT 5110 -CG8+ $363.50
Heska 2 iSTAT CG4+ 25pack of cartridges 5110-CG4+ $359.00
Heska 2 CG8+ iSTAT Cartridges (25 per pack) CAT5110-CG8+ $363.50
Heska 1 CG8+ iSTAT Cartridges (10 per pack) CAT 5140 CG8 $162.00
Heska 1 Control solution CAT 5130 89.50
Heska 1 CG8+ iSTAT Cartridges (10 per pack) CAT 5140-CG8 $162.00
Heska 1 Control solution CAT 5130 89.50
Heska 3 CG8+ iSTAT Cartridges (10 per pack) CAT 5140-CG8 $486.00
Howard Electronic 
Instruments, Inc 1 Flushing Cannulae 862.35
Howard Electronic 
Instruments. Inc. 1
JG26-0.5 Jensen Global Industrial Stainless 
Steel Needles, pack of 1000 JG26-0.5 875.00
Indigo Instruments 1 Forceps. Roch Pean. 10" curved 22473 811.00
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Table J-l Continued
Vendor/Supplier QTY Description
Catalogue/ 
Reorder No. Price
Indigo Instrume nts
1 Forceps, Roch Pean. 12" straight 22474 513.00
Kent Scientific
1
Reusable W a rm in g  Pad. 30.5cm W X 38. lcmL 
(12" X 15”) TPZ-1215EA 545.00
Kent Scientific
1 TPZ Connector for TP-500 pump 50.00
Kent Scientific
2 TPZ connector 50.00
Lowe's 1 Cabmet for Nikon Microscope Supplies 551.96
Med-Yet
Intern.irion.iI 1 Sharps Containers 10 gallons SHARP- 10G 512.99
Med-Yet
International 3 Sharps Containers 3 gal SHARP-3G 517.85
Omega 2 Hypodermic Needle Probe (30 gauge)
HYP1 -30-1/2-T-G- 
60-SMP-M $204.00
Omega
2 Thermocouple probe model HYP1. Tvpe T. thermocouple
HYP 1-30-1/2-T-G- 
60-SMP-M $204.00
Omega 2 Benchtop Controller, type T CSC32T $690.00
Omega
2 Thermocouple Probe Model HYP-1
HYP1-30-1/2-T-G-
60-SMP-M $204.00
Omega 1 5-Pack, Epoxy coated tip. Type T Thermocouple 5TC-PVC-T-24-180 550.00
Omega 1 Thermocouple TC-PVC-T-24-180 51600
Omega
1 Thermocouple
HYP1-30-1/2-T-G-
60-SMP-M $102.00
Omega 1 Thermocouple probe model HYP1. Tape T. thermocouple
HYP1-30-1/2-T-G-
60-SMP-M $102.00
Pall Corporation
1 ACRODISC Syringe Filters 25MM HT-200 50 PK STRL Prod. No. 4192 $144.94
Prescott’s Inc
1 PS 2001 Microscope Stand
PS 2001 (alternate # 
PMPOSM99) $4,000.00
Q n u
1
Tracheal Tube Components—Polysulfone Straight 
Connectors (15mm x 6.0mm I D. Tubing) 31307
Qosina
1
2-Way, 3 Port Luer Lock, Lipid Resistant. 
Labeled Handle Feature. Clear Stopcock 
(High Density' Polyethylene. Polycarbonate) 99745
Replacement Light 
Bulbs 4 Philips EKE 21V 150W 533.08
Replacement Light 
Bulbs 2
Philips EKE 21V 150W 
SKU: Philips EKE 21V 150W 93638 516.54
Rohoz 1 Mister curved, extra delicate length 5.5” RS-7291 $113.40
Rohoz 1 Semken tip width 1.6mm. length 6”, 1x2 teeth RS-524S 545.80
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Table J-l C ontinued
Vendor'Suppher QTY Description
Catalogue/ 
Reorder No. Price
Roboz 1 Mavo-Shlle curved blade length 49mm. length 5 : RS-6891 $65.40
Roboz 1 Micro-Dissect Forceps (seirated. full curve. 4") R.S-5137 $45.00
Roboz 1 Blunt Scissors (5.5”, curved. 42 mm) RS-6891 560.00
Sci Notebook 8 96-page notebook seconds 1201 seconds $56.00
Sci Notebook 4 96-page notebook 1201 $48.00
Sigma 1 D-cycloserine lg C6880-1G $54.10
Sigma 1 Paraformaldehyde, prilled. 95% 441244-1KG $22.10
Sigma 1 Epinephrine HCL, 5 grams E4642-5g $38.40
Simonson Labs
4/wk
Sprague-dawlev Rats: male. 180-200 grams, and 45 
days old at time of order; ($21.25/rat); experimental 
use after 2 wks (250-350g)
S/A SMONSEN 
ALBINO $85.00
StrictlyPetSupplies
.com 1
Sunbeam Products Inc Oster Professional Blade 
Set For A-5 Clip Size 40 UPC4 34264403772 $4278
UAF Facilities 
Servic es 2
AirGas® Nitrous Oxide Gas Tank (N:0). 
$25/scrip ("refill") $25.00
UAF Facilities 
Services 2
Medical Grade Oxygen Gas Tank (0 2), 
$25/scrip {"refill") $25.00
UAF Vet Services 1 Vetbond $27.10
UAF Yet Services 1 Table top unit with flow meter {no vaporizer) $565.00
UAF Vet Services 1 Ketamine $13.72
UAF Vet Services 1 Instiucal1 Concentrated Lubricating Milk (surgical tools) $26.60
UAF Vet Services 1 Sterile Surgical Gloves
UAF Vet Services 30-50 Surgical Clear Plastic Mouse Drapes
UAF Yet Services
1
1/2 Liter Non-Rebreathe Bag with specialized valve 
ti$10 fora 3-LBag) $115.00
UAF Vet Services
1
Black fitted tubing for Rebreath Bag +1/2 liter non- 
rebreathe set-up (total for both bag &  tubing -  $150) $150.00
UAF Yet Services 1
lOmL Hepann vial; 1000 USP Units:mL; APP 
Pharmaceuticals, LLC; NDC 63323-540-11
UAF Yet Services 30
lOmL Vials of Vecuronium; Hospira Inc., 
NDC 0409-1632-01
UAF Vet Services
2
250mL containers of Sterile Saline Solution 
(one bottle for heparinized-saline dilution)
UAF Vet Services 1 250mL container of Sterile Water
UAF Vet Services 2 Isoflurane Liquid Anesthetic
UAF Vet Services
2
Bottle of Sodium Bicarbonate (8.4%NaHC03‘ in a 
lOOmL)
UAF Vet Services 2 Epinephrine HCL, Injectable Solution
UAF Yet Services 1
18ga x 1.5" needle from BD, 100 box 
(used for perfusion tubing)
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UAF Yet Services N/A
Gas Sterilization (e.g. cannulation packs, 
pressure transducer, etc.)
UAF Yet Services
15
Small or Large "Visi-Peel Pouches size 12"xl5" 
(for gas sterilization of pressure transducer)
UAF Yet Sendees
10
Converters Self-Seal Pouches size 3 1/2" x 9 (for gas 
sterilization of cannulae)
UAF Yet Services
l.'ea
Medical Grade (Rx) Oxygen Gas Tank tubing, fitting. 
& regulator attachment $800.00
UMECO 1 SurgiPro 3-0 Blue 18" C-14 Surgical Suture SP684G
Vitality Medical 1 Gaymar T Pump Localized Heat Therapy System
GMRTPP522
ea $376.82
\YVR
1
(95% Ethanol-histologv grade) 
BDH ALCOHOL REAGENT 4L POLY BDH1156-4LP S3 5.52
\YVR
2
10 mT. BD Plastipak* Syringes with Eccentric Tip. BD
BD305482 529.42Medical (Pack of 100): VWR Cat. No. 305482
VWR
1
10 mL BD Plasticak* Syringes with Eccentric Tin. BD
BD305482 29.42Medical (Pack of 1001: VWR Cat. No. 305482
VWR
1
36% Formaldehyde Solution; Histology Grade 
Solvents. EMD Chemicals: Case of 4 Polv Bottles. 4L E.M-FX0415M 574.46
VWR 1 ACETIC ACID GLACIAL 99.5% 2.5L MK250144 516.93
VWR 2 Autoclave tape. 3/4" x60 yds 58752-704 58.76
VWR 6 Autoclave Tape. Pronner 1 9cm x 55.4m (3 4" x 60 yds ) 268005 531.56
VWR
1
BAG BIOHAZARD DISP19X23INPK200: HDPE. 
WR, SUPER BIOHAZARD DISPOSAL 11215-864 $180.88
5VYR
1
BAG BIOHZ AC DSP 14X19 PK200: HDPE. 
WR. BIOHAZARD DISPOSAL 11215-862 579 41
5VYR 1 BD Vacutamer Venous Blood Collection Tubes (1001 VT6430 519.70
VWR
1
BD Vacutamer Venous Blood Collection Tubes (Serum 
Determination Tubes. Silicone-Coated - BD366460) VT6430 519.70
"VWR
1
BD Vacutamer Venous Blood Collection Tubes (Serum 
Determination Tnhes Silicone-Coated - BD366460) VT6430 519.70
VWR 1 Clamp Day Pinchcock (pk of 10) 21730-001 57.56
5VYR 1
Convertors TSM Stenlitv Maintenance Covers. 
Cardinal Health (8 xl2) 54110-562 $102.48
\YVR 1 Curitv Gauze Srionges. cs of 5000 82004-740 573.24
VWR 1
CURITY* Nonsterile Gauze Snonges. 8-Plv. 
Covidien: Case of 5000 82004-740 573.24
5VYR 1
CURITY* Nonsterrle Gauze Sponges. 8-Plv. 
Covidien: Case of 5000 82004-740 73.24
VWR 1 DuPont* Mask with Earloons 80076-670 $181.12
\YVR 1 GAUZE DERMACEA 4X4 8 PLY EA200 89004-984 573.97
VWR I GAUZE DERMACEA 4X4 8 PLY EA200 89004-984 573.97
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3TVR 2
MAXYMum Recovery* Research-Grade Pipet Tips. 
Axveen Scientific (200ul - pk of 10001 22234-070 $89.68
3TVR METHANOL OMNISOLV 4L EM-MX04SS-1 $67.20
3TVR 1 MethanoL ACS Grade (case of 41 BDH1135-ILG $169.20
3TVR Methanol. ACS Grade. 99 8“ ■> nnn. (bv GO: 
Case of 4: 4L Glass Bottles BDH1135-1LG $335.00
3TVR 1
Methanol. ACS Grade. 99 8“ ■> nnn (bv GO: 
Case of 4: 4L Glass Bottles BDH1135-1LG $83.75
3TVR 1 Methanol. Case of 4: 4L BDH1135-ILG S83.75
3TVR 1 Micro Shde Holders (Pack of 121 48457-107 $9.55
3TVR
3
Needles. BD Med (Rea Bevell: Pk 100: 21ea. 
25 4mm (lrn.l: Green BD-305165 S36.21
3TVR Needles. BD Med (Rea Bevell: Pk 100: 23aa. 25 4mm flin.l: Turauoise BD305145 S60.35
3TVR Needles. BD Med (Rea Bevel): Pk 100; 26ea. 12.7mm (l/2in.): Tan BD305111 $48.28
3TVR Puritan Applicator Cotton Tip Cleaning Sticks PK 1000 (6 in. or 15 cml: Polvstvrene Shafts 10805-148 $125.66
3TVR
1
Puritan* Swab. Mini Cotton Head. Puntan Medical 
Products (100 'baa. 10 baas per pack. lOpk/cs) 82004-050 $103.01
3TVR
2
Sinale-Use Needles. BD Medical (Reaular Bevell: 
Pk of 100: 23aa. 25 4mm (lin.l: Turquoise BD305145 $12.07
3TVR Smale-Use Needles. BD Medical (Reaular Bevell: Pk of 100: 23aa. 25 4mm (lin.): Turouoise BD305145 12.07
3TVR
1
Steel VWR® Micro Slide Double Drawer Cabinet: 
Stores 200 micro shde holders (up to 800 slides) 89030-198 $72.53
3TVR SYRINGE TUBERCULIN 1ML PK100 BD309602 $77.16
3TVR SYRINGE TUBERCULIN 1ML PK100 BD309602 $57.87
3TVR 2 SYRINGE TUBERCULIN 1ML PK100 BD309602 $19.29
3TVR 3 SYRINGE TUBERCULIN 1ML PK100 BD309602 $57.87
3TVR 2 Tape Durapore lm X 1 I'D (Box of 121—Suraical tape 56222-186 $11.44
3TVR 2 Tape Durapore lin X 1 YD (Box of 121—Suraical tape 56222-186 11.44
3TVR 1 Tape Drnapore lm X  1YD (box of 12) 56222-186 $11.44
3TVR 1 Tape Durapore lin. X 10yd BX12 56222-186 $12.25
3TVR 1 Three-wav stopcock KT420163-1503 $42.22
3TVR TubmaLFL 3/16x5/16 25' 63008-866 $84.32
$TUt 1 Tvaon* Lab Tubma. R-3603. 3/8”IDxT2"OD 63009-178 $25.79
3TVR 2
VERSI-DRY* Lab Table Soakers. NALGENE 
(20" x 300) 52857-106 $281.82
3TVR VWR Absorbent Bench Underpads (23x24. 410mL absorbencv. deluxe pads) 56616-032 $95.11
3TVR 1 VWR CLOCK HUMIDITY MONITOR (for CA Incubator) 62344-734 31.65
3TVR 1 VWR Glass Jars. Wide M (500ml. cap) 89043-274 $25.57
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v w r 1 VWR PETRI DISH 100X15MM CS500 25384-070 $50.33
VWR 1
VWR Power-Free Nitrile Examination Gloves -  
Larne (Case of 101 82026-428 $69.58
5YYR 1
VWR Power-Free Nitrile Examination Gloves — 
Small (Case of 101 82026-424 $69.58
VWR 1 VWR Power-Free Nitrile Gloves - Sm (es of 101 82026-424 $69.58
$YYR 1 VWR razor blades, pk of 100 55411-050 $25.30
v w r 1 VWR razor blades, pk of 100 55411-050 $25.30
VWR 1 VWR UNDERPAD DISP 23X24 GS200 56616-032 $42.80
VWR 1 VWR UNDERPAD DISP 23X24 GS200 56616-032 $42.80
VWR
1
VWR® Clear Glass Jars. Wide Month: 500ml ( 1 6 o z . 1 l 
Case of 12: 91 x 95mm dia. x height: Pulp V 1:1.1 89043-274 $25.57
5YYR 1 VWR® Powder-Free Nitrile Exam Gloves Medium 82026-426 $71.62
VWR 1 VWR® Powder-Free Nitrile Exam Gloves Medium 82026-426 71.62
VWR 1 VWR® Powder-Free Nittile Exam Gloves Small 82026-424 $71.62
VWR 4
VWR® Razor Blades: 100 pk. Single-edge industrial 
razor blades, hard carbon steel. &  individually wrapped 55411-050 $45.52
World Precision 
Instruments 1
Surgical Needles. Cutting. 5 16 circle. 18inni. 
size 2. pk of 12 501960 $20.00
World Precision 
Instillments 1
Surgical Needles. Cutting. 3 S circle. 21mm.
size 0. ok of 12 501803 $20.00
World Precision 
Instr. 1
Surgical Needles. Cutting, 1 2 circle. 32mm. 
size 5. pk of 12 501796 $20.00
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A ppendix K  
IACUC A pproval L etters for Research Protocols
(907 ) 474-7800 
(907 ) 474-5638  fa*
jNMivtrrr or mama fy iacu cA u a f.ed uFAIRBANKS
www u a f e d u /ia cu c
Institutional Animal Care and Use Committee
909 N Koyukuk Dr. Suite 212. P.O. Box 757270 . Fairbanks. Alaska 99775-7270
November 23. 2009
To: Kelly Drew
Principal Investigator
From: University of Alaska Fairbanks IA C U C
Re: [142656-3] D-cydoserine (D C S ) research protocol
The IA C U C  reviewed and approved the Response/Follow-Up referenced below by Designated Member 
Review
Received: November 11, 2009
Approval Date: November 23, 2009
Initial Approval Date: November 23, 2009
Expiration Date: November 23, 2010
Note: The revisions have answered the questions made by the committee. The protocol is approved, 
however approval of Standard Operating Procedures for Surgical Supplements referenced in this protocol 
are pending review and approval by Dr Blake
This action is included on the December 3, 2009 IA C U C  Agenda
The P I is responsible for acquiring and maintaining all necessary permits and permissions 
prior to beginning work on this protocol Failure to obtain or maintain valid permits is 
considered a violation of an IACUC protocol, and could result in revocation of IACUC approval.
Figure K-1. IACUC approval letter for “D-cycloserine (DCS)” research continuation.
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m
UMIVCRSITV O f  ALASKA
FAIRBANKS
Institutional Animal Care and Use Committee
90S N Koyukuk Dr. Suite 212, P.O. Box 757270, Fairtanks, Alaska 99775-7270
November 11,2009
To: Kelly Drew
Principal Investigator 
From: University of Alaska Fairbanks IACUC
Re [142673-1] SSOP Cardiac Arrest
The IACUC reviewed and approved the New Project referenced below by Designated Member Review
Received: October 27, 2009
Approval Date November 11,2009
Initial Approval Date: November 11,2009
Expiration Date November 11,2010
This action is included on the November 2,2009 IACUC Agenda.
The P I is responsible for acquiring anti maintaining all necessary permits and permissions 
prior to beginning work on this protocol. Failure to obtain or maintain valid permits is 
considered a violation of an IACUC protocol, and could result in revocation of IACUC approval.
Figure K-2. IACUC approval for cardiac arrest surgical procedure. [SSOP: “Surgical 
Standard Operating Procedure”]
(907) 474-7800 
(907J 474-5638 lax 
fyiacuc@uaf.edu 
www.uaf.edu/iacuc
150
(907)474-7800 
(907) 474-5638 fax 
fyiacuc@uaf.edu 
www. uaf.ed u/iacucFAIRBANKS
Institutional Animal Care and Use Committee
909 N Koyukuk Dr. Suite 212, P.O. Box 757270, Fairbanks, Alaska 99775-7270
November 10,2009
To: Kelly Drew, PHD
Principal Investigator
University o f Alaska Fairbanks IACUC
[142652-2] Ischemia resistance research protocol 3y rewrite
From:
Re:
The IACUC reviewed and approved the Revision referenced below by Designated M ember Review.
The revision has incorporated the recommendations and additional information requested by the 
committee. Approval o f surgical supplements is pending review by Dr. Blake.
This action is included on the December 3, 2009 IACUC Agenda.
The PI is responsible for acquiring and maintaining all necessary permits and permissions 
prior to beginning work on this protocol. Failure to obtain or maintain valid permits is 
considered a violation o f an IACUC protocol, and could result in revocation o f IACUC approval.
Figure K-3. “Ischemia Resistance” IACUC approval letter. IACUC approval granted for a 3- 
year renewal for the “Ischemia Resistance” research protocol.
Received:
Approval Date:
Initial Approval Date: 
Expiration Date:
Novem ber 5, 2009 
Novem ber 10, 2009 
Novem ber 10, 2009 
Novem ber 10, 2010
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Figure K-4. IACUC approval to increase total rat number for cardiac arrest experiments.
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Figure K-5. Euthanasia IACUC approval letter. Approval regarding the use of euthanasia in 
rats during recovery from cardiac arrest.
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Figure K-6. IACUC approval for perfusion and histological assessment (0-22days) post 
resuscitation.
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FAIRBANKS
Institutional An im al Care  and U se  Com m ittee
900 N Koyukuk Dr. Suite 212. P.O. Box 757270. Farb^iks. Alaska 99775-7270
(907) 474-7500 
(907) 474-5444 fax 
■71 acuogiuaf.edu 
www. u af. eduriacuc
November 11, 2008
To: Kelly Drew. PhD 
Principal Investigator
From: John B la te . D V M  
Alteudina Veterinarian
IACUC Cootimiing Review
On behalf o f  the University o f  Alaska Fairbanks Institutional Animal Care and Use Committee 
(IACUC) I have reviewed the request for renewal o f the following assurance. This renewal request has 
been approved.
Protocol: tf06^15
Received: November 7, 2008
Approved; November 12, 2003
This Assurance is valid through November 8, 2009, but must be kept current with respect to new 
methods, techniques and personnel. This protocol will not be eligible for renewal in 2009; lather, it 
will need to be resubmitted for IACUC review approval. We recommend submitting two months prior 
to the expiration date (9/8/09) to prevent any delay in the work covered by this assurance o f  an im al care 
and use.
Thank you fo r  keeping y o u r IACUC A ssurance up to date.
U N I V E R S I T Y  O F  A L A S K A  F A I R B A N K S
Figure K-7. “Neuroprotection in Hibernation” research IACUC approval. Approval granted to 
continue cardiac arrest research.
Title: Neuroprotection in Hibernation
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Figure K-8. IACUC approval letter for D-cycloserine (DCS) administration 24 and 48hr after 
cardiac arrest injury.
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Figure K-9. IACUC approval letter shown regarding endotracheal intubation guidelines.
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FAIRBANKS
Institutional Anim al Care and U se Committee
906 N Koyukuk Dr. Suite 21Z P.O. Bax 757270. Farbaiks. Alaska 96775-7270
(B07) 474-7.500 
{907:! 474-5444 fax 
^yiaojoguaf edu 
www uaf ediViacuc
O ctober 13, 2 0 0 8
To Kelly Drew. PLD 
Principal Investigator
From: John Blake. DVM 
Attendine Veterinarian
Re: IACUC Modification Request
On behalf o f the University o f Alaska Fairbanks Institutional Animal Care and Use Committee 
(IACUC) I have reviewed and approved the following request for modification:
Protocol": 06-45
Modification: Allow time during endrotracheal tubation training for visualization of larynx.
If technique is successful, induction using injectable anesthetic agents may 
replace induction with isoflurane via induction chamber
Ketamine and medetomidine with atipamezole reversal: Rat induction dose 
is: 75 mg.kg BW IP and 0.5 mg.kg BW IP; atipamezole: 1 mg,kg BW IP. 
SC. Arctic ground squirrel dose will evaluated: the attending veterinarian 
requires starting at rat dose and modifying level o f ketamine to achieve 
desired level o f anesthesia. Protective eye ointment is placed post induction.
Animals used for training may be monitored for 4 hours and i f  no signs o f  
respiratory' distress are noted, returned to their home cage, monitored the 
following day and made available for subsequent experiments.
Received: October 9, 2008
Approved; October 13, 2003
Thank you fo r keeping your A ssurance o f  Animal C are form  C urrent
T itle : N europrotection in hibernation
U N I V E R S I T Y O F A L A S K A F A I R B A N K S
Figure K-10. Ketamine and medetomidine IACUC approval. Approval to use ketamine and 
medetomidine during endotracheal intubation training.
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Figure K-11. Lidocaine IACUC approval letter. Approval to use lidocaine during 
endotracheal intubation.
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Figure K-12. IACUC approval granted for Heather Crispell (formerly Heather McFarland).
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Figure K-13. IACUC approval to perform euthanasia for unexpected complications during 
cardiac arrest surgery.
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Figure K-14. Intubation and resuscitation training IACUC approval.
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U N I V E R S I T Y  O F  A L A S K A  F A I R B A N K S
Figure K-15. IACUC approval granted for Velva Combs to perform anesthesia or euthanasia.
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Figure K-16. IPTT temperature transponder IACUC approval.
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Figure K-17. Personnel and isoflurane IACUC approval. Approval granted for the addition of 
Tulasi Jinka and isoflurane induction for intracardial perfusion experiments.

